Endogenous tumor-derived circular rna and proteins thereof for use as vaccine

ABSTRACT

The present invention relates to an endogenous tumor-derived circular ribonucleic acid (circ RNA) as well as one or more proteins expressed from said tumor-derived circ RNA. The invention further relates said tumor-derived circ RNA and the protein(s) expressed thereof for use vaccines in the prophylaxis and/or treatment of cancer.

TECHNICAL FIELD

The present invention relates to a tumor-derived circular ribonucleic acid (circRNA) as well as one or more proteins expressed from said tumor-derived circRNA for use as vaccine. The invention further relates said tumor-derived circRNA and the protein(s) expressed thereof for use as vaccine in the prophylaxis and/or treatment of cancer.

BACKGROUND OF THE INVENTION

Cancer is a generic term for a large group of diseases characterized by the growth of abnormal cells beyond their usual boundaries that can then invade adjoining parts of the body and/or spread to other organs [1]. Other common terms used are malignant tumors and neoplasms. Cancer can affect almost any part of the body and has many anatomic and molecular subtypes that each require specific management strategies.

Cancer is the second leading cause of death globally and accounted for 8.8 million deaths in 2015. Lung, prostate, colorectal, stomach and liver cancer are the most common types of cancer in men, while breast, colorectal, lung, cervix and stomach cancer are the most common among women. Cancer can be treated by surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy (including immunotherapy such as monoclonal antibody therapy) and synthetic lethality. US$1.16 trillion is the estimated total annual economic cost of cancer in 2010. Hence, there is a need for more effective and cost-efficient pharmaceuticals for use in the prophylaxis and treatment of cancer.

The adaptive immune response, mediated by antibody-producing B cells and cytotoxic T cells, protects us from disease by the killing of invading pathogens and performs immune surveillance to eliminate tumors prior to metastasis. Antibody-based and T-cell based therapy has been used with success to treat a number of malignancies. However, it would be advantageous, both for patients and for public health, to develop prophylaxis, such as vaccines, against different cancers, and to activate the immune system against the cancer.

To avoid killing of “self” and induction of severe autoimmunity, cells of the adaptive immune system undergo a stringent selection process during their development, where self-reactive cells are eliminated. With few exceptions (mutations changing the structure or gene fusions), cancer cells express proteins that will be considered “self” to the immune system. Effectively, this means that the frequency of circulating B cells and T cells that have a potential to recognize cancer cells are exceedingly low. This is true even in the form of fusion proteins, and mutations, where both proteins retain much of their original structure. However, even though small changes induced by mutations they have been used to elicit an immune response against the tumor [2,3].

Messenger RNA (mRNA) based vaccines for the treatment of tumors are described in US2008171711. The use of mRNA and peptides as vaccines is safer than using DNA-based vaccines and gene therapeutics since there is no risk of RNA and peptides being integrated into the genome. However, the instability of mRNA or of RNA for example due to RNA-degrading enzymes is a problem in using RNA in pharmaceutical compositions.

Hence, there is a need for vaccine which are not degraded by RNA-degrading enzymes.

Personalized RNA and peptide vaccines for the prophylaxis of cancer have been reported in the art [2,3]. However, the reported personalized peptide vaccines were not fully effective, the time to develop treatment is time consuming, and the treatment had to be combined with other immunotherapies [2]. Moreover, one of the patients had a late relapse when a personalized RNA vaccine was used [3]. Hence, there is a need for more effective and rapid vaccine development for the treatment of cancer. The use of circular RNAs (circRNA or cRNA) could potentially overcome these obstacles.

Recently, it was shown that circular RNAs (circRNA or cRNA) can form during RNA processing (e.g. back splicing) within cancer cells as well as normal cells [4-6]. During the formation of the circular RNA, the back-splicing process will introduce a unique fusion of two RNA nucleotides stretches. The function of circRNA is not well understood, but it has been shown that protein peptides can be generated from (open reading frames) ORFs [7,8].

Depending on the circRNA, proteins can be expressed from the RNA template, and the ORFs may overlap with the ‘true mRNA’ sequence and produce parts of the ‘true protein’, there is also a chance that the circRNA allow new ORFs to be expressed that is ‘out of frame’ and therefore contain a new composition of amino acids that will be recognized as “non-self”, and potentially reactive to the immune system. Another possible outcome of the circulation is that the ORF will cover the back-splicing site (BSS) and translate a protein that is ‘in-frame’ until the fusion site and then becomes ‘out of frame’ when it passes the BSS.

US2017298347 relates to fusion-circular RNAs (f-circRNAs) for diagnosis of cancer. Additionally, US2017298347 discloses a f-circRNA inhibiting agent which binds to f-circRNAs and said inhibiting agent is used for treating cancer. However, said inhibiting agent is neither a circRNA nor a protein derived from circRNA (paragraph 145; claims 15 and 26). Consequently, US2017298347 is silent about circRNAs and peptide products thereof being used for the treatment of cancer.

CN107384909 relates to the use of circRNA in a screening of gastric cancer. However, CN107384909 is altogether silent about using circRNA as a vaccine.

CN106480033 relates to a kit for detecting the circRNA-005365 gene. However, CN106480033 is altogether silent about using circRNA as a vaccine.

US20160194368 relates to synthetically produced circRNA. However, the circRNA are neither tumor-derived nor endogenous. More importantly, circRNA of US20160194368 does not comprise at least one open reading frame (ORF) not expressed in non-tumorous healthy cells.

OBJECT OF THE INVENTION

The object of the invention is to provide a vaccine for the prophylaxis and treatment of cancer.

The object of the invention is to provide an RNA-based vaccine for the prophylaxis and treatment of cancer.

The object of the invention is to provide an RNA-based vaccine for the prophylaxis and treatment of cancer wherein the RNA is not degraded by RNA-degrading enzymes and nucleases.

The object of the invention is to provide a peptide-based vaccine for the prophylaxis and treatment of cancer.

The object of the invention is to overcome the disadvantages of DNA-based vaccines and immunotherapies.

The object of the invention is to overcome the disadvantages of mRNA-based vaccines and immunotherapies.

SUMMARY OF THE INVENTION

The objects of the present invention are solved by the subject-matter disclosed in the claims.

The present invention relates to a plurality of interrelated products listed below and therefore discloses a single inventive concept:

-   -   DNA     -   RNA     -   protein (RNA product)     -   vaccine (DNA, RNA or protein for use in prophylaxis or treatment         of cancer),     -   methods of preparing said RNA and protein, and     -   diagnostics (protein for the use in screening of disease)

Tumor-derived circRNA

In the preferred embodiment of the invention, the objects of the invention are solved by an endogenous tumor-derived circRNA for use as a vaccine in the prophylaxis and/or treatment of cancer. Preferably said circRNA comprises at least one open reading frame (ORF) not expressed in non-tumorous cells.

In one embodiment of the invention, the tumor-derived circRNA comprises a nucleotide sequence selected from SEQ ID No: 1 to 299 or homologous nucleotide sequences thereof having at least 80% homology.

In a further embodiment of the invention, the tumor-derived circRNA is for use as vaccine in the prophylaxis and/or treatment of prostate cancer, breast cancer, colon cancer, lung cancer and/or pancreatic cancer.

In a further embodiment of the invention, the tumor-derived circRNA is for use as a prophylactic vaccine.

In a further embodiment of the invention, the tumor-derived circRNA is for use as a therapeutic vaccine.

In a further embodiment of the invention, the tumor-derived circRNA is administered (i) to the lymphatic system or proximity of the lymphatic system, preferably to at least one lymph node or proximity of lymph node, or (ii) ex-vivo for immune cell stimulation and cell-based therapy.

The invention also relates to a method of prophylaxis and/or treatment of cancer by using a tumor-derived circRNA. The circRNA may comprise a nucleotide sequence selected from SEQ ID No: 1 to 299 or homologous nucleotide sequences thereof having at least 80% homology.

The invention also relates to a method of preparing a tumor-derived circRNA. The circRNA may comprise a nucleotide sequence selected from SEQ ID No: 1 to 299 or homologous nucleotide sequences thereof having at least 80% homology, comprising the steps of:

-   -   a. Extracting total RNA content from tumor cells, and     -   a. Enriching circRNA by enzyme digestion of linear RNA and     -   b. Return circRNA to antigen presenting cells in vivo or ex         vivo.

The invention also relates to a vaccine comprising a tumor-derived circRNA. The circRNA may comprise a nucleotide sequence selected from SEQ ID No: 1 to 299 or homologous nucleotide sequences thereof having at least 80% homology.

Proteins from Tumor-Derived circRNA

In the preferred embodiment of the invention, the objects of the invention are solved by a protein derived from a tumor-derived circRNA.

In a further embodiment of the invention, the protein is derived from a tumor-derived circRNA comprising a nucleotide sequence selected from SEQ ID No: 1 to 299 or homologous nucleotide sequences thereof having at least 80% homology, wherein said protein comprise an amino acid sequence selected from SEQ ID No: 300 to 598 or homologous amino acid sequences thereof having at least 80% homology.

In a further embodiment of the invention, the protein comprise an amino acid sequence selected from SEQ ID No: 301 to 598 or homologous amino acid sequences thereof having at least 80% homology.

In a further embodiment of the invention, the protein comprises an amino acid selected from SEQ ID No: 301 to 598.

In a further embodiment of the invention, the protein is for use in the prophylaxis and/or treatment of cancer.

In a further embodiment of the invention, the protein is for use in the prophylaxis and/or treatment of prostate cancer, breast cancer, colon cancer, lung cancer and pancreatic cancer.

In a further embodiment of the invention, the protein is for use as a prophylactic vaccine.

In a further embodiment of the invention, the protein is for use as a therapeutic vaccine.

In a further embodiment of the invention, the protein is administered (i) to the lymphatic system or proximity of the lymphatic system, preferably to at least one lymph node or proximity of lymph node, or (ii) ex-vivo for immune cell stimulation and cell-based therapy.

The invention also relates to a method of prophylaxis and/or treatment of cancer by using a protein derived from tumor-derived circRNA. The protein may comprise a protein sequence selected from SEQ ID No: 300 to 598 or homologous nucleotide sequences thereof having at least 80% homology.

The invention also relates to a method of preparing the protein, comprising the steps of:

-   -   c. Extracting total RNA content from tumor cells,     -   d. Enriching circRNA by enzyme digestion of linear RNA,     -   e. Identifying proteins:         -   i. RNA sequencing,         -   ii. protein mass-spectrometry,         -   iii. In vitro translation, and/or         -   iv. Prediction of MHC class I/II-binding     -   f. identification of personalized/general potential of the         protein as immunogen by:         -   v. In vitro stimulation of T-cells from patients with             neoantigens, and/or         -   vi. Determination of B cell-responses to neoantigen

The invention also relates to vaccine comprising the protein derived from a tumor-derived circRNA.

The invention also relates to a pharmaceutical composition comprising the protein derived from a tumor-derived circRNA.

DNA Expressing (or Encoding) RNA and/or Proteins

The invention also relates to DNA which encodes for a circRNA discussed above.

The invention is also related to DNA which encodes for a protein discussed above.

The DNA may have a DNA sequence disclosed in Table 1.

In a further embodiment, said DNA is administered (i) to the lymphatic system or proximity of the lymphatic system, preferably to at least one lymph node or proximity of lymph node, or (ii) ex-vivo for immune cell stimulation and cell-based therapy.

The invention also relates to a vaccine vector or genetic vector which comprises DNA as discussed above.

The invention also relates to a vaccine vector or genetic vector which comprises DNA or RNA that express a protein (described above) corresponding to a protein encoded by a tumor-derived circRNA

BRIEF DESCRIPTION OF FIGURES

FIG. 1A illustrates RNA splicing and FIG. 1B illustrates circRNA splicing.

FIG. 2 illustrates the translation of circRNA into proteins.

FIG. 3 illustrates the process for manufacturing circRNA-based vaccines.

FIG. 4 illustrates the process for manufacturing vaccines comprising proteins derived from circRNA.

FIGS. 5 and 6 show experimental results from circRNA vaccination of rats. There is increased proliferation of CD8+ T cells in vaccinated rats compared to a control rat group.

FIG. 7 show experimental results from circRNA vaccination of rats. There is no difference in proliferation of CD4+ T cells between vaccinated rats and a control rat group.

FIG. 8 show experimental results from circRNA vaccination of rats. In vaccinated rats there is an increased tumor necrosis.

FIGS. 9a-9c show experimental results from circRNA vaccination of mice. There is increased proliferation of CD4+ T cells and B cells in vaccinated mice compared to a control mice group, FIG. 9a and FIG. 9c , respectively. There is a minimal effect on proliferation of CD8+ T-cells, FIG. 9 b.

DETAILED DESCRIPTION

Splicing is the editing of the nascent precursor messenger RNA (pre-mRNA) transcript into a mature mRNA. As illustrated in FIG. 1A, after splicing (i.e. normal RNA splicing), introns are removed and exons are joined together (ligated). The splicing of the tumor-derived circRNA of the present invention differs from normal RNA splicing in that, during the formation of the circular RNA, the back-splicing process will introduce a unique fusion of two RNA nucleotides stretches as illustrated in FIG. 1B.

The tumor-derived circRNA of the present invention can be translated into proteins by at least the three types of processes as illustrated in FIG. 2. Both the circRNA and the resulting proteins can be used for use in the prophylaxis and treatment of cancer.

In the Type-I process illustrated in FIG. 2A, the ORF is out of frame and the RNA is translated into a (neo-antigen) protein from an alternative read frame compared to the normal gene product.

The type-II process which is illustrated in FIG. 2B differs from the Type-I process in that, the Type-II process the translation of the (neo-antigen) protein cross a back-splicing site (BSS), and therefore, in the type-II process novel (neo-antigen) proteins can be produced by out-of-frame (from the normal gene product) translation of the ORF both before and/or after the BSS. In the type-II process the fusion site at the BSS can as well generate neo-antigen peptides.

The type III process which is illustrated in FIG. 2C involves a rolling circle amplified protein. The circRNA has an ORF that only contains a start codon (AUG) and produce a peptide that is in-frame with itself after passing the start codon and protein can continue to be translated in a rolling circle amplification manner. This leads to a rolling circle amplification of the generated peptide and potentiate the neo-antigen production, which leads to an enhanced immune response to the antigen.

Delivering RNA to subjects and induction of an adaptive immune response against said RNA is known in the art. This approach has previously been used in eliciting an immune response to RNA. Hence, full-length mRNAs or short oligonucleotide repeats against mutated regions have been selected and amplified in prior art techniques.

The present invention differs from prior art techniques in that tumor tissue is used and total RNA is extracted from the tumor cells. Within the total pool of tumor derived RNA molecules there is a fraction that consist of circularized RNA molecules (due to back-splicing events). The tumor-derived circRNA pool contains tumor specific circRNA with unique open-reading frames (ORFs) not normally expressed. ORFs that can be translated into peptides as novel proteins and hence be presented as novel neo-antigens that can stimulate immune responses toward the neo-antigens.

The strength of the present invention is that it is totally new protein sequence that compose the epitopes that are inducing the immune response, compared to mutations that only change a single or a few amino acids or full proteins over expressed in cancer that already have had a negative selection against their epitopes. Another aspect is that circRNAs are very diverse in their composition and that cancer induced changes have big impact on the repertoire of expressed circRNAs, thus a wide range of neo-antigens can be present at the same time within a tumor. Moreover, circRNAs are nuclease resistant by their circular structure and much more resistant against degradation than linear RNA molecules once injected in the patient enhancing the delivering potential.

The circRNA extracted from the patient will contain the multiplicity of unique tumor-derived circRNAs that have the potential to via antigen presenting cells present novel neo-antigens for the immune system.

In the present invention, tumor-derived circRNA from the patient will be prepared and divided into vaccination batches and booster batches, and administered either by injection in-vivo at sites of immune presentation (like adjacent to lymph nodes, within lymph nodes) or ex-vivo for immune cell stimulation and cell based therapy.

In the present invention, tumor-derived circRNA are isolated and sequenced from subjects (i.e. patients) with well-defined tumor types. The invention is not limited to a certain cancer type and is therefore applicable for all types of cancer. Subsequently, a database with identified and potential unique open reading frames within circRNA are built that are not present within normal cell transcription within the patients. This will:

-   -   1. Allow for the identification of potential neo-antigens within         (back-spliced) circRNA that are common for a certain tumor type,         and     -   2. Allow for the identification of potential neo-antigens within         (back-spliced) circRNA that are unique for a single patient

Importantly, results from (1) will identify circRNA neo-antigens that are suitable for prophylactic vaccination (i.e. to vaccinate healthy individuals against a particular cancer) and therapeutic vaccination (i.e. patients with corresponding cancer). Results from (2) will identify circRNA neo-antigens that can be rapidly introduced into a delivery vector for personalized therapeutic vaccination against pre-existing tumors in a cancer patient.

The pharmaceutical compositions and vaccines of the present invention may comprise pharmaceutical excipients used in the art [9,10]. Preservatives, adjuvants, stabilizers and buffers are examples excipients which may be used but the present invention is not restricted to these examples.

Preservatives are used to prevent growth of bacteria or fungi that may be introduced into the vaccine during its use, for example by repeated puncture of a multi-dose vaccine vial with a needle.

Adjuvants helping stimulate a stronger immune response of vaccinated individuals.

Aluminum salts may be incorporated into a vaccine formulation as an adjuvant. Examples of aluminum salts are aluminum hydroxide, aluminum phosphate, alum (potassium aluminum sulfate), or mixed aluminum salts. Organic compounds such as squalene or oil-based compounds may also be used as adjuvant.

Stabilizers keep vaccines potent during transportation and storage. They help protect the vaccine from adverse conditions such as the freeze-drying process, for those vaccines that are freeze dried. Some examples of stabilizers which may be added to vaccines include: sugars such as sucrose and lactose, amino acids such as glycine or the monosodium salt of glutamic acid and proteins such as human serum albumin or gelatin.

In the present invention, the term “protein” is defined as a molecule which comprises one or more chains of amino acid residues. The terms peptide, oligopeptide and polypeptide are in the present invention also included in the definition of protein.

In the present invention, the expression “tumor-derived circRNA” is defined as “tumor-isolated circRNA” (or alternatively “circRNA isolated from tumor”).

In the present invention, the expression “protein derived from a tumor-derived circRNA” is defined as “protein encoded by tumor-derived circRNA” (or alternatively “protein expressed from tumor-derived circRNA”.

EXAMPLES Example 1—Tumor-derived circRNA

The method described in Example 1 is briefly illustrated in FIG. 3.

Tumor tissue is harvested from the patient and the total RNA content in the tumor cells are extracted with RNA isolation methodology used in the art. The circular RNA fraction is further enriched by for example enzyme digestion of linear RNA (by for example using RNAse R).

RNA quality control and content may be monitored by a combination of Bioanalyser (Agilent) and Qubit (Thermofisher) measurements or by similar instruments. circRNA is aliquoted and may be stored at −80° C. (or at other suitable temperatures) in different batches (e.g. vaccination and booster) ready to be administered to the patient after reconstituting the frozen batches with physiological buffer (such as Hanks Buffers Saline Solution/NaCl).

The endogenous tumor-derived circRNA prepared according to Example 1 comprises a nucleotide sequence selected from SEQ ID No: 1 to 299 (which are disclosed in Table 1 and the sequence listing) or homologous nucleotide sequences thereof having at least 80% homology. However, the present invention is not restricted to these specific sequences, and therefore, tumor-derived circRNA having other RNA sequences may be used for prophylaxis and/or treatment of disease.

The resulting vaccine is a therapeutic vaccine which is personalized for the patient from whom the tumor tissue has been harvested.

The personalized vaccine described in Example 1 is advantageous since it can be produced in 1-2 days. As a contrast, it takes several months, if not longer, to produce the vaccines described in the prior art.

The usability of the method described has been demonstrated in a pilot experiment where personalized therapeutic vaccination led to an increased immune activation against prostate cancer cells in two animal models (the Dunning Rat prostate cancer model and the TRAMP-C1 prostate cancer mouse model).

Example 2—Proteins from Tumor-Derived Circular RNA

The method described in Example 2 is briefly illustrated in FIG. 4.

Tumor tissue is harvested from the patient and the total RNA content in the tumor cells are extracted with RNA isolation methodology used in the art. The circular RNA fraction is further enriched by for example enzyme digestion of linear RNA (by for example using RNAse R).

RNA quality control and content may be monitored by a combination of Bioanalyser (Agilent) and Qubit (Thermofisher) measurements or by similar instruments. circRNA is aliquoted and may be stored at −80° C. (or at other suitable temperatures) in different batches.

The neoantigen proteins which can be expressed by circRNA are identified by using one or more of the following methods:

-   -   RNA sequencing     -   protein mass-spectrometry     -   In vitro translation     -   Prediction of MHC class I/II-binding

The next step in the method involves the identification of personalized/general potential of the neoantigen protein as immunogen by using one or more of the following methods:

-   -   In vitro stimulation of T-cells from patients with neo-antigens         and detection of specific T cell responses by standard         immunological assays, such as immune cell proliferation of         cytokine production by Flow cytometry or ELISpot Determination         of B cell-responses to neoantigen by standard immunological         assays (such as ELISA/ELISpot)

The proteins derived from the tumor-derived circRNA isolated according to the method described in Example 2 comprise a protein sequence selected from SEQ ID No: 300 to 598 (which are disclosed in Table 1 and the sequence listing). However, the present invention is not restricted to these specific sequences, and therefore, proteins derived from tumor-derived circRNA having other protein sequences may be used for prophylaxis and/or treatment of disease.

The proteins can be extracted from tumor cells. Moreover, the proteins can also be prepared by liquid-phase synthesis [11,13], solid-phase synthesis [11,13] or by an expression vector [12,13], or by any other method known in the art.

The proteins can also be synthesized by the patient's cell by genetic vaccination or gene therapy with DNA or RNA vectors coding for neoantigen sequences corresponding to a tumor-derived circRNA sequence.

EXPERIMENTS

Rat Experiment:

-   1. Total RNA was isolated from MAT-Ly-Lu (Dunning R-3327 prostate     cancer animal model) cells. -   2. Linear RNA was digested with RNAse R (Epicenter) to enrich for     circRNA (1U RNAse R/ug total RNA). The digest total RNA was     cleaned-up (Agencourt RNAClean XP), and yielded 12 vaccine doses of     30 ug circRNA per dose. -   3. Vaccine was prepared for the four Copenhagen rats: One dose (30     ug) circRNA was mixed with physiological NaCl solution to a volume     of 100 ul, and the prepared “vaccine” was injected intradermal,     close to the inguinal lymph nodes in four Copenhagen rats. Resulting     in a dose of 80 ug circRNA/kg animal. -   4. To four rats in a control group, 100 ul physiological NaCl     solution was injected in the same way as in the vaccination group. -   5. Time plan: Vaccination took place during three weeks before     injecting 10.000 MAT-Ly-Lu cells within prostate. In brief, at day 0     the first dose was administered, and the second and third was     injected at day 7 and day 14. At day 21, ten thousand MAT-Ly-Lu     cells was injected into the prostate, and at day 35 the animal was     sacrificed. -   6. Sample collected: Spleen and lymph nodes where collected, as well     as prostate tumor and lung. -   7. Analysis: Immune activation was measured by labelling     splenocytes/lymphocytes with CFSE and exposing them to mitomycin     C-treated MAT-Ly-Lu cells for 5 days. Cells were then labelled with     anti-CD8 and anti-CD4 and subjected to flow cytometry. Activation     and subsequent proliferation of CD4+ and CD8+ T cells were measured     as a decrease in CFSE-intensity (the CFSE is diluted in cells upon     cell division). The necrotic tumor areas within the tumor was also     investigated and measured between the control group and the     vaccinated group. -   8. Results: The main mediators of tumor induced immune response are     the CD8+ T-cells, the so called cytotoxic T-cells. These cells are     well-known to mediate tumor cell elimination of cells expressing     neoantigen epitopes on their MHC-I complexes. Interestingly there     was a more than threefold induction of proliferation in 50% of the     animals (2/4) of the CD8+ T-cells after in vitro exposure to     MAT-Ly-Lu cells (2:1 spleenocyte/tumor cell ratio), indicative that     two rats have acquired an adaptive immune response against the tumor     (see FIGS. 5 and 6). In line with an increased CD8+ T-cell activity     there was also a trend toward an increased tumor cell death and     necrotic area in vaccinated animals (see FIG. 8). There was no     difference in induced CD4 activity between vaccinated rats and a     control rat group (see FIG. 7). -   9. Summary: We could see an increased mobilization of the adaptive     immune system toward the tumor cells after administration of a     circRNA vaccination program.

Mouse Experiment:

-   1. Total RNA was isolated from TRAMP-C1 (prostate cancer mouse cell     line with C57BL/6 background) cells. -   2. Linear RNA was digested with RNAse R (Epicenter) to enrich for     circRNA (1U RNAse R/ug total RNA). The digest total RNA was     cleaned-up (Agencourt RNAClean XP), and yielded RNA for eight     vaccine doses of 10 ug circRNA per dose. -   3. Vaccine was prepared for the four C57BL/6 mice: One dose (10 ug)     circRNA was prepared as following, 5 ug circRNA was prepared with 5     ug protamine, incubated 30 min RT for complex binding and then     another 5 ug of circRNA was added to the tube in a volume of 100 ul     in ringers salt solution. The prepared “vaccine” was injected     intradermal, on the flanks close to the groins. Resulting in a dose     of −300 ug circRNA/kg animal. -   4. To four mice in a control group, 100 ul ringers salt solution     containing 5 ug of protamine was injected in the same way as in the     vaccination group. -   5. Time plan: Animals were vaccinated day 0 and day 14, and then     sacrificed on day 21. -   6. Sample collected: Spleens where collected. -   7. Analysis: Single cell suspension of CFSE-labelled splenocytes     were co-incubated with lysate from TRAMP-C1 cells for 4-5 days.     Proliferation/activation of B and T cells was measured as reduced     CFSE-intensity on B220+ B cells, CD8+ T cells or CD4+ T cells by     flow cytometry. -   8. Results: The tumor induced immune response were a pronounced     effect seen among the CD4+ T-cell (FIG. 9a ) and the B-cells (FIG.     9b ), with minimal effect on the CD8+ T-cells (FIG. 9c ). In this     experiment the mice had not been exposed to the tumor cells in     question before analysis, contrary to in the rat experiment     (discussed above) where the rats had known the tumor cells for two     weeks and thereby triggering a potential immune response. -   9. Summary: We could see an increased mobilization of the adaptive     immune system toward the tumor cells after administration of a     circRNA vaccination program.

TABLE 1 SEQ KLK3 neo- ID NO antigen cRNA/protein DNA sequence RNA sequence Protein sequence   1   1/300 TTGCTAGGAAAAGAAATCAGCAGACACAGGTGTA UUGCUAGGAAAAGAAAUCAGCAGACACAG LLGKEISRHRCRPECFLNGVILSSLCPGEY GACCAGAGTGTTTCTTAAATGGTGTAATTTTGTCC GUGUAGACCAGAGUGUUUCUUAAAUGGU WPCLETYHSISLRTQIGWGVCVICGVQR TCTCTGTGTCCTGGGGAATACTGGCCATGCCTGGA GUAAUUUUGUCCUCUCUGUGUCCUGGGG GACATATCACTCAATTTCTCTGAGGACACAGATAG AAUACUGGCCAUGCCUGGAGACAUAUCAC GATGGGGTGTCTGTGTTATTTGTGGGGTACAGAG UCAAUUUCUCUGAGGACACAGAUAGGAUG ATGA GGGUGUCUGUGUUAUUUGUGGGGUACAG AGAUGA   2   2/301 ATGTGCCCTGCCCGAAAGGCCTTCCCTGTACACCA AUGUGCCCUGCCCGAAAGGCCUUCCCUGU MCPARKAFPVHQGGALPEVDQGHHRG AGGTGGTGCATTACCGGAAGTGGATCAAGGACAC ACACCAAGGUGGUGCAUUACCGGAAGUGG QPLSTPINPLL CATCGTGGCCAACCCCTGAGCACCCCTATCAACCC AUCAAGGACACCAUCGUGGCCAACCCCUGA CCTATTGTAG GCACCCCUAUCAACCCCCUAUUGUAG   3   3/302 GTGTCTGTGTTATTTGTGGGGTACAGAGATGAAA GUGUCUGUGUUAUUUGUGGGGUACAGAG VSVLFVGYRDERGVGSTLREWRVTCAGH GAGGGGTGGGATCCACACTGAGAGAGTGGAGAG AUGAAAGAGGGGUGGGAUCCACACUGAGA CP TGACATGTGCTGGACACTGTCCATGA GAGUGGAGAGUGACAUGUGCUGGACACU GUCCAUGA   4   4/303 TTGTCCTTAGGTGTGAGGTCCAGGGTTGCTAGGA UUGUCCUUAGGUGUGAGGUCCAGGGUUG LSLGVRSRVARKRNQQTQV AAAGAAATCAGCAGACACAGGTGTAG CUAGGAAAAGAAAUCAGCAGACACAGGUG UAG   5   5/304 GTGTTTCTTAAATGGTGTAATTTTGTCCTCTCTGTG GUGUUUCUUAAAUGGUGUAAUUUUGUCC VFLKWCNFVLSVSWGILAMPGDISLNFS TCCTGGGGAATACTGGCCATGCCTGGAGACATAT UCUCUGUGUCCUGGGGAAUACUGGCCAUG EDTDRMGCLCYLWGTEMKEGWDPH CACTCAATTTCTCTGAGGACACAGATAGGATGGG CCUGGAGACAUAUCACUCAAUUUCUCUGA GTGTCTGTGTTATTTGTGGGGTACAGAGATGAAA GGACACAGAUAGGAUGGGGUGUCUGUGU GAGGGGTGGGATCCACACTGA UAUUUGUGGGGUACAGAGAUGAAAGAGG GGUGGGAUCCACACUGA   6   6/305 GTGCTGGACACTGTCCATGAAGCACTGAGCAGAA GUGCUGGACACUGUCCAUGAAGCACUGAG VLDTVHEALSRSWRHNAPDTHSKDGAE GCTGGAGGCACAACGCACCAGACACTCACAGCAA CAGAAGCUGGAGGCACAACGCACCAGACAC NITHSVLEALGSLEKAVSQGGRVFLWHG GGATGGAGCTGAAAACATAACCCACTCTGTCCTG UCACAGCAAGGAUGGAGCUGAAAACAUAA MGMK GAGGCACTGGGAAGCCTAGAGAAGGCTGTGAGC CCCACUCUGUCCUGGAGGCACUGGGAAGC CAAGGAGGGAGGGTCTTCCTTTGGCATGGGATGG CUAGAGAAGGCUGUGAGCCAAGGAGGGAG GGATGAAGTAA GGUCUUCCUUUGGCAUGGGAUGGGGAUG AAGUAA   7 (BSS)   7/306 TTGAGCCCCAAGCTTACCACCTGCACCCGGAGAGC UUGAGCCCCAAGCUUACCACCUGCACCCGG LSPKLTTCTRRAVSPCGSRLSSSPCP TGTGTCACCATGTGGGTCCCGGTTGTCTTCCTCAC AGAGCUGUGUCACCAUGUGGGUCCCGGUU CCTGTCCGTGA GUCUUCCUCACCCUGUCCGUGA   8 (BSS)   8/307 GTGCTGCACCCCTCATCCTGTCTCGGATTGTGGGA GUGCUGCACCCCUCAUCCUGUCUCGGAUU VLHPSSCLGLWEAGSARSIPNPGRCLWP GGCTGGGAGTGCGAGAAGCATTCCCAACCCTGGC GUGGGAGGCUGGGAGUGCGAGAAGCAUU LVAGQSAAVFWCTPSGSSQLPTASGSAA AGGTGCTTGTGGCCTCTCGTGGCAGGGCAGTCTG CCCAACCCUGGCAGGUGCUUGUGGCCUCU PLILSRIVGGWECEKHSQPWQVLVASRG CGGCGGTGTTCTGGTGCACCCCCAGTGGGTCCTC CGUGGCAGGGCAGUCUGCGGCGGUGUUC RAVCGGVLVHPQWVLTAAHCIR ACAGCTGCCCACTGCATCAGGAAGTGCTGCACCCC UGGUGCACCCCCAGUGGGUCCUCACAGCU TCATCCTGTCTCGGATTGTGGGAGGCTGGGAGTG GCCCACUGCAUCAGGAAGUGCUGCACCCCU CGAGAAGCATTCCCAACCCTGGCAGGTGCTTGTG CAUCCUGUCUCGGAUUGUGGGAGGCUGG GCCTCTCGTGGCAGGGCAGTCTGCGGCGGTGTTC GAGUGCGAGAAGCAUUCCCAACCCUGGCA TGGTGCACCCCCAGTGGGTCCTCACAGCTGCCCAC GGUGCUUGUGGCCUCUCGUGGCAGGGCA TGCATCAGG GUCUGCGGCGGUGUUCUGGUGCACCCCCA GUGGGUCCUCACAGCUGCCCACUGCAUCA GG   9 (BSS)   9/308 CTGGGAGTGCGAGAAGCATTCCCAACCCTGGCAG CUGGGAGUGCGAGAAGCAUUCCCAACCCU LGVREAFPTLAGACGLSWQGSLRRCSGA GTGCTTGTGGCCTCTCGTGGCAGGGCAGTCTGCG GGCAGGUGCUUGUGGCCUCUCGUGGCAG PPVGPHSCPLHQEVLHPSSCLGLWEAGS GCGGTGTTCTGGTGCACCCCCAGTGGGTCCTCACA GGCAGUCUGCGGCGGUGUUCUGGUGCACC ARSIPNPGRCLWPLVAGQSAAVFWCTPS GCTGCCCACTGCATCAGGAAGTGCTGCACCCCTCA CCCAGUGGGUCCUCACAGCUGCCCACUGCA GSSQLPTASG TCCTGTCTCGGATTGTGGGAGGCTGGGAGTGCGA UCAGGAAGUGCUGCACCCCUCAUCCUGUC GAAGCATTCCCAACCCTGGCAGGTGCTTGTGGCCT UCGGAUUGUGGGAGGCUGGGAGUGCGAG CTCGTGGCAGGGCAGTCTGCGGCGGTGTTCTGGT AAGCAUUCCCAACCCUGGCAGGUGCUUGU GCACCCCCAGTGGGTCCTCACAGCTGCCCACTGCA GGCCUCUCGUGGCAGGGCAGUCUGCGGCG TCAGGA GUGUUCUGGUGCACCCCCAGUGGGUCCUC ACAGCUGCCCACUGCAUCAGGA  10 (BSS)  10/309 GTGCTGGACGCTGGACAGGGGGCAAAAGCACCT GUGCUGGACGCUGGACAGGGGGCAAAAGC VLDAGQGAKAPARLDPKETSVCGPPCYF GCTCGTCTTGACCCCAAAGAAACTTCAGTGTGTGGACC UGCUCGUCUUGACCCCAAAGAAACUUC Q ACCTCCATGTTATTTCCAATGA AGUGUGUGGACCUCCAUGUUAUUUCCAAU GA  11 (BSS)  11/310 GTGTGCGCAAGTTCACCCTCAGAAGGTGACCAAG GUGUGCGCAAGUUCACCCUCAGAAGGUGA VCASSPSEGDQVHAVCWTLDRGQKHLL TTCATGCTGTGTGCTGGACGCTGGACAGGGGGCA CCAAGUUCAUGCUGUGUGCUGGACGCUGG VLTPKKLQCVDLHVISNDVCAQVHPQKV AAAGCACCTGCTCGTCTTGACCCCAAAGAAACTTC ACAGGGGGCAAAAGCACCUGCUCGUCUUG TKFMLCAGRWTGGKSTCS AGTGTGTGGACCTCCATGTTATTTCCAATGACGTG ACCCCAAAGAAACUUCAGUGUGUGGACCU TGTGCGCAAGTTCACCCTCAGAAGGTGACCAAGT CCAUGUUAUUUCCAAUGACGUGUGUGCGC TCATGCTGTGTGCTGGACGCTGGACAGGGGGCAA AAGUUCACCCUCAGAAGGUGACCAAGUUC AAGCACCTGCTCG AUGCUGUGUGCUGGACGCUGGACAGGGG GCAAAAGCACCUGCUCG  12 (BSS)  12/311 ATGTGCCCTGCCCGAAAGGCCTTCCCTGTACACCA AUGUGCCCUGCCCGAAAGGCCUUCCCUGU MCPARKAFPVHQGGALPEVDQGHHRG AGGTGGTGCATTACCGGAAGTGGATCAAGGACAC ACACCAAGGUGGUGCAUUACCGGAAGUGG QPLSTPINPLL CATCGTGGCCAACCCCTGAGCACCCCTATCAACCC AUCAAGGACACCAUCGUGGCCAACCCCUGA CCTATTGTAG GCACCCCUAUCAACCCCCUAUUGUAG  13 (BSS)  13/312 CTGATTCACTATGGGGGGAGGTGTATTGAAGTCC CUGAUUCACUAUGGGGGGAGGUGUAUUG LIHYGGRCIEVLQTTLRFDDFLVELTEIKSC TCCAGACAACCCTCAGATTTGATGATTTCCTAGTA AAGUCCUCCAGACAACCCUCAGAUUUGAU YTVGDSGGPLVCNGVLQGITSWGSEPCA GAACTCACAGAAATAAAGAGCTGTTATACTGTGG GAUUUCCUAGUAGAACUCACAGAAAUAAA LPERPSLYTKVVHYRKWIKDTIVANP GTGATTCTGGGGGCCCACTTGTCTGTAATGGTGTG GAGCUGUUAUACUGUGGGUGAUUCUGGG CTTCAAGGTATCACGTCATGGGGCAGTGAACCAT GGCCCACUUGUCUGUAAUGGUGUGCUUCA GTGCCCTGCCCGAAAGGCCTTCCCTGTACACCAAG AGGUAUCACGUCAUGGGGCAGUGAACCAU GTGGTGCATTACCGGAAGTGGATCAAGGACACCA GUGCCCUGCCCGAAAGGCCUUCCCUGUACA TCGTGGCCAACCCCTGA CCAAGGUGGUGCAUUACCGGAAGUGGAUC AAGGACACCAUCGUGGCCAACCCCUGA  14  14/313 GTGATCTTGCTGGGTCGGCACAGCCTGTTTCATCC GUGAUCUUGCUGGGUCGGCACAGCCUGUU VILLGRHSLFHPEDTGQVFQVSHSFPHPL (BSS + RCA) TGAAGACACAGGCCAGGTATTTCAGGTCAGCCAC UCAUCCUGAAGACACAGGCCAGGUAUUUC YDMSLLKNRFLRPGDDSSHDLMLLRLSEP AGCTTCCCACACCCGCTCTACGATATGAGCCTCCT AGGUCAGCCACAGCUUCCCACACCCGCUCU AELTDAVKVMDLPTQEPALGTTCYASG GAAGAATCGATTCCTCAGGCCAGGTGATGACTCC ACGAUAUGAGCCUCCUGAAGAAUCGAUUC WGSIEPEECAAPLILSRIVGGWECEKHSQ AGCCACGACCTCATGCTGCTCCGCCTGTCAGAGCC CUCAGGCCAGGUGAUGACUCCAGCCACGAC PWQVLVASRGRAVCGGVLVHPQWVLT TGCCGAGCTCACGGATGCTGTGAAGGTCATGGAC CUCAUGCUGCUCCGCCUGUCAGAGCCUGC AAHCIR CTGCCCACCCAGGAGCCAGCACTGGGGACCACCT CGAGCUCACGGAUGCUGUGAAGGUCAUGG GCTACGCCTCAGGCTGGGGCAGCATTGAACCAGA ACCUGCCCACCCAGGAGCCAGCACUGGGGA GGAGTGTGCTGCACCCCTCATCCTGTCTCGGATTG CCACCUGCUACGCCUCAGGCUGGGGCAGCA TGGGAGGCTGGGAGTGCGAGAAGCATTCCCAACC UUGAACCAGAGGAGUGUGCUGCACCCCUC CTGGCAGGTGCTTGTGGCCTCTCGTGGCAGGGCA AUCCUGUCUCGGAUUGUGGGAGGCUGGG GTCTGCGGCGGTGTTCTGGTGCACCCCCAGTGGG AGUGCGAGAAGCAUUCCCAACCCUGGCAG TCCTCACA GUGCUUGUGGCCUCUCGUGGCAGGGCAG UCUGCGGCGGUGUUCUGGUGCACCCCCAG UGGGUCCUCACA PCA3 neo- antigen DNA sequence RNA sequence Protein Sequence   1  15/314 CTGGCATCAGAAAAACAGAGGGGAGATTTGTGTG CUGGCAUCAGAAAAACAGAGGGGAGAUUU LASEKQRGDLCGCSRGRPGRSAWWEGP GCTGCAGCCGAGGGAGACCAGGAAGATCTGCAT GUGUGGCUGCAGCCGAGGGAGACCAGGAA DDTEVRNKKGC GGTGGGAAGGACCTGATGATACAGAGGTGAGAA GAUCUGCAUGGUGGGAAGGACCUGAUGA ATAAGAAAGGCTGCTGA UACAGAGGUGAGAAAUAAGAAAGGCUGCU GA   2  16/315 GTGCCTGGTCCCGCTTGTGAGGGAAGGACATTAG GUGCCUGGUCCCGCUUGUGAGGGAAGGAC VPGPACEGRTLENELMCSLKDGQENRSC AAAATGAATTGATGTGTTCCTTAAAGGATGGGCA AUUAGAAAAUGAAUUGAUGUGUUCCUUA CGYLFERDYRFEMKSQSEHYQ GGAAAACAGATCCTGTTGTGGATATTTATTTGAAC AAGGAUGGGCAGGAAAACAGAUCCUGUUG GGGATTACAGATTTGAAATGAAGTCACAAAGTGA UGGAUAUUUAUUUGAACGGGAUUACAGA GCATTACCAATGA UUUGAAAUGAAGUCACAAAGUGAGCAUUA CCAAUGA   3  17/316 ATGGAATACTGTGATGACATGAGGCAGCCAAGCT AUGGAAUACUGUGAUGACAUGAGGCAGCC MEYCDDMRQPSWGGDNHGAEGQDSG GGGGAGGAGATAACCACGGGGCAGAGGGTCAGG AAGCUGGGGAGGAGAUAACCACGGGGCAG PAA ATTCTGGCCCTGCTGCCTAA AGGGUCAGGAUUCUGGCCCUGCUGCCUAA   4  18/317 CTGATCTCTACGGTTCCTTCTGGGCCCAACATTCTC CUGAUCUCUACGGUUCCUUCUGGGCCCAA LISTVPSGPNILHISSHTHF CATATATCCAGCCACACTCATTTTTAA CAUUCUCCAUAUAUCCAGCCACACUCAUUU UUAA   5  19/318 GTGTTCTGGCCCAGGGGATCTGTGAACAGGCTGG GUGUUCUGGCCCAGGGGAUCUGUGAACAG VFWPRGSVNRLGSISRSFQGYTY GAAGCATCTCAAGATCTTTCCAGGGTTATACTTAC GCUGGGAAGCAUCUCAAGAUCUUUCCAGG TAG GUUAUACUUACUAG   6  20/319 GTGCCCATTCTCAAGACCTCAAAATGTCATTCCATT GUGCCCAUUCUCAAGACCUCAAAAUGUCA VPILKTSKCHSINITGLTFFFNLEEFNVTCS AATATCACAGGATTAACTTTTTTTTTTAACCTGGAA UUCCAUUAAUAUCACAGGAUUAACUUUUU YGNLITYFVFQCKDD GAATTCAATGTTACATGCAGCTATGGGAATTTAAT UUUUUAACCUGGAAGAAUUCAAUGUUACA TACATATTTTGTTTTCCAGTGCAAAGATGACTAA UGCAGCUAUGGGAAUUUAAUUACAUAUU UUGUUUUCCAGUGCAAAGAUGACUAA   7  21/320 TTGAACATGTCAGGCATACATTATTCCTTCTGCCTG UUGAACAUGUCAGGCAUACAUUAUUCCUU LNMSGIHYSFCLRSSSLSLKSRMM AGAAGCTCTTCCTTGTCTCTTAAATCTAGAATGAT CUGCCUGAGAAGCUCUUCCUUGUCUCUUA GTAA AAUCUAGAAUGAUGUAA   8  22/321 CTGGCAATAAAGAATTTACAAAGAGCTACTCAGG CUGGCAAUAAAGAAUUUACAAAGAGCUAC LAIKNLQRATQDQLLRALCVCVCV ACCAGTTGTTAAGAGCTCTGTGTGTGTGTGTGTGT UCAGGACCAGUUGUUAAGAGCUCUGUGU GTGTGA GUGUGUGUGUGUGUGUGA   9  23/322 GTGTACATGCCAAAGTGTGCCTCTCTCTCTTTGAC GUGUACAUGCCAAAGUGUGCCUCUCUCUC VYMPKCASLSLTHYFRLKNKHVFKWHYE CCATTATTTCAGACTTAAAAACAAGCATGTTTTCAA UUUGACCCAUUAUUUCAGACUUAAAAACA LPMMYHHHISLFSSKCDNNVIC ATGGCACTATGAGCTGCCAATGATGTATCACCACC AGCAUGUUUUCAAAUGGCACUAUGAGCUG ATATCTCATTATTCTCCAGTAAATGTGATAATAATG CCAAUGAUGUAUCACCACCAUAUCUCAUU TCATCTGTTAA AUUCUCCAGUAAAUGUGAUAAUAAUGUCA UCUGUUAA  10  24/323 TTGACTTCACAAAAGCAGCTGGAAATGGACAACC UUGACUUCACAAAAGCAGCUGGAAAUGGA LTSQKQLEMDNHNMHKSNSYHQLHTA ACAATATGCATAAATCTAACTCCTACCATCAGCTA CAACCACAAUAUGCAUAAAUCUAACUCCUA CACACTGCTTGA CCAUCAGCUACACACUGCUUGA  11  25/324 CTGAGCTGTCATCGTCCCCATCTCTGTGAGCCACA CUGAGCUGUCAUCGUCCCCAUCUCUGUGA LSCHRPHLCEPQPTAGPNACLRSLNQGN ACCAACAGCAGGACCCAACGCATGTCTGAGATCC GCCACAACCAACAGCAGGACCCAACGCAUG QCHELNSPIMDASFWPSLALLLTHISF TTAAATCAAGGAAACCAGTGTCATGAGTTGAATTC UCUGAGAUCCUUAAAUCAAGGAAACCAGU TCCTATTATGGATGCTAGCTTCTGGCCATCTCTGG GUCAUGAGUUGAAUUCUCCUAUUAUGGA CTCTCCTCTTGACACATATTAGCTTCTAG UGCUAGCUUCUGGCCAUCUCUGGCUCUCC UCUUGACACAUAUUAGCUUCUAG  12  26/325 TTGCTTCCACGACTTTTATCTTTTCTCCAACACATC UUGCUUCCACGACUUUUAUCUUUUCUCCA LLPRLLSFLQHIAYQSSLCSVALDFPTRIST GCTTACCAATCCTCTCTCTGCTCTGTTGCTTTGGAC ACACAUCGCUUACCAAUCCUCUCUCUGCUC TLKSFLPSPPLT TTCCCCACAAGAATTTCAACGACTCTCAAGTCTTTT UGUUGCUUUGGACUUCCCCACAAGAAUUU CTTCCATCCCCACCACTAACCTGA CAACGACUCUCAAGUCUUUUCUUCCAUCCC CACCACUAACCUGA  13  27/326 ATGCCTAGACCCTTATTTTTATTAATTTCCAATAGA AUGCCUAGACCCUUAUUUUUAUUAAUUUC MPRPLFLLISNRCCLWAILL TGCTGCCTATGGGCTATATTGCTTTAG CAAUAGAUGCUGCCUAUGGGCUAUAUUGC UUUAG  14  28/327 ATGAACATTAGATATTTAAAGCTCAAGAGGTTCAA AUGAACAUUAGAUAUUUAAAGCUCAAGAG MNIRYLKLKRFKIQLIIFSFFHLPAPLPILLIA AATCCAACTCATTATCTTCTCTTTCTTTCACCTCCCT GUUCAAAAUCCAACUCAUUAUCUUCUCUU LNSMVPNVAMQMRNPVAPCGTCMQD GCTCCTCTCCCTATATTACTGATTGCACTGAACAGC UCUUUCACCUCCCUGCUCCUCUCCCUAUAU C ATGGTCCCCAATGTAGCCATGCAAATGAGAAACC UACUGAUUGCACUGAACAGCAUGGUCCCC CAGTGGCTCCTTGTGGTACATGCATGCAAGACTGC AAUGUAGCCAUGCAAAUGAGAAACCCAGU TGA GGCUCCUUGUGGUACAUGCAUGCAAGACU GCUGA  15  29/328 GTGCCGAGAAGCTGGCATCAGAAAAACAGAGGG GUGCCGAGAAGCUGGCAUCAGAAAAACAG VPRSWHQKNRGEICVAAAEGDQEDLHG GAGATTTGTGTGGCTGCAGCCGAGGGAGACCAG AGGGGAGAUUUGUGUGGCUGCAGCCGAG GKDLMIQR GAAGATCTGCATGGTGGGAAGGACCTGATGATAC GGAGACCAGGAAGAUCUGCAUGGUGGGAA AGAGGTGA GGACCUGAUGAUACAGAGGUGA  16  30/329 ATGTTTTTGCACATTTCCAGCCCCTTTAAATATCCA AUGUUUUUGCACAUUUCCAGCCCCUUUAA MFLHISSPFKYPHTQEAQKEAQRSLGEM CACACACAGGAAGCACAAAAGGAAGCACAGAGA AUAUCCACACACACAGGAAGCACAAAAGGA PGRHLGSSMSLALCLVPLVREGH TCCCTGGGAGAAATGCCCGGCCGCCATCTTGGGT AGCACAGAGAUCCCUGGGAGAAAUGCCCG CATCGATGAGCCTCGCCCTGTGCCTGGTCCCGCTT GCCGCCAUCUUGGGUCAUCGAUGAGCCUC GTGAGGGAAGGACATTAG GCCCUGUGCCUGGUCCCGCUUGUGAGGGA AGGACAUUAG  17  31/330 ATGGGCAGGAAAACAGATCCTGTTGTGGATATTT AUGGGCAGGAAAACAGAUCCUGUUGUGGA MGRKTDPVVDIYLNGITDLK ATTTGAACGGGATTACAGATTTGAAATGA UAUUUAUUUGAACGGGAUUACAGAUUUG AAAUGA  18  32/331 GTGAGCATTACCAATGAGAGGAAAACAGACGAG GUGAGCAUUACCAAUGAGAGGAAAACAGA VSITNERKTDEKILMASQDMQQTKWNT AAAATCTTGATGGCTTCACAAGACATGCAACAAAC CGAGAAAAUCUUGAUGGCUUCACAAGACA VMT AAAATGGAATACTGTGATGACATGA UGCAACAAACAAAAUGGAAUACUGUGAUG ACAUGA  19  33/332 GTGAATTATCTAATCAACATCATCCTCAGTGTCTTT GUGAAUUAUCUAAUCAACAUCAUCCUCAG VNYLINIILSVFAHTEIHFPLLCPFSRPQNVI GCCCATACTGAAATTCATTTCCCACTTTTGTGCCCA UGUCUUUGCCCAUACUGAAAUUCAUUUCC PLISQD TTCTCAAGACCTCAAAATGTCATTCCATTAATATCA CACUUUUGUGCCCAUUCUCAAGACCUCAA CAGGATTAA AAUGUCAUUCCAUUAAUAUCACAGGAUUA A  20  34/333 TTGTTTTCCAGTGCAAAGATGACTAAGTCCTTTATC UUGUUUUCCAGUGCAAAGAUGACUAAGUC LFSSAKMTKSFIPPLCLIFFPV CCTCCCCTTTGTTTGATTTTTTTTCCAGTATA CUUUAUCCCUCCCCUUUGUUUGAUUUUU UUUCCAGUAUA  21  35/334 ATGCAAGAGCCACAGAGGGAATGTTTATGGGGCA AUGCAAGAGCCACAGAGGGAAUGUUUAUG MQEPQRECLWGTFVSLGCEAKAGNLIVS CGTTTGTAAGCCTGGGATGTGAAGCAAAGGCAGG GGGCACGUUUGUAAGCCUGGGAUGUGAA YIIYFISLSLSQYPTSFSQNSCSANPQR GAACCTCATAGTATCTTATATAATATACTTCATTTC GCAAAGGCAGGGAACCUCAUAGUAUCUUA TCTATCTCTATCACAATATCCAACAAGCTTTTCACA UAUAAUAUACUUCAUUUCUCUAUCUCUAU GAATTCATGCAGTGCAAATCCCCAAAGGTAA CACAAUAUCCAACAAGCUUUUCACAGAAU UCAUGCAGUGCAAAUCCCCAAAGGUAA  22  36/335 GTGGGTTCTCTTAAGCAAAATACTTGCATTAGGTC GUGGGUUCUCUUAAGCAAAAUACUUGCAU VGSLKQNTCIRSQLGLCIRRFEKYSILSRSQ TCAGCTGGGGCTGTGCATCAGGCGGTTTGAGAAA UAGGUCUCAGCUGGGGCUGUGCAUCAGGC NLNSLIF TATTCAATTCTCAGCAGAAGCCAGAATTTGAATTC GGUUUGAGAAAUAUUCAAUUCUCAGCAGA CCTCATCTTTTAG AGCCAGAAUUUGAAUUCCCUCAUCUUUUA G  23  37/336 CTGTCCCTCTTTGTGTTCATGGATAGTCCAATAAAT CUGUCCCUCUUUGUGUUCAUGGAUAGUCC LSLFVFMDSPINNVIFELMLIGENIRTLSDI AATGTTATCTTTGAACTGATGCTCATAGGAGAGAA AAUAAAUAAUGUUAUCUUUGAACUGAUGC NIRDSKKY TATAAGAACTCTGAGTGATATCAACATTAGGGATT UCAUAGGAGAGAAUAUAAGAACUCUGAGU CAAAGAAATATTAG GAUAUCAACAUUAGGGAUUCAAAGAAAUA UUAG  24  38/337 CTGTTGCTTTGGACTTCCCCACAAGAATTTCAACG CUGUUGCUUUGGACUUCCCCACAAGAAUU LLLWTSPQEFQRLSSLFFHPHH ACTCTCAAGTCTTTTCTTCCATCCCCACCACTAA UCAACGACUCUCAAGUCUUUUCUUCCAUC CCCACCACUAA  25  39/338 GTGGTACATGCATGCAAGACTGCTGAAGCCAGAA GUGGUACAUGCAUGCAAGACUGCUGAAGC VVHACKTAEARRMTDYASWVEGTTPGP GGATGACTGATTACGCCTCATGGGTGGAGGGGAC CAGAAGGAUGACUGAUUACGCCUCAUGGGS CACTCCTGGGCCTTCGTGA UGGAGGGGACCACUCCUGGGCCUUCGUGA  26  40/339 TTGTCAGGAGCAAGACCTGAGATGCTCCCTGCCTT UUGUCAGGAGCAAGACCUGAGAUGCUCCC LSGARPEMLPAFSVLCISPF CAGTGTCCTCTGCATCTCCCCTTTCTAA UGCCUUCAGUGUCCUCUGCAUCUCCCCUU UCUAA  27  41/340 TTGGCATACTATATCAACTTTGATTCTTTGTTACAA UUGGCAUACUAUAUCAACUUUGAUUCUU LAYYINFDSLLQLFLLFYHQSGFYSLYYYYF CTTTTCTTACTCTTTTATCACCAAAGTGGCTTTTATT UGUUACAACUUUUCUUACUCUUUUAUCAC LLLLYYVVIILFSIVSIYLI CTCTTTATTATTATTATTTTCTTTTACTACTATATTA CAAAGUGGCUUUUAUUCUCUUUAUUAUU CGTTGTTATTATTTTGTTCTCTATAGTATCAATTTAT AUUAUUUUCUUUUACUACUAUAUUACGU TTGATTTAG UGUUAUUAUUUUGUUCUCUAUAGUAUCA AUUUAUUUGAUUUAG  28  42/341 GTGACATGTTTTTGCACATTTCCAGCCCCTTTAAAT GUGACAUGUUUUUGCACAUUUCCAGCCCC VTCFCTFPAPLNIHTHRKHKRKHRDPWE ATCCACACACACAGGAAGCACAAAAGGAAGCACA UUUAAAUAUCCACACACACAGGAAGCACAA KCPAAILGHR GAGATCCCTGGGAGAAATGCCCGGCCGCCATCTT AAGGAAGCACAGAGAUCCCUGGGAGAAAU GGGTCATCGATGA GCCCGGCCGCCAUCUUGGGUCAUCGAUGA  29  43/342 GTGACCTTTCTACACTGTAGAATAACATTACTCATT GUGACCUUUCUACACUGUAGAAUAACAUU VTFLHCRITLLILFKDPSCCCLICS TTGTTCAAAGACCCTTCGTGTTGCTGCCTAATATGT ACUCAUUUUGUUCAAAGACCCUUCGUGUU AGCTGA GCUGCCUAAUAUGUAGCUGA  30  44/343 CTGTTTTTCCTAAGGAGTGTTCTGGCCCAGGGGAT CUGUUUUUCCUAAGGAGUGUUCUGGCCCA LFFLRSVLAQGICEQAGKHLKIFPGLYLLA CTGTGAACAGGCTGGGAAGCATCTCAAGATCTTTC GGGGAUCUGUGAACAGGCUGGGAAGCAUC HSMIITE CAGGGTTATACTTACTAGCACACAGCATGATCATT UCAAGAUCUUUCCAGGGUUAUACUUACUA ACGGAGTGA GCACACAGCAUGAUCAUUACGGAGUGA  31  45/344 GTGTCTTTGCCCATACTGAAATTCATTTCCCACTTT GUGUCUUUGCCCAUACUGAAAUUCAUUUC VSLPILKFISHFCAHSQDLKMSFH TGTGCCCATTCTCAAGACCTCAAAATGTCATTCCAT CCACUUUUGUGCCCAUUCUCAAGACCUCA TAA AAAUGUCAUUCCAUUAA  32  46/345 ATGCTTAGCCTTGTACTGAGGCTGTATACAGCCAC AUGCUUAGCCUUGUACUGAGGCUGUAUAC MLSLVLRLYTATASPHPSSLICHHHQPLPC AGCCTCTCCCCATCCCTCCAGCCTTATCTGTCATCA AGCCACAGCCUCUCCCCAUCCCUCCAGCCU T CCATCAACCCCTCCCATGCACCTAA UAUCUGUCAUCACCAUCAACCCCUCCCAUG CACCUAA  33  47/346 ATGCAAAGAAGGGACACATATGAGATTCATCATC AUGCAAAGAAGGGACACAUAUGAGAUUCA MQRRDTYEIHHHMRQQILKV ACATGAGACAGCAAATACTAAAAGTGTAA UCAUCACAUGAGACAGCAAAUACUAAAAG UGUAA  34  48/347 GTGCAAATCCCCAAAGGTAACCTTTATCCATTTCAT GUGCAAAUCCCCAAAGGUAACCUUUAUCC VQIPKGNLYPFHGECALEFWQIILVTYLNF GGTGAGTGCGCTTTAGAATTTTGGCAAATCATACT AUUUCAUGGUGAGUGCGCUUUAGAAUUU EMCLSL GGTCACTTATCTCAACTTTGAGATGTGTTTGTCCTT UGGCAAAUCAUACUGGUCACUUAUCUCAA GTAG CUUUGAGAUGUGUUUGUCCUUGUAG  35  49/348 GTGTGTGTGTGTGTGTGTGTGAGTGTACATGCCA GUGUGUGUGUGUGUGUGUGUGAGUGUA VCVCVCVSVHAKVCLSLFDPLFQT AAGTGTGCCTCTCTCTCTTTGACCCATTATTTCAGA CAUGCCAAAGUGUGCCUCUCUCUCUUUGA CTTAA CCCAUUAUUUCAGACUUAA  36  50/349 TTGACATATATTGTTAGAAGCACCTCGCATTTGTG UUGACAUAUAUUGUUAGAAGCACCUCGCA LTYIVRSTSHLWVLLSKILALGLSWGCASG GGTTCTCTTAAGCAAAATACTTGCATTAGGTCTCA UUUGUGGGUUCUCUUAAGCAAAAUACUU GLRNIQFSAEARI GCTGGGGCTGTGCATCAGGCGGTTTGAGAAATAT GCAUUAGGUCUCAGCUGGGGCUGUGCAUC TCAATTCTCAGCAGAAGCCAGAATTTGA AGGCGGUUUGAGAAAUAUUCAAUUCUCAG CAGAAGCCAGAAUUUGA  37  51/350 TTGGAGAGGATTCAGACAGCTCAGGTGCTTTCACT UUGGAGAGGAUUCAGACAGCUCAGGUGCU LERIQTAQVLSLMSLNFCPSLCSWIVQ AATGTCTCTGAACTTCTGTCCCTCTTTGTGTTCATG UUCACUAAUGUCUCUGAACUUCUGUCCCU GATAGTCCAATAA CUUUGUGUUCAUGGAUAGUCCAAUAA  38  52/351 GTGATATCAACATTAGGGATTCAAAGAAATATTAG GUGAUAUCAACAUUAGGGAUUCAAAGAAA VISTLGIQRNIRFKLTLVKRNQDTKNSELS ATTTAAGCTCACACTGGTCAAAAGGAACCAAGAT UAUUAGAUUUAAGCUCACACUGGUCAAAA SSPSL ACAAAGAACTCTGAGCTGTCATCGTCCCCATCTCT GGAACCAAGAUACAAAGAACUCUGAGCUG GTGA UCAUCGUCCCCAUCUCUGUGA  39  53/352 CTGCTCTGTTGCTTTGGACTTCCCCACAAGAATTTC CUGCUCUGUUGCUUUGGACUUCCCCACAA LLCCFGLPHKNFNDSQVFSSIPTTNLNA AACGACTCTCAAGTCTTTTCTTCCATCCCCACCACT GAAUUUCAACGACUCUCAAGUCUUUUCUU AACCTGAATGCCTAG CCAUCCCCACCACUAACCUGAAUGCCUAG  40  54/353 CTGATTACGCCTCATGGGTGGAGGGGACCACTCC CUGAUUACGCCUCAUGGGUGGAGGGGACC ITPHGWRGPLLGLRDCQEQDLRCSLPSVS TGGGCCTTCGTGATTGTCAGGAGCAAGACCTGAG ACUCCUGGGCCUUCGUGAUUGUCAGGAGC SASPLSNEDP ATGCTCCCTGCCTTCAGTGTCCTCTGCATCTCCCCT AAGACCUGAGAUGCUCCCUGCCUUCAGUG TTCTAATGAAGATCCATAG UCCUCUGCAUCUCCCCUUUCUAAUGAAGA UCCAUAG  41  55/354 TTGCTACATTTGAGAATTCCAATTAGGAACTCACA UUGCUACAUUUGAGAAUUCCAAUUAGGAA LLHLRIPIRNSHVLSALSIF TGTTTTATCTGCCCTATCAATTTTTTAA CUCACAUGUUUUAUCUGCCCUAUCAAUUU UUUAA  42  56/355 GTGTCTTGGCATACTATATCAACTTTGATTCTTTGT GUGUCUUGGCAUACUAUAUCAACUUUGA VSWHTISTLILCYNFSYSFITKVAFILFIIIIFF TACAACTTTTCTTACTCTTTTATCACCAAAGTGGCT UUCUUUGUUACAACUUUUCUUACUCUUU YYYITLLLFCSL TTTATTCTCTTTATTATTATTATTTTCTTTTACTACTA UAUCACCAAAGUGGCUUUUAUUCUCUUUA TATTACGTTGTTATTATTTTGTTCTCTATAG UUAUUAUUAUUUUCUUUUACUACUAUAU UACGUUGUUAUUAUUUUGUUCUCUAUAG  43  57/356 TTGCTGACTTTTAAAATAAGTGATTCGGGGGGTG UUGCUGACUUUUAAAAUAAGUGAUUCGG LLTFKISDSGGGRTGEGEH GGAGAACAGGGGAGGGAGAGCATTAG GGGGUGGGAGAACAGGGGAGGGAGAGCA UUAG  44  58/357 GTGCAGCAAACCACTATGGCACACGTATACCTGTG GUGCAGCAAACCACUAUGGCACACGUAUA VQQTTMAHVYLCNKPTHSAHVSQNVK TAACAAACCTACACATTCTGCACATGTATCCCAGA CCUGUGUAACAAACCUACACAUUCUGCACA ACGTAAAGTAA UGUAUCCCAGAACGUAAAGUAA  45 (BSS)  59/358 GTGCAGCAAAGAAAGACTACAGACATCTCAATGG GUGCAGCAAAGAAAGACUACAGACAUCUC VQQRKTTDISMAGELQHIYLVFQ CAGGGGAATTACAACACATATACTTAGTGTTTCAA AAUGGCAGGGGAAUUACAACACAUAUACU TGA UAGUGUUUCAAUGA  46 (BSS)  60/359 GTGAGTCTCCTCAGTGACACAGGGCTGGATCACC GUGAGUCUCCUCAGUGACACAGGGCUGGA VSLLSDTGLDHHRRHFLSTQCSKERLQTS ATCGACGGCACTTTCTGAGTACTCAGTGCAGCAAA UCACCAUCGACGGCACUUUCUGAGUACUC QWQGNYNTYT GAAAGACTACAGACATCTCAATGGCAGGGGAATT AGUGCAGCAAAGAAAGACUACAGACAUCU ACAACACATATACTTAG CAAUGGCAGGGGAAUUACAACACAUAUAC UUAG  47 (BSS)  61/360 GTGACATGTTTTTGCACATTTCCAGCCCCTTTAAAT GUGACAUGUUUUUGCACAUUUCCAGCCCC VTCFCTFPAPLNIHTHRKHKRKHRGEK ATCCACACACACAGGAAGCACAAAAGGAAGCACA UUUAAAUAUCCACACACACAGGAAGCACAA GAGGTGAGAAATAA AAGGAAGCACAGAGGUGAGAAAUAA  48 (BSS)  62/361 GTGCAGCAAAGAAAGACTACAGACATCTCAATGG GUGCAGCAAAGAAAGACUACAGACAUCUC VQQRKTTDISMAGELQHIYLVFQ CAGGGGAATTACAACACATATACTTAGTGTTTCAA AAUGGCAGGGGAAUUACAACACAUAUACU TGA UAGUGUUUCAAUGA  49 (BSS)  63/362 ATGTTTTTGCACATTTCCAGCCCCTTTAAATATCCA AUGUUUUUGCACAUUUCCAGCCCCUUUAA MFLHISSPFKYPHTQEAQKEAQRNYNTY CACACACAGGAAGCACAAAAGGAAGCACAGAGG AUAUCCACACACACAGGAAGCACAAAAGGA T AATTACAACACATATACTTAG AGCACAGAGGAAUUACAACACAUAUACUU AG  50 (BSS)  64/363 GTGACATGTTTTTGCACATTTCCAGCCCCTTTAAAT GUGACAUGUUUUUGCACAUUUCCAGCCCC VTCFCTFPAPLNIHTHRKHKRKHRGITTHI ATCCACACACACAGGAAGCACAAAAGGAAGCACA UUUAAAUAUCCACACACACAGGAAGCACAA LSVSMNTKINK GAGGAATTACAACACATATACTTAGTGTTTCAATG AAGGAAGCACAGAGGAAUUACAACACAUA AACACCAAGATAAATAAGTGA UACUUAGUGUUUCAAUGAACACCAAGAUA AAUAAGUGA AR neo- antigen DNA sequence RNA sequence Protein sequence   1  65/364 CTGCCTTCCCCACCCCGAGTGCGGAGCCAGAGAT CUGCCUUCCCCACCCCGAGUGCGGAGCCAG LPSPPRVRSQRSKDEKAVRSSVAKKQNK CAAAAGATGAAAAGGCAGTCAGGTCTTCAGTAGC AGAUCAAAAGAUGAAAAGGCAGUCAGGUC QKQKSRNKRKR CAAAAAACAAAACAAACAAAAACAAAAAAGCCGA UUCAGUAGCCAAAAAACAAAACAAACAAAA AATAAAAGAAAAAGATAA ACAAAAAAGCCGAAAUAAAAGAAAAAGAUA A   2  66/365 TTGCACCTACTTCAGTGGACACTGAATTTGGAAGG UUGCACCUACUUCAGUGGACACUGAAUUU LHLLQWTLNLEGGGFCFFLLRSGHLLNLP TGGAGGATTTTGTTTTTTTCTTTTAAGATCTGGGCA GGAAGGUGGAGGAUUUUGUUUUUUUCUU FKY TCTTTTGAATCTACCCTTCAAGTATTAA UUAAGAUCUGGGCAUCUUUUGAAUCUACC CUUCAAGUAUUAA   3  67/366 GTGTCTTCTTCTGCACGAGACTTTGAGGCTGTCAG GUGUCUUCUUCUGCACGAGACUUUGAGGC VSSSARDFEAVRALFAWLLPQVSFSGASR AGCGCTTTTTGCGTGGTTGCTCCCGCAAGTTTCCTT UGUCAGAGCGCUUUUUGCGUGGUUGCUC RWAASCSDYRIITAC CTCTGGAGCTTCCCGCAGGTGGGCAGCTAGCTGC CCGCAAGUUUCCUUCUCUGGAGCUUCCCG AGCGACTACCGCATCATCACAGCCTGTTGA CAGGUGGGCAGCUAGCUGCAGCGACUACC GCAUCAUCACAGCCUGUUGA   4  68/367 CTGAGCAAGAGAAGGGGAGGCGGGGTAAGGGA CUGAGCAAGAGAAGGGGAGGCGGGGUAAG LSKRRGGGVREVGGRFSQAQGWKCS AGTAGGTGGAAGATTCAGCCAAGCTCAAGGATGG GGAAGUAGGUGGAAGAUUCAGCCAAGCUC AAGTGCAGTTAG AAGGAUGGAAGUGCAGUUAG   5  69/368 GTGAGGATGGTTCTCCCCAAGCCCATCGTAGAGG GUGAGGAUGGUUCUCCCCAAGCCCAUCGU VRMVLPKPIVEAPQATWSWMRNSNLH CCCCACAGGCTACCTGGTCCTGGATGAGGAACAG AGAGGCCCCACAGGCUACCUGGUCCUGGA SRSRPWSATPREVASQSLEPPWPPARGC CAACCTTCACAGCCGCAGTCGGCCCTGGAGTGCC UGAGGAACAGCAACCUUCACAGCCGCAGUC RSSCQHLRTRMTQLPHPRCPCWAPLSPA ACCCCGAGAGAGGTTGCGTCCCAGAGCCTGGAGC GGCCCUGGAGUGCCACCCCGAGAGAGGUU CGCCGTGGCCGCCAGCAAGGGGCTGCCGCAGCA GCGUCCCAGAGCCUGGAGCCGCCGUGGCC GCTGCCAGCACCTCCGGACGAGGATGACTCAGCT GCCAGCAAGGGGCUGCCGCAGCAGCUGCCA GCCCCATCCACGTTGTCCCTGCTGGGCCCCACTTT GCACCUCCGGACGAGGAUGACUCAGCUGC CCCCGGCTTAA CCCAUCCACGUUGUCCCUGCUGGGCCCCAC UUUCCCCGGCUUAA   6  70/369 CTGACAACGCCAAGGAGTTGTGTAAGGCAGTGTC CUGACAACGCCAAGGAGUUGUGUAAGGCA LTTPRSCVRQCRCPWAWVWRRWSI GGTGTCCATGGGCCTGGGTGTGGAGGCGTTGGA GUGUCGGUGUCCAUGGGCCUGGGUGUGG GCATCTGA AGGCGUUGGAGCAUCUGA   7  71/370 GTGTCAAAAGCGAAATGGGCCCCTGGATGGATAG GUGUCAAAAGCGAAAUGGGCCCCUGGAUG VSKAKWAPGWIATPDLTGTCVWRLPGT CTACTCCGGACCTTACGGGGACATGCGTTTGGAG GAUAGCUACUCCGGACCUUACGGGGACAU MFCPLTITFHPRRPA ACTGCCAGGGACCATGTTTTGCCCATTGACTATTA GCGUUUGGAGACUGCCAGGGACCAUGUUU CTTTCCACCCCAGAAGACCTGCCTGA UGCCCAUUGACUAUUACUUUCCACCCCAG AAGACCUGCCUGA   8  72/371 GTGGAGATGAAGCTTCTGGGTGTCACTATGGAGC GUGGAGAUGAAGCUUCUGGGUGUCACUA VEMKLLGVTMELSHVEAARSSSKEPLKG TCTCACATGTGGAAGCTGCAAGGTCTTCTTCAAAA UGGAGCUCUCACAUGUGGAAGCUGCAAGG NRSTCAPAEMIALLINSEGKIVHLVVFGN GAGCCGCTGAAGGGAAACAGAAGTACCTGTGCGC UCUUCUUCAAAAGAGCCGCUGAAGGGAAA VMKQG CAGCAGAAATGATTGCACTATTGATAAATTCCGAA CAGAAGUACCUGUGCGCCAGCAGAAAUGA GGAAAAATTGTCCATCTTGTCGTCTTCGGAAATGT UUGCACUAUUGAUAAAUUCCGAAGGAAAA TATGAAGCAGGGATGA AUUGUCCAUCUUGUCGUCUUCGGAAAUG UUAUGAAGCAGGGAUGA   9  73/372 TTGCATGCAAAAGAAAAAATCCCACATCCTGCTCA UUGCAUGCAAAAGAAAAAAUCCCACAUCCU LHAKEKIPHPAQDASTSSPSSWTPCSLLR AGACGCTTCTACCAGCTCACCAAGCTCCTGGACTC GCUCAAGACGCUUCUACCAGCUCACCAAGC ESCISSLLTC CGTGCAGCCTATTGCGAGAGAGCTGCATCAGTTC UCCUGGACUCCGUGCAGCCUAUUGCGAGA ACTTTTGACCTGCTAA GAGCUGCAUCAGUUCACUUUUGACCUGCU AA  10  74/373 CTGTGCAAGTGCCCAAGATCCTTTCTGGGAAAGTC CUGUGCAAGUGCCCAAGAUCCUUUCUGGGLC KCPRSFLGKSSPSISTPSEALETLFPHPS AAGCCCATCTATTTCCACACCCAGTGAAGCATTGG AAAGUCAAGCCCAUCUAUUUCCACACCCAG SCPLSDVFCLL AAACCCTATTTCCCCACCCCAGCTCATGCCCCCTTT UGAAGCAUUGGAAACCCUAUUUCCCCACCC CAGATGTCTTCTGCCTGTTATAA CAGCUCAUGCCCCCUUUCAGAUGUCUUCU GCCUGUUAUAA  11  75/374 ATGGTGTTGTATGCCTTTAAATCTGTGATGATCCT AUGGUGUUGUAUGCCUUUAAAUCUGUGA MVLYAFKSVMILIWPSVKLCLFTALLCAS CATATGGCCCAGTGTCAAGTTGTGCTTGTTTACAG UGAUCCUCAUAUGGCCCAGUGUCAAGUUG HTNVYLSYATGSLES CACTACTCTGTGCCAGCCACACAAACGTTTACTTA UGCUUGUUUACAGCACUACUCUGUGCCAG TCTTATGCCACGGGAAGTTTAGAGAGCTAA CCACACAAACGUUUACUUAUCUUAUGCCA CGGGAAGUUUAGAGAGCUAA  12  76/375 CTGGGGAAATCAAAACAAAAACAAGCAAACAAAA CUGGGGAAAUCAAAACAAAAACAAGCAAAC LGKSKQKQANKKKKQKQNKK AAAAAAAGCAAAAACAAAACAAAAAATAA AAAAAAAAAAAGCAAAAACAAAACAAAAAA UAA  13  77/376 GTGGAGCAATTCATTATACTGAAAATGTGCTTGTT GUGGAGCAAUUCAUUAUACUGAAAAUGU VEQFIILKMCLLLKICLHVNASPPNPFLSHS GTTGAAAATTTGTCTGCATGTTAATGCCTCACCCC GCUUGUUGUUGAAAAUUUGUCUGCAUGU LPPTSD CAAACCCTTTTCTCTCTCACTCTCTGCCTCCAACTTC UAAUGCCUCACCCCCAAACCCUUUUCUCUC AGATTGA UCACUCUCUGCCUCCAACUUCAGAUUGA  14  78/377 ATGTTCTCTTCAGCCAAAACTTGGCGACTTCCACA AUGUUCUCUUCAGCCAAAACUUGGCGACU MFSSAKTWRLPQKSLTTEKKESRDLTLCK GAAAAGTCTGACCACTGAGAAGAAGGAGAGCAG UCCACAGAAAAGUCUGACCACUGAGAAGA APFGSRSAFSCVSQGGAGARGEENDSLA AGATTTAACCCTTTGTAAGGCCCCATTTGGATCCA AGGAGAGCAGAGAUUUAACCCUUUGUAAG VLLLRTLTE GGTCTGCTTTCTCATGTGTGAGTCAGGGAGGAGC GCCCCAUUUGGAUCCAGGUCUGCUUUCUC TGGAGCCAGAGGAGAAGAAAATGATAGCTTGGCT AUGUGUGAGUCAGGGAGGAGCUGGAGCC GTTCTCCTGCTTAGGACACTGACTGAATAG AGAGGAGAAGAAAAUGAUAGCUUGGCUG UUCUCCUGCUUAGGACACUGACUGAAUAG  15  79/378 CTGCCAAACTCCGTGAAGCCACAAGCACCTTATGT CUGCCAAACUCCGUGAAGCCACAAGCACCU LPNSVKPQAPYVLPSVFCGPEFHHTAFQP CCTCCCTTCAGTGTTTTGTGGGCCTGAATTTCATCA UAUGUCCUCCCUUCAGUGUUUUGUGGGCC WSSSLFASFGHVHRFSVKSPHHQEG CACTGCATTTCAGCCATGGTCATCAAGCCTGTTTG UGAAUUUCAUCACACUGCAUUUCAGCCAU CTTCTTTTGGGCATGTTCACAGATTCTCTGTTAAGA GGUCAUCAAGCCUGUUUGCUUCUUUUGG GCCCCCACCACCAAGAAGGTTAG GCAUGUUCACAGAUUCUCUGUUAAGAGCC CCCACCACCAAGAAGGUUAG  16  80/379 GTGGGAAGAATGAAGGCACTAGAACCAGAAACC GUGGGAAGAAUGAAGGCACUAGAACCAGA VGRMKALEPETLQMLFLSPSISTCRSHEK CTGCAAATGCTCTTCTTGTCACCCAGCATATCCACC AACCCUGCAAAUGCUCUUCUUGUCACCCA REGTKRRL TGCAGAAGTCATGAGAAGAGAGAAGGAACAAAG GCAUAUCCACCUGCAGAAGUCAUGAGAAG AGGAGACTCTGA AGAGAAGGAACAAAGAGGAGACUCUGA  17  81/380 CTGACATTGCCCATACTCACTCAGATTCCCCACCTT CUGACAUUGCCCAUACUCACUCAGAUUCCC LTLPILTQIPHLCCCLLVRGRPNH TGTTGCTGCCTCTTAGTCAGAGGGAGGCCAAACC CACCUUUGUUGCUGCCUCUUAGUCAGAGG ATTGA GAGGCCAAACCAUUGA  18  82/381 ATGAGTAATATGCCAATCCAAGACTGCTGGAGAA AUGAGUAAUAUGCCAAUCCAAGACUGCUG MSNMPIQDCWRKLKLTGSLFGVG AACTAAAGCTGACAGGTTCCCTTTTTGGGGTGGG GAGAAAACUAAAGCUGACAGGUUCCCUUU ATAG UUGGGGUGGGAUAG  19  83/382 ATGTACAGGATCACTTTTAGCTGTTTTAAACAGAA AUGUACAGGAUCACUUUUAGCUGUUUUA MYRITFSCFKQKKISTTLFSYTRLHFNRSFT AAAAATATCCACCACTCTTTTCAGTTACACTAGGTT AACAGAAAAAAAUAUCCACCACUCUUUUCA SVLE ACATTTTAATAGGTCCTTTACATCTGTTTTGGAATG GUUACACUAGGUUACAUUUUAAUAGGUCC A UUUACAUCUGUUUUGGAAUGA  20  84/383 GTGATACACAGATTGAATTATATCATTTTCATATCT GUGAUACACAGAUUGAAUUAUAUCAUUU VIHRLNYIIFISLLVNTRSSPLHFSIKFFIFM CTCCTTGTAAATACTAGAAGCTCTCCTTTACATTTC UCAUAUCUCUCCUUGUAAAUACUAGAAGC GFPIVTLVFMNICFSFAKAKNQ TCTATCAAATTTTTCATCTTTATGGGTTTCCCAATT UCUCCUUUACAUUUCUCUAUCAAAUUUUU GTGACTCTTGTCTTCATGAATATATGTTTTTCATTT CAUCUUUAUGGGUUUCCCAAUUGUGACUC GCAAAAGCCAAAAATCAGTGA UUGUCUUCAUGAAUAUAUGUUUUUCAUU UGCAAAAGCCAAAAAUCAGUGA  21  85/384 ATGACAAAACTAGGGAAAAATAGCCTACACAAGC AUGACAAAACUAGGGAAAAAUAGCCUACA MTKLGKNSLHKPLGLLFLCLGLSEQRRF CTTTAGGCCTACTCTTTCTGTGCTTGGGTTTGAGTG CAAGCCUUUAGGCCUACUCUUUCUGUGCU AACAAAGGAGATTTTAG UGGGUUUGAGUGAACAAAGGAGAUUUUA G  22  86/385 CTGCTCTACAAACAGAGTTGGTATGGTTGGTATAC CUGCUCUACAAACAGAGUUGGUAUGGUUG LLYKQSWYGWYTVLTCEGLATQTHLAGE TGTACTCACCTGTGAGGGACTGGCCACTCAGACCC GUAUACUGUACUCACCUGUGAGGGACUGG LEDEDHSLEKSQGPSPNKLAVLDVDEE ACTTAGCTGGTGAGCTAGAAGATGAGGATCACTC CCACUCAGACCCACUUAGCUGGUGAGCUA ACTGGAAAAGTCACAAGGACCATCTCCAAACAAG GAAGAUGAGGAUCACUCACUGGAAAAGUC TTGGCAGTGCTCGATGTGGACGAAGAGTGA ACAAGGACCAUCUCCAAACAAGUUGGCAG UGCUCGAUGUGGACGAAGAGUGA  23  87/386 CTGTGCTGGGCAGCAGACAGCTGCCAGGATCACG CUGUGCUGGGCAGCAGACAGCUGCCAGGA LCWAADSCQDHELCSQRKESCGSFSSRSL AACTCTGTAGTCAAAGAAAAGAGTCGTGTGGCAG UCACGAACUCUGUAGUCAAAGAAAAGAGU GSSPRPSL TTTCAGCTCTCGTTCATTGGGCAGCTCGCCTAGGC CGUGUGGCAGUUUCAGCUCUCGUUCAUU CCAGCCTCTGA GGGCAGCUCGCCUAGGCCCAGCCUCUGA  24  88/387 CTGAGAAAGGGATATTTTGAAGGACTGTCATATA CUGAGAAAGGGAUAUUUUGAAGGACUGU LRKGYFEGLSYIFEKRKSVIHIFLCMFTGTK TCTTTGAAAAAAGAAAATCTGTAATACATATATTTT CAUAUAUCUUUGAAAAAAGAAAAUCUGUA KYRELHSVLWVVAEVIVQVEK TATGTATGTTCACTGGCACTAAAAAATATAGAGAG AUACAUAUAUUUUUAUGUAUGUUCACUG CTTCATTCTGTCCTTTGGGTAGTTGCTGAGGTAATT GCACUAAAAAAUAUAGAGAGCUUCAUUCU GTCCAGGTTGAAAAATAA GUCCUUUGGGUAGUUGCUGAGGUAAUUG UCCAGGUUGAAAAAUAA  25  89/388 CTGCCCCTTCCCAGCCCTGCACCAAAGCTGCATTT CUGCCCCUUCCCAGCCCUGCACCAAAGCUG LPLPSPAPKLHFRRLSPDSPVTTRAWPLH CAGGAGACTCTCTCCAGACAGCCCAGTAACTACCC CAUUUCAGGAGACUCUCUCCAGACAGCCCA SPGKIRG GAGCATGGCCCCTGCATAGCCCTGGAAAAATAAG GUAACUACCCGAGCAUGGCCCCUGCAUAGC AGGCTGA CCUGGAAAAAUAAGAGGCUGA  26  90/389 CTGTCTACGAATTATCTTGTGCCAGTTGCCCAGGT CUGUCUACGAAUUAUCUUGUGCCAGUUGC LSTNYLVPVAQVRGHWAKGVVFMFDPL GAGAGGGCACTGGGCCAAGGGAGTGGTTTTCAT CCAGGUGAGAGGGCACUGGGCCAAGGGAG QGVMGIRNAKAPDQIQNLKSK GTTTGACCCACTACAAGGGGTCATGGGAATCAGG UGGUUUUCAUGUUUGACCCACUACAAGGG AATGCCAAAGCACCAGATCAAATCCAAAACTTAAA GUCAUGGGAAUCAGGAAUGCCAAAGCACC GTCAAAATAA AGAUCAAAUCCAAAACUUAAAGUCAAAAU AA  27  91/390 GTGTGTGTGTGTGTTCTGATAGCTTTAACTTTCTCT GUGUGUGUGUGUGUUCUGAUAGCUUUAA VCVCVLIALTFSASLYLVPDHT GCATCTTTATATTTGGTTCCAGATCACACCTGA CUUUCUCUGCAUCUUUAUAUUUGGUUCC AGAUCACACCUGA  28  92/391 GTGAGAGAGGATGCAGTTTTGTTTTGGAAGCTCT GUGAGAGAGGAUGCAGUUUUGUUUUGGA VREDAVLFWKLSQNKQDTWIDQLTKSFL CTCAGAACAAACAAGACACCTGGATTGATCAGTTA AGCUCUCUCAGAACAAACAAGACACCUGGA PYWV ACTAAAAGTTTTCTCCCCTATTGGGTTTGA UUGAUCAGUUAACUAAAAGUUUUCUCCCC UAUUGGGUUUGA  29  93/392 GTGAAGGAGCAGAGGGATAAAAAGAGTAGAGGA GUGAAGGAGCAGAGGGAUAAAAAGAGUAG VKEQRDKKSRGHDTLYFTSSRQMNVESI CATGATACATTGTACTTTACTAGTTCAAGACAGAT AGGACAUGAUACAUUGUACUUUACUAGUU KTQWN GAATGTGGAAAGCATAAAAACTCAATGGAACTGA CAAGACAGAUGAAUGUGGAAAGCAUAAAA ACUCAAUGGAACUGA  30  94/393 CTGAGATTTACCACAGGGAAGGCCCAAACTTGGG CUGAGAUUUACCACAGGGAAGGCCCAAAC LRFTTGKAQTWGQKPTQVIDQWPPNGT GCCAAAAGCCTACCCAAGTGATTGACCAGTGGCC UUGGGGCCAAAAGCCUACCCAAGUGAUUG CCCTAATGGGACCTGA ACCAGUGGCCCCCUAAUGGGACCUGA  31  95/394 CTGTTCCTTGGTCTTCACCATCCTTGTGAGAGAAG CUGUUCCUUGGUCUUCACCAUCCUUGUGA LFLGLHHPCERRAVSCIGTWSKRSIFHTNS GGCAGTTTCCTGCATTGGAACCTGGAGCAAGCGC GAGAAGGGCAGUUUCCUGCAUUGGAACCULT TCTATCTTTCACACAAATTCCCTCACCTGA GGAGCAAGCGCUCUAUCUUUCACACAAAU UCCCUCACCUGA  32  96/395 CTGATTCCAATTCAGTATAGCAAGGTGCTAGGTTT CUGAUUCCAAUUCAGUAUAGCAAGGUGCU LIPIQYSKVLGFFLSPPVS TTTCCTTTCCCCACCTGTCTCTTAG AGGUUUUUUCCUUUCCCCACCUGUCUCUU AG  33  97/396 CTGGTGGTTCCCTCTCTGGCTGCTGCCTCACAGTA CUGGUGGUUCCCUCUCUGGCUGCUGCCUC LVVPSLAAASQYGNLYSAEVTGQICIISQP TGGGAACCTGTACTCTGCAGAGGTGACAGGCCAG ACAGUAUGGGAACCUGUACUCUGCAGAGG ATTTGCATTATCTCACAACCTTAG UGACAGGCCAGAUUUGCAUUAUCUCACAA CCUUAG  34  98/397 TTGCTTGAAATCTCTTTAGATGGGGCTCATTTCTCA UUGCUUGAAAUCUCUUUAGAUGGGGCUC LLEISLDGAHFSRWHLASTGQQDQLQAL CGGTGGCACTTGGCCTCCACTGGGCAGCAGGACC AUUUCUCACGGUGGCACUUGGCCUCCACU VFCSLFVILESFVALNTIKNGRNLFVGLHV AGCTCCAAGCGCTAGTGTTCTGTTCTCTTTTTGTAA GGGCAGCAGGACCAGCUCCAAGCGCUAGU TCTTGGAATCTTTTGTTGCTCTAAATACAATTAAAA GUUCUGUUCUCUUUUUGUAAUCUUGGAA ATGGCAGAAACTTGTTTGTTGGACTACATGTGTGA UCUUUUGUUGCUCUAAAUACAAUUAAAAA UGGCAGAAACUUGUUUGUUGGACUACAU GUGUGA  35  99/398 GTGAGCCTAGCAGGGCAGATCTTGTCCACCGTGT GUGAGCCUAGCAGGGCAGAUCUUGUCCAC VSLAGQILSTVCLLLHETLRLSERFLRGCSR GTCTTCTTCTGCACGAGACTTTGAGGCTGTCAGAG CGUGUGUCUUCUUCUGCACGAGACUUUGA KFPSLELPAGGQLAAATTASSQPVELF CGCTTTTTGCGTGGTTGCTCCCGCAAGTTTCCTTCT GGCUGUCAGAGCGCUUUUUGCGUGGUUG CTGGAGCTTCCCGCAGGTGGGCAGCTAGCTGCAG CUCCCGCAAGUUUCCUUCUCUGGAGCUUC CGACTACCGCATCATCACAGCCTGTTGAACTCTTC CCGCAGGUGGGCAGCUAGCUGCAGCGACU TGA ACCGCAUCAUCACAGCCUGUUGAACUCUU CUGA  36 100/399 GTGGAAGATTCAGCCAAGCTCAAGGATGGAAGTG GUGGAAGAUUCAGCCAAGCUCAAGGAUGG VEDSAKLKDGSAVRAGKGLPSAAVQDLP CAGTTAGGGCTGGGAAGGGTCTACCCTCGGCCGC AAGUGCAGUUAGGGCUGGGAAGGGUCUA RSFPESVPERARSDPEPGPQAPRGRERST CGTCCAAGACCTACCGAGGAGCTTTCCAGAATCTG CCCUCGGCCGCCGUCCAAGACCUACCGAGG SRRQFAAAAAAAAAAAAAAAAAAAAAA TTCCAGAGCGTGCGCGAAGTGATCCAGAACCCGG AGCUUUCCAGAAUCUGUUCCAGAGCGUGC AAAARD GCCCCAGGCACCCAGAGGCCGCGAGCGCAGCACC GCGAAGUGAUCCAGAACCCGGGCCCCAGGC TCCCGGCGCCAGTTTGCTGCTGCTGCAGCAGCAG ACCCAGAGGCCGCGAGCGCAGCACCUCCCG CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG GCGCCAGUUUGCUGCUGCUGCAGCAGCAG CAGCAGCAGCAGCAGCAGCAGCAGCAAGAGACT CAGCAGCAGCAGCAGCAGCAGCAGCAGCAG AG CAGCAGCAGCAGCAGCAGCAGCAGCAGCAA GAGACUAG  37 101/400 GTGCCACCCCGAGAGAGGTTGCGTCCCAGAGCCT GUGCCACCCCGAGAGAGGUUGCGUCCCAG VPPRERLRPRAWSRRGRQQGAAAAAAS GGAGCCGCCGTGGCCGCCAGCAAGGGGCTGCCG AGCCUGGAGCCGCCGUGGCCGCCAGCAAG TSGRG CAGCAGCTGCCAGCACCTCCGGACGAGGATGA GGGCUGCCGCAGCAGCUGCCAGCACCUCCG GACGAGGAUGA  38 102/401 TTGCATGTACGCCCCACTTTTGGGAGTTCCACCCG UUGCAUGUACGCCCCACUUUUGGGAGUUC LHVRPTFGSSTRCASHSLCPIGRMQRFSA CTGTGCGTCCCACTCCTTGTGCCCCATTGGCCGAA CACCCGCUGUGCGUCCCACUCCUUGUGCCC RRQRRQEH TGCAAAGGTTCTCTGCTAGACGACAGCGCAGGCA CAUUGGCCGAAUGCAAAGGUUCUCUGCUA AGAGCACTGA GACGACAGCGCAGGCAAGAGCACUGA  39 103/402 CTGGGCGGCTGCGGCGGCGCAGTGCCGCTATGG CUGGGCGGCUGCGGCGGCGCAGUGCCGCU LGGCGGAVPLWGPGEPAWRGCSGTRF GGACCTGGCGAGCCTGCATGGCGCGGGTGCAGC AUGGGGACCUGGCGAGCCUGCAUGGCGCG WVTLSRRFLILAHSLHSRRRPVVWTVW GGGACCCGGTTCTGGGTCACCCTCAGCCGCCGCTT GGUGCAGCGGGACCCGGUUCUGGGUCACC WWWGWWRRRRRRRRRRRRRRRRRG CCTCATCCTGGCACACTCTCTTCACAGCCGAAGAA CUCAGCCGCCGCUUCCUCAUCCUGGCACAC GSCSPLRLHSAPSGAGGPGKRLHRT GGCCAGTTGTATGGACCGTGTGGTGGTGGTGGG UCUCUUCACAGCCGAAGAAGGCCAGUUGU GGTGGTGGCGGCGGCGGCGGCGGCGGCGGCGG AUGGACCGUGUGGUGGUGGUGGGGGUGG CGGCGGCGGCGGCGGCGGCGGCGGCGAGGCGG UGGCGGCGGCGGCGGCGGCGGCGGCGGCG GAGCTGTAGCCCCCTACGGCTACACTCGGCCCCCT GCGGCGGCGGCGGCGGCGGCGGCGAGGCG CAGGGGCTGGCGGGCCAGGAAAGCGACTTCACC GGAGCUGUAGCCCCCUACGGCUACACUCG GCACCTGA GCCCCCUCAGGGGCUGGCGGGCCAGGAAA GCGACUUCACCGCACCUGA  40 104/403 GTGGTACCCTGGCGGCATGGTGAGCAGAGTGCCC GUGGUACCCUGGCGGCAUGGUGAGCAGAG VVPWRHGEQSALSQSHLCQKRNGPLDG TATCCCAGTCCCACTTGTGTCAAAAGCGAAATGGG UGCCCUAUCCCAGUCCCACUUGUGUCAAA CCCCTGGATGGATAG AGCGAAAUGGGCCCCUGGAUGGAUAG  41 105/404 GTGTCACTATGGAGCTCTCACATGTGGAAGCTGC GUGUCACUAUGGAGCUCUCACAUGUGGAA VSLWSSHMWKLQGLLQKSR AAGGTCTTCTTCAAAAGAGCCGCTGA GCUGCAAGGUCUUCUUCAAAAGAGCCGCU GA  42 106/405 GTGGGCCAAGGCCTTGCCTGGCTTCCGCAACTTAC GUGGGCCAAGGCCUUGCCUGGCUUCCGCA VGQGLAWLPQLTRGRPDGCHSVLLDGA ACGTGGACGACCAGATGGCTGTCATTCAGTACTCC ACUUACACGUGGACGACCAGAUGGCUGUC HGVCHGLAILHQCQLQDALLRP TGGATGGGGCTCATGGTGTTTGCCATGGGCTGGC AUUCAGUACUCCUGGAUGGGGCUCAUGGU GATCCTTCACCAATGTCAACTCCAGGATGCTCTAC GUUUGCCAUGGGCUGGCGAUCCUUCACCA TTCGCCCCTGA AUGUCAACUCCAGGAUGCUCUACUUCGCC CCUGA  43 107/406 GTGTGTCCGAATGAGGCACCTCTCTCAAGAGTTTG GUGUGUCCGAAUGAGGCACCUCUCUCAAG VCPNEAPLSRVWMAPNHPPGIPVHEST GATGGCTCCAAATCACCCCCCAGGAATTCCTGTGC AGUUUGGAUGGCUCCAAAUCACCCCCCAG ATLQHYSSGWAEKSKIL ATGAAAGCACTGCTACTCTTCAGCATTATTCCAGT GAAUUCCUGUGCAUGAAAGCACUGCUACU GGATGGGCTGAAAAATCAAAAATTCTTTGA CUUCAGCAUUAUUCCAGUGGAUGGGCUGA AAAAUCAAAAAUUCUUUGA  44 108/407 ATGCAAAAGAAAAAATCCCACATCCTGCTCAAGAC AUGCAAAAGAAAAAAUCCCACAUCCUGCUC MQKKKSHILLKTLLPAHQAPGLRAAYCER GCTTCTACCAGCTCACCAAGCTCCTGGACTCCGTG AAGACGCUUCUACCAGCUCACCAAGCUCCU AASVHF CAGCCTATTGCGAGAGAGCTGCATCAGTTCACTTT GGACUCCGUGCAGCCUAUUGCGAGAGAGC TGA UGCAUCAGUUCACUUUUGA  45 109/408 GTGAAGCATTGGAAACCCTATTTCCCCACCCCAGC GUGAAGCAUUGGAAACCCUAUUUCCCCAC VKHWKPYFPTPAHAPFQMSSACYNSALL TCATGCCCCCTTTCAGATGTCTTCTGCCTGTTATAA CCCAGCUCAUGCCCCCUUUCAGAUGUCUUC LCSALGNFLY CTCTGCACTACTCCTCTGCAGTGCCTTGGGGAATT UGCCUGUUAUAACUCUGCACUACUCCUCU TCCTCTATTGA GCAGUGCCUUGGGGAAUUUCCUCUAUUGA  46 110/409 TTGCTGGGCTTTTTTTTTCTCTTTCTCTCCTTTCTTTT UUGCUGGGCUUUUUUUUUCUCUUUCUCU LLGFFFLFLSFLFLLPSLSNPPMAPSDFASH TCTTCTTCCCTCCCTATCTAACCCTCCCATGGCACC CCUUUCUUUUUCUUCUUCCCUCCCUAUCU CGSYLCFEWCCMPLNL TTCAGACTTTGCTTCCCATTGTGGCTCCTATCTGTG AACCCUCCCAUGGCACCUUCAGACUUUGCU TTTTGAATGGTGTTGTATGCCTTTAAATCTGTGA UCCCAUUGUGGCUCCUAUCUGUGUUUUG AAUGGUGUUGUAUGCCUUUAAAUCUGUG A  47 111/410 GTGTCAAGTTGTGCTTGTTTACAGCACTACTCTGT GUGUCAAGUUGUGCUUGUUUACAGCACU VSSCACLQHYSVPATQTFTYLMPREV GCCAGCCACACAAACGTTTACTTATCTTATGCCAC ACUCUGUGCCAGCCACACAAACGUUUACU GGGAAGTTTAG UAUCUUAUGCCACGGGAAGUUUAG  48 112/411 GTGAAAATTGCAGGCCCATGGGGAGTTACTGATT GUGAAAAUUGCAGGCCCAUGGGGAGUUAC VKIAGPWGVTDFFISSLHGRLYFLPMAIAI TTTTCATCTCCTCCCTCCACGGGAGACTTTATTTTC UGAUUUUUUCAUCUCCUCCCUCCACGGGA RGQSDPRAELGRGVDREERTRRAMEHQ TGCCAATGGCTATTGCCATTAGAGGGCAGAGTGA GACUUUAUUUUCUGCCAAUGGCUAUUGCC YLPTALVPGG CCCCAGAGCTGAGTTGGGCAGGGGGGTGGACAG AUUAGAGGGCAGAGUGACCCCAGAGCUGA AGAGGAGAGGACAAGGAGGGCAATGGAGCATCA GUUGGGCAGGGGGGUGGACAGAGAGGAG GTACCTGCCCACAGCCTTGGTCCCTGGGGGCTAG AGGACAAGGAGGGCAAUGGAGCAUCAGUA CCUGCCCACAGCCUUGGUCCCUGGGGGCU AG  49 113/412 ATGTTAATGCCTCACCCCCAAACCCTTTTCTCTCTC AUGUUAAUGCCUCACCCCCAAACCCUUUUC MLMPHPQTLFSLTLCLQLQIDFQ ACTCTCTGCCTCCAACTTCAGATTGACTTTCAATAG UCUCUCACUCUCUGCCUCCAACUUCAGAU UGACUUUCAAUAG  50 114/413 ATGTCCTCCCTTCAGTGTTTTGTGGGCCTGAATTTC AUGUCCUCCCUUCAGUGUUUUGUGGGCCU MSSLQCFVGLNFITLHFSHGHQACLLLLG ATCACACTGCATTTCAGCCATGGTCATCAAGCCTG GAAUUUCAUCACACUGCAUUUCAGCCAUG MFTDSLLRAPTTKKVSRPTALTSICRCQ TTTGCTTCTTTTGGGCATGTTCACAGATTCTCTGTT GUCAUCAAGCCUGUUUGCUUCUUUUGGG AAGAGCCCCCACCACCAAGAAGGTTAGCAGGCCA CAUGUUCACAGAUUCUCUGUUAAGAGCCC ACAGCTCTGACATCTATCTGTAGATGCCAGTAG CCACCACCAAGAAGGUUAGCAGGCCAACAG CUCUGACAUCUAUCUGUAGAUGCCAGUAG  51 115/414 CTGGGCGTCTTGCCCTTGTCCCCCAGAGATGATAC CUGGGCGUCUUGCCCUUGUCCCCCAGAGA LGVLPLSPRDDTLPASGEVLTSFFRAAKG CCTCCCAGCAAGTGGAGAAGTTCTCACTTCCTTCT UGAUACCCUCCCAGCAAGUGGAGAAGUUC ATQIRVEEKTQLPGWEE TTAGAGCAGCTAAAGGGGCTACCCAGATCAGGGT UCACUUCCUUCUUUAGAGCAGCUAAAGGG TGAAGAGAAAACTCAATTACCAGGGTGGGAAGAA GCUACCCAGAUCAGGGUUGAAGAGAAAAC TGA UCAAUUACCAGGGUGGGAAGAAUGA  52 116/415 ATGGCTTCTTTCGGAAAGGTCTGGTTGGTGTGGCT AUGGCUUCUUUCGGAAAGGUCUGGUUGG MASFGKVWLVWLQYFATHELRVCPGTL CCAATACTTTGCCACCCATGAACTCAGGGTGTGCC UGUGGCUCCAAUACUUUGCCACCCAUGAA VLYSLLAHLCSVDFVLQAQVQGKMSTYFL CTGGGACACTGGTTTTATATAGTCTTTTGGCACAC CUCAGGGUGUGCCCUGGGACACUGGUUUU ILASASLLSS CTGTGTTCTGTTGACTTCGTTCTTCAAGCCCAAGTG AUAUAGUCUUUUGGCACACCUGUGUUCU CAAGGGAAAATGTCCACCTACTTTCTCATCTTGGC GUUGACUUCGUUCUUCAAGCCCAAGUGCA CTCTGCCTCCTTACTTAGCTCTTAA AGGGAAAAUGUCCACCUACUUUCUCAUCU UGGCCUCUGCCUCCUUACUUAGCUCUUAA  53 117/416 CTGTTGAACTCAAGAAATCAAGGGCCAGTCATCA CUGUUGAACUCAAGAAAUCAAGGGCCAGU LLNSRNQGPVIKLPILIDSLCLLRG AGCTGCCCATTTTAATTGATTCACTCTGTTTGTTGA CAUCAAGCUGCCCAUUUUAAUUGAUUCAC GAGGATAG UCUGUUUGUUGAGAGGAUAG  54 118/417 TTGGGGTGGGATAGACATGTTCTGGTTTTCTTTAT UUGGGGUGGGAUAGACAUGUUCUGGUUU LGWDRHVLVFFIITQSGSCTGSLLAVLNR TATTACACAATCTGGCTCATGTACAGGATCACTTTT UCUUUAUUAUUACACAAUCUGGCUCAUGU KKYPPLFSVTLGYILIGPLHLFWNDFHLL AGCTGTTTTAAACAGAAAAAAATATCCACCACTCT ACAGGAUCACUUUUAGCUGUUUUAAACAG TTTCAGTTACACTAGGTTACATTTTAATAGGTCCTT AAAAAAAUAUCCACCACUCUUUUCAGUUA TACATCTGTTTTGGAATGATTTTCATCTTTTGTGA CACUAGGUUACAUUUUAAUAGGUCCUUUA CAUCUGUUUUGGAAUGAUUUUCAUCUUU UGUGA  55 119/418 TTGGCCATTGATGTTCTAGCCAATGTAATTGACAG UUGGCCAUUGAUGUUCUAGCCAAUGUAAU LAIDVLANVIDRSLILHALCSTNRVGMVGI AAGTCTCATTTTGCATGCGCTCTGCTCTACAAACA UGACAGAAGUCUCAUUUUGCAUGCGCUCU LYSPVRDWPLRPT GAGTTGGTATGGTTGGTATACTGTACTCACCTGTG GCUCUACAAACAGAGUUGGUAUGGUUGG AGGGACTGGCCACTCAGACCCACTTAG UAUACUGUACUCACCUGUGAGGGACUGGC CACUCAGACCCACUUAG  56 120/419 TTGTCCAGGTTGAAAAATAATGTGCTGATGCTAGA UUGUCCAGGUUGAAAAAUAAUGUGCUGA LSRLKNNVLMLESLSVHTLLLNTYRHT GTCCCTCTCTGTCCATACTCTACTTCTAAATACATA UGCUAGAGUCCCUCUCUGUCCAUACUCUA TAGGCATACATAG CUUCUAAAUACAUAUAGGCAUACAUAG  57 121/420 CTGGCAGGGCATAAAGGCCCAGGCCACTTCCTCT CUGGCAGGGCAUAAAGGCCCAGGCCACUU LAGHKGPGHFLCPFPALHQSCISGDSLQT GCCCCTTCCCAGCCCTGCACCAAAGCTGCATTTCA CCUCUGCCCCUUCCCAGCCCUGCACCAAAG AQ GGAGACTCTCTCCAGACAGCCCAGTAA CUGCAUUUCAGGAGACUCUCUCCAGACAG CCCAGUAA  58 122/421 TTGACCCACTACAAGGGGTCATGGGAATCAGGAA UUGACCCACUACAAGGGGUCAUGGGAAUC LTHYKGSWESGMPKHQIKSKT TGCCAAAGCACCAGATCAAATCCAAAACTTAA AGGAAUGCCAAAGCACCAGAUCAAAUCCAA AACUUAA  59 123/422 ATGTTCAGTTTCTTGGAAAAGGAAGTTTCTACCCC AUGUUCAGUUUCUUGGAAAAGGAAGUUU MFSFLEKEVSTPDAFVGRSVLTINLFENLL TGATGCCTTTGTAGGCAGATCTGTTCTCACCATTA CUACCCCUGAUGCCUUUGUAGGCAGAUCU KQFLKREMKASHYITKDYIVPAKIPKFIRA ATCTTTTTGAAAATCTTTTAAAGCAGTTTTTAAAAA GUUCUCACCAUUAAUCUUUUUGAAAAUCU GGEQALVPL GAGAGATGAAAGCATCACATTATATAACCAAAGA UUUAAAGCAGUUUUUAAAAAGAGAGAUG TTACATTGTACCTGCTAAGATACCAAAATTCATAA AAAGCAUCACAUUAUAUAACCAAAGAUUA GGGCAGGGGGGGAGCAAGCATTAGTGCCTCTTTG CAUUGUACCUGCUAAGAUACCAAAAUUCA A UAAGGGCAGGGGGGGAGCAAGCAUUAGU GCCUCUUUGA  60 124/423 TTGCTGAGCAAATTGTTGAAGCTCCATCATTGCAT UUGCUGAGCAAAUUGUUGAAGCUCCAUCA LLSKLLKLHHCMVGNGAVLSHCVC GGTTGGAAATGGAGCTGTTCTTAGCCACTGTGTTT UUGCAUGGUUGGAAAUGGAGCUGUUCUU GCTAG AGCCACUGUGUUUGCUAG  61 125/424 TTGAAATACATTGTAAATGAATATTTGTATCCATG UUGAAAUACAUUGUAAAUGAAUAUUUGU LKYIVNEYLYPCFKIEIYIYIYIYIYIYI TTTCAAAATTGAAATATATATATATATATATATATA AUCCAUGUUUCAAAAUUGAAAUAUAUAUA TATATATATATATATATAG UAUAUAUAUAUAUAUAUAUAUAUAUAUA UAUAG  62 126/425 ATGCAGTTTTGTTTTGGAAGCTCTCTCAGAACAAA AUGCAGUUUUGUUUUGGAAGCUCUCUCA MQFCFGSSLRTNKTPGLIS CAAGACACCTGGATTGATCAGTTAA GAACAAACAAGACACCUGGAUUGAUCAGU UAA  63 127/426 TTGACCAGTGGCCCCCTAATGGGACCTGAGCTGTT UUGACCAGUGGCCCCCUAAUGGGACCUGA LTSGPLMGPELLEEENCSLVFTILVREGQF GGAAGAAGAGAACTGTTCCTTGGTCTTCACCATCC GCUGUUGGAAGAAGAGAACUGUUCCUUG PALEPGASALSFTQIPSPEIEVLLLLGVCVL TTGTGAGAGAAGGGCAGTTTCCTGCATTGGAACC GUCUUCACCAUCCUUGUGAGAGAAGGGCA TGGAGCAAGCGCTCTATCTTTCACACAAATTCCCT GUUUCCUGCAUUGGAACCUGGAGCAAGCG CACCTGAGATTGAGGTGCTCTTGTTACTGGGTGTC CUCUAUCUUUCACACAAAUUCCCUCACCUG TGTGTGCTGTAA AGAUUGAGGUGCUCUUGUUACUGGGUGU CUGUGUGCUGUAA  64 128/427 TTGACAAATGAAAATGTGTTTTTCTCTGTTAAAACT UUGACAAAUGAAAAUGUGUUUUUCUCUG LTNENVFFSVKTCQSTRSCISVGAGPFLPT TGTCAGAGTACTAGAAGTTGTATCTCTGTAGGTGC UUAAAACUUGUCAGAGUACUAGAAGUUG GRVFFFD AGGTCCATTTCTGCCCACAGGTAGGGTGTTTTTCT UAUCUCUGUAGGUGCAGGUCCAUUUCUGC TTGATTAA CCACAGGUAGGGUGUUUUUCUUUGAUUA A  65 129/428 ATGAGAAGCCTTAGAATGGGTGGCCCTTGTGACC AUGAGAAGCCUUAGAAUGGGUGGCCCUUG MRSLRMGGPCDLKHFPHKLLNKIVMEL TGAAACACTTCCCACATAAGCTACTTAACAAGATT UGACCUGAAACACUUCCCACAUAAGCUACU QIPLPTKD GTCATGGAGCTGCAGATTCCATTGCCCACCAAAGA UAACAAGAUUGUCAUGGAGCUGCAGAUUC CTAG CAUUGCCCACCAAAGACUAG  66 130/429 ATGCTGTTTCTCTGGTGGTTCCCTCTCTGGCTGCTG AUGCUGUUUCUCUGGUGGUUCCCUCUCU MLFLWWFPLWLLPHSMGTCTLQR CCTCACAGTATGGGAACCTGTACTCTGCAGAGGT GGCUGCUGCCUCACAGUAUGGGAACCUGU GA ACUCUGCAGAGGUGA  67 131/430 CTGTCCTACAGTGAAGTGCCTGGGGGGTTGTCCT CUGUCCUACAGUGAAGUGCCUGGGGGGU LSYSEVPGGLSYPISHLDADSSHHQNDPR ATCCCATAAGCCACTTGGATGCTGACAGCAGCCAC UGUCCUAUCCCAUAAGCCACUUGGAUGCU KKKKKKIKKSPHNPVTPFCFPLDWNID CATCAGAATGACCCACGCAAAAAAAAGAAAAAAA GACAGCAGCCACCAUCAGAAUGACCCACGC AAATTAAAAAGTCCCCTCACAACCCAGTGACACCT AAAAAAAAGAAAAAAAAAAUUAAAAAGUCC TTCTGCTTTCCTCTAGACTGGAACATTGATTAG CCUCACAACCCAGUGACACCUUUCUGCUUU CCUCUAGACUGGAACAUUGAUUAG  68 132/431 ATGGGGCTCATTTCTCACGGTGGCACTTGGCCTCC AUGGGGCUCAUUUCUCACGGUGGCACUUG MGLISHGGTWPPLGSRTSSKR ACTGGGCAGCAGGACCAGCTCCAAGCGCTAG GCCUCCACUGGGCAGCAGGACCAGCUCCAA GCGCUAG  69 133/432 ATGGCAGAAACTTGTTTGTTGGACTACATGTGTGA AUGGCAGAAACUUGUUUGUUGGACUACA MAETCLLDYMCDFGSVSASAFRNVIHCV CTTTGGGTCTGTCTCTGCCTCTGCTTTCAGAAATGT UGUGUGACUUUGGGUCUGUCUCUGCCUC KYWLTGLPAKTWPHPLLWLQDRVIVNKE CATCCATTGTGTAAAATATTGGCTTACTGGTCTGC UGCUUUCAGAAAUGUCAUCCAUUGUGUAA TQEKLLMSSYHCC CAGCTAAAACTTGGCCACATCCCCTGTTATGGCTG AAUAUUGGCUUACUGGUCUGCCAGCUAAA CAGGATCGAGTTATTGTTAACAAAGAGACCCAAG ACUUGGCCACAUCCCCUGUUAUGGCUGCA AAAAGCTGCTAATGTCCTCTTATCATTGTTGTTAA GGAUCGAGUUAUUGUUAACAAAGAGACCC AAGAAAAGCUGCUAAUGUCCUCUUAUCAU UGUUGUUAA  70 134/433 CTGTTTTCCCCCACTCTCTCTCCACCTCCTCCTGCCT CUGUUUUCCCCCACUCUCUCUCCACCUCCU LFSPTLSPPPPAFPTPSAEPEIKR TCCCCACCCCGAGTGCGGAGCCAGAGATCAAAAG CCUGCCUUCCCCACCCCGAGUGCGGAGCCA ATGA GAGAUCAAAAGAUGA  71 135/434 GTGGACACTGAATTTGGAAGGTGGAGGATTTTGT GUGGACACUGAAUUUGGAAGGUGGAGGA VDTEFGRWRILFFSFKIWASFESTLQVLR TTTTTTCTTTTAAGATCTGGGCATCTTTTGAATCTA UUUUGUUUUUUUCUUUUAAGAUCUGGGC DRL CCCTTCAAGTATTAAGAGACAGACTGTGA AUCUUUUGAAUCUACCCUUCAAGUAUUAA GAGACAGACUGUGA  72 136/435 ATGGCCCAGTGTCAAGTTGTGCTTGTTTACAGCAC AUGGCCCAGUGUCAAGUUGUGCUUGUUU MAQCQVVLVYSTTLCQPHKRLLILCHGKF TACTCTGTGCCAGCCACACAAACGTTTACTTATCTT ACAGCACUACUCUGUGCCAGCCACACAAAC RELRLSGEIKTKTSKQKKKAKTKQKISQKT ATGCCACGGGAAGTTTAGAGAGCTAAGATTATCT GUUUACUUAUCUUAUGCCACGGGAAGUU LLVFFPQK GGGGAAATCAAAACAAAAACAAGCAAACAAAAA UAGAGAGCUAAGAUUAUCUGGGGAAAUCA AAAAAAGCAAAAACAAAACAAAAAATAAGCCAAA AAACAAAAACAAGCAAACAAAAAAAAAAAG AAACCTTGCTAGTGTTTTTTCCTCAAAAATAA CAAAAACAAAACAAAAAAUAAGCCAAAAAA CCUUGCUAGUGUUUUUUCCUCAAAAAUAA  73 137/436 TTGACTTTCAATAGTTTTTCTAAGACCTTTGAACTG UUGACUUUCAAUAGUUUUUCUAAGACCU LTFNSFSKTFELNVLFSQNLATSTEKSDH AATGTTCTCTTCAGCCAAAACTTGGCGACTTCCAC UUGAACUGAAUGUUCUCUUCAGCCAAAAC AGAAAAGTCTGACCACTGA UUGGCGACUUCCACAGAAAAGUCUGACCA CUGA  74 138/437 ATGAAGTTTTCTGCCAAACTCCGTGAAGCCACAAG AUGAAGUUUUCUGCCAAACUCCGUGAAGC MKFSAKLREATSTLCPPFSVLWA CACCTTATGTCCTCCCTTCAGTGTTTTGTGGGCCTG CACAAGCACCUUAUGUCCUCCCUUCAGUG A UUUUGUGGGCCUGA  75 139/438 CTGCTGGAGAAAACTAAAGCTGACAGGTTCCCTTT CUGCUGGAGAAAACUAAAGCUGACAGGUU LLEKTKADRFPFWGGIDMFWFSLLLHNL TTGGGGTGGGATAGACATGTTCTGGTTTTCTTTAT CCCUUUUUGGGGUGGGAUAGACAUGUUC AHVQDHF TATTACACAATCTGGCTCATGTACAGGATCACTTTT UGGUUUUCUUUAUUAUUACACAAUCUGG AG CUCAUGUACAGGAUCACUUUUAG  76 140/439 ATGATTTTCATCTTTTGTGATACACAGATTGAATTA AUGAUUUUCAUCUUUUGUGAUACACAGA MIFIFCDTQIELYHFHISPCKY TATCATTTTCATATCTCTCCTTGTAAATACTAG UUGAAUUAUAUCAUUUUCAUAUCUCUCCU UGUAAAUACUAG  77 141/440 TTGACAGAAGTCTCATTTTGCATGCGCTCTGCTCT UUGACAGAAGUCUCAUUUUGCAUGCGCUC LTEVSFCMRSALQTELVWLVYCTHL ACAAACAGAGTTGGTATGGTTGGTATACTGTACTC UGCUCUACAAACAGAGUUGGUAUGGUUG ACCTGTGA GUAUACUGUACUCACCUGUGA  78 142/441 GTGAGGAAGAGAAAAAGAAGGAGCACCAGGGA GUGAGGAAGAGAAAAAGAAGGAGCACCAG VRKRKRRSTREKAPSVLGSRQLPGSRTL GAAGGCTCCGTCTGTGCTGGGCAGCAGACAGCTG GGAGAAGGCUCCGUCUGUGCUGGGCAGCA CCAGGATCACGAACTCTGTAG GACAGCUGCCAGGAUCACGAACUCUGUAG  79 143/442 CTGACTGTCTACGAATTATCTTGTGCCAGTTGCCC CUGACUGUCUACGAAUUAUCUUGUGCCAG LTVYELSCASCPGERALGQGSGFHV AGGTGAGAGGGCACTGGGCCAAGGGAGTGGTTT UUGCCCAGGUGAGAGGGCACUGGGCCAAG TCATGTTTGA GGAGUGGUUUUCAUGUUUGA  80 144/443 TTGTGGGTTTTTTTTTCCCTAATAATATACATGTTT UUGUGGGUUUUUUUUUCCCUAAUAAUAU LWVFFSLIIYMFRRIENNFGKMGLWVLH AGAAGAATTGAAAATAATTTCGGGAAAATGGGAT ACAUGUUUAGAAGAAUUGAAAAUAAUUUC TATGGGTCCTTCACTAA GGGAAAAUGGGAUUAUGGGUCCUUCACU AA  81 145/444 TTGGAAATGGAGCTGTTCTTAGCCACTGTGTTTGC UUGGAAAUGGAGCUGUUCUUAGCCACUG LEMELFLATVFASAHVSLSEDVKPLLIREH TAGTGCCCATGTTAGCTTATCTGAAGATGTGAAAC UGUUUGCUAGUGCCCAUGUUAGCUUAUC LKY CCTTGCTGATAAGGGAGCATTTAAAGTACTAG UGAAGAUGUGAAACCCUUGCUGAUAAGGG AGCAUUUAAAGUACUAG  82 146/445 ATGAATATTTGTATCCATGTTTCAAAATTGAAATAT AUGAAUAUUUGUAUCCAUGUUUCAAAAU MNICIHVSKLKYIYIYIYIYIYIYSVCVCSDSF ATATATATATATATATATATATATATATATATATAT UGAAAUAUAUAUAUAUAUAUAUAUAUAU NFLCIFIFGSRSHLMPCTCERGCSFVLEAL AGTGTGTGTGTGTGTTCTGATAGCTTTAACTTTCTC AUAUAUAUAUAUAUAUAGUGUGUGUGUG SEQTRHLD TGCATCTTTATATTTGGTTCCAGATCACACCTGATG UGUUCUGAUAGCUUUAACUUUCUCUGCA CCATGTACTTGTGAGAGAGGATGCAGTTTTGTTTT UCUUUAUAUUUGGUUCCAGAUCACACCUG GGAAGCTCTCTCAGAACAAACAAGACACCTGGAT AUGCCAUGUACUUGUGAGAGAGGAUGCAG TGA UUUUGUUUUGGAAGCUCUCUCAGAACAAA CAAGACACCUGGAUUGA  83 147/446 ATGGAACTGACTGAGATTTACCACAGGGAAGGCC AUGGAACUGACUGAGAUUUACCACAGGGA MELTEIYHREGPNLGPKAYPSD CAAACTTGGGGCCAAAAGCCTACCCAAGTGATTG AGGCCCAAACUUGGGGCCAAAAGCCUACCC A AAGUGAUUGA  84 148/447 CTGCATTGGAACCTGGAGCAAGCGCTCTATCTTTC CUGCAUUGGAACCUGGAGCAAGCGCUCUA LHWNLEQALYLSHKFPHLRLRCSCYWVS ACACAAATTCCCTCACCTGAGATTGAGGTGCTCTT UCUUUCACACAAAUUCCCUCACCUGAGAU VCCNSGFGYVL GTTACTGGGTGTCTGTGTGCTGTAATTCTGGTTTT UGAGGUGCUCUUGUUACUGGGUGUCUGU GGATATGTTCTGTAA GUGCUGUAAUUCUGGUUUUGGAUAUGUU CUGUAA  85 149/448 ATGAAAATGTGTTTTTCTCTGTTAAAACTTGTCAG AUGAAAAUGUGUUUUUCUCUGUUAAAAC MKMCFSLLKLVRVLEVVSL AGTACTAGAAGTTGTATCTCTGTAG UUGUCAGAGUACUAGAAGUUGUAUCUCU GUAG  86 150/449 GTGCAGGTCCATTTCTGCCCACAGGTAGGGTGTTT GUGCAGGUCCAUUUCUGCCCACAGGUAGG VQVHFCPQVGCFSLIKRLTLLLPRTSQLN TTCTTTGATTAAGAGATTGACACTTCTGTTGCCTAG GUGUUUUUCUUUGAUUAAGAGAUUGACA HF GACCTCCCAACTCAACCATTTCTAG CUUCUGUUGCCUAGGACCUCCCAACUCAAC CAUUUCUAG  87 151/450 TTGTCATGGAGCTGCAGATTCCATTGCCCACCAAA UUGUCAUGGAGCUGCAGAUUCCAUUGCCC LSWSCRFHCPPKTRTHTYPYTKGKTILKCC GACTAGAACACACACATATCCATACACCAAAGGA ACCAAAGACUAGAACACACACAUAUCCAUA FSGGSLSGCCLTVWEPVLCRGDRPDLHYL AAGACAATTCTGAAATGCTGTTTCTCTGGTGGTTC CACCAAAGGAAAGACAAUUCUGAAAUGCU TTLALGANCPTVKCLGGCPIP CCTCTCTGGCTGCTGCCTCACAGTATGGGAACCTG GUUUCUCUGGUGGUUCCCUCUCUGGCUGC TACTCTGCAGAGGTGACAGGCCAGATTTGCATTAT UGCCUCACAGUAUGGGAACCUGUACUCUG CTCACAACCTTAGCCCTTGGTGCTAACTGTCCTAC CAGAGGUGACAGGCCAGAUUUGCAUUAUC AGTGAAGTGCCTGGGGGGTTGTCCTATCCCATAA UCACAACCUUAGCCCUUGGUGCUAACUGU CCUACAGUGAAGUGCCUGGGGGGUUGUCC UAUCCCAUAA  88 152/451 ATGCTGACAGCAGCCACCATCAGAATGACCCACG AUGCUGACAGCAGCCACCAUCAGAAUGACC MLTAATIRMTHAKKRKKKLKSPLTTQ CAAAAAAAAGAAAAAAAAAATTAAAAAGTCCCCT CACGCAAAAAAAAGAAAAAAAAAAUUAAAA CACAACCCAGTGA AGUCCCCUCACAACCCAGUGA  89 153/452 TTGATTAGGGAGTGCCTCAGACATGACATTCTTGT UUGAUUAGGGAGUGCCUCAGACAUGACAU LIRECLRHDILVLSLELIWQQEGADYVNR GCTGTCCTTGGAATTAATCTGGCAGCAGGAGGGA UCUUGUGCUGUCCUUGGAAUUAAUCUGG DKN GCAGACTATGTAAACAGAGATAAAAATTAA CAGCAGGAGGGAGCAGACUAUGUAAACAG AGAUAAAAAUUAA  90 154/453 TTGAAGGAAAAAAGAAATAAGAAGAGAGAGAGA UUGAAGGAAAAAAGAAAUAAGAAGAGAGA LKEKRNKKRERKKASHKDFLKRNNFA AAGAAAGCATCACACAAAGATTTTCTTAAAAGAA GAGAAAGAAAGCAUCACACAAAGAUUUUC ACAATTTTGCTTGA UUAAAAGAAACAAUUUUGCUUGA  91 155/454 GTGGCACTTGGCCTCCACTGGGCAGCAGGACCAG GUGGCACUUGGCCUCCACUGGGCAGCAGG VALGLHWAAGPAPSASVLFSFCNLGIFCC CTCCAAGCGCTAGTGTTCTGTTCTCTTTTTGTAATC ACCAGCUCCAAGCGCUAGUGUUCUGUUCU SKYN TTGGAATCTTTTGTTGCTCTAAATACAATTAA CUUUUUGUAAUCUUGGAAUCUUUUGUUG CUCUAAAUACAAUUAA  92 156/455 CTGGTCTGCCAGCTAAAACTTGGCCACATCCCCTG CUGGUCUGCCAGCUAAAACUUGGCCACAU LVCQLKLGHIPCYGCRIELLLTKRPKKSC TTATGGCTGCAGGATCGAGTTATTGTTAACAAAGA CCCCUGUUAUGGCUGCAGGAUCGAGUUAU GACCCAAGAAAAGCTGCTAA UGUUAACAAAGAGACCCAAGAAAAGCUGC UAA  93 157/456 GTGTCACTATGGAGCTCTCACATGTGGAAGCTGC GUGUCACUAUGGAGCUCUCACAUGUGGAA VSLWSSHMWKLQGLLQKSR AAGGTCTTCTTCAAAAGAGCCGCTGA GCUGCAAGGUCUUCUUCAAAAGAGCCGCU GA  94 158/457 CTGCCAGGGACCATGTTTTGCCCATTGACTATTAC CUGCCAGGGACCAUGUUUUGCCCAUUGAC LPGTMFCPLTITFHPRRPA TTTCCACCCCAGAAGACCTGCCTGA UAUUACUUUCCACCCCAGAAGACCUGCCU GA  95 159/458 GTGGAGATGAAGCTTCTGGGTGTCACTATGGAGC GUGGAGAUGAAGCUUCUGGGUGUCACUA VEMKLLGVTMELSHVEAARSSSKEPLK TCTCACATGTGGAAGCTGCAAGGTCTTCTTCAAAA UGGAGCUCUCACAUGUGGAAGCUGCAAGG GAGCCGCTGAAG UCUUCUUCAAAAGAGCCGCUGAAG  96 160/459 TTGGAGACTGCCAGGGACCATGTTTTGCCCATTGA UUGGAGACUGCCAGGGACCAUGUUUUGCC LETARDHVLPIDYYFPPQKTCLICGDEASG CTATTACTTTCCACCCCAGAAGACCTGCCTGATCT CAUUGACUAUUACUUUCCACCCCAGAAGA CHYGALTCGSCKVFFKRAAEVWRLPGT GTGGAGATGAAGCTTCTGGGTGTCACTATGGAGC CCUGCCUGAUCUGUGGAGAUGAAGCUUCU MFCPLTITFHPRRPA TCTCACATGTGGAAGCTGCAAGGTCTTCTTCAAAA GGGUGUCACUAUGGAGCUCUCACAUGUGG GAGCCGCTGAAGTTTGGAGACTGCCAGGGACCAT AAGCUGCAAGGUCUUCUUCAAAAGAGCCG GTTTTGCCCATTGACTATTACTTTCCACCCCAGAAG CUGAAGUUUGGAGACUGCCAGGGACCAUG ACCTGCCTGA UUUUGCCCAUUGACUAUUACUUUCCACCC CAGAAGACCUGCCUGA  97 161/460 GTGGAGATGAAGCTTCTGGGTGTCACTATGGAGC GUGGAGAUGAAGCUUCUGGGUGUCACUA VEMKLLGVTMELSHVEAARSSSKEPLKFG TCTCACATGTGGAAGCTGCAAGGTCTTCTTCAAAA UGGAGCUCUCACAUGUGGAAGCUGCAAGG DCQGPCFAH GAGCCGCTGAAGTTTGGAGACTGCCAGGGACCAT UCUUCUUCAAAAGAGCCGCUGAAGUUUGG GTTTTGCCCATTGA AGACUGCCAGGGACCAUGUUUUGCCCAUU GA  98 (BSS) 162/461 CTGTGCGCCAGCAGAAATGATTGCACTATTGATAA CUGUGCGCCAGCAGAAAUGAUUGCACUAU LCASRNDCTIDKFRRKNCPSCRLRKCYEA ATTCCGAAGGAAAAATTGTCCATCTTGTCGTCTTC UGAUAAAUUCCGAAGGAAAAAUUGUCCAU GMTLGVWRLPGTMFCPLTITFHPRRPA GGAAATGTTATGAAGCAGGGATGACTCTGGGAGT CUUGUCGUCUUCGGAAAUGUUAUGAAGCA TTGGAGACTGCCAGGGACCATGTTTTGCCCATTGA GGGAUGACUCUGGGAGUUUGGAGACUGC CTATTACTTTCCACCCCAGAAGACCTGCCTGA CAGGGACCAUGUUUUGCCCAUUGACUAUU ACUUUCCACCCCAGAAGACCUGCCUGA  99 (BSS) 163/462 ATGCACAAGTCCCGGATGTACAGCCAGTGTGTCC AUGCACAAGUCCCGGAUGUACAGCCAGUG MHKSRMYSQCVRMRHLSQEFGWLQITP GAATGAGGCACCTCTCTCAAGAGTTTGGATGGCT UGUCCGAAUGAGGCACCUCUCUCAAGAGU QEFLCMKALLLFSISFRNLHVDDQMAVIQ CCAAATCACCCCCCAGGAATTCCTGTGCATGAAAG UUGGAUGGCUCCAAAUCACCCCCCAGGAA YSWMGLMVFAMGWRSFTNVNSRMLY CACTGCTACTCTTCAGCATTAGCTTCCGCAACTTAC UUCCUGUGCAUGAAAGCACUGCUACUCUU FAPDLVFN ACGTGGACGACCAGATGGCTGTCATTCAGTACTCC CAGCAUUAGCUUCCGCAACUUACACGUGG TGGATGGGGCTCATGGTGTTTGCCATGGGCTGGC ACGACCAGAUGGCUGUCAUUCAGUACUCC GATCCTTCACCAATGTCAACTCCAGGATGCTCTAC UGGAUGGGGCUCAUGGUGUUUGCCAUGG TTCGCCCCTGATCTGGTTTTCAAT GCUGGCGAUCCUUCACCAAUGUCAACUCCA GGAUGCUCUACUUCGCCCCUGAUCUGGUU UUCAAU 100 (BSS) 164/463 TTGCATGCAAAAGAAAAAATCCCACATCCTGCTCA UUGCAUGCAAAAGAAAAAAUCCCACAUCCU LHAKEKIPHPAQDASTSSPSSWTPCSLLP AGACGCTTCTACCAGCTCACCAAGCTCCTGGACTC GCUCAAGACGCUUCUACCAGCUCACCAAGC QLTRGRPDGCHSVLLDGAHGVCHGLAIL CGTGCAGCCTGCTTCCGCAACTTACACGTGGACGA UCCUGGACUCCGUGCAGCCUGCUUCCGCA HQCQLQDALLRP CCAGATGGCTGTCATTCAGTACTCCTGGATGGGG ACUUACACGUGGACGACCAGAUGGCUGUC CTCATGGTGTTTGCCATGGGCTGGCGATCCTTCAC AUUCAGUACUCCUGGAUGGGGCUCAUGGU CAATGTCAACTCCAGGATGCTCTACTTCGCCCCTG GUUUGCCAUGGGCUGGCGAUCCUUCACCA A AUGUCAACUCCAGGAUGCUCUACUUCGCC CCUGA 101 (BSS) 165/464 ATGCAAAAGAAAAAATCCCACATCCTGCTCAAGAC AUGCAAAAGAAAAAAUCCCACAUCCUGCUC MQKKKSHILLKTLLPAHQAPGLRAACFRN GCTTCTACCAGCTCACCAAGCTCCTGGACTCCGTG AAGACGCUUCUACCAGCUCACCAAGCUCCU LHVDDQMAVIQYSWMGLMVFAMGW CAGCCTGCTTCCGCAACTTACACGTGGACGACCAG GGACUCCGUGCAGCCUGCUUCCGCAACUU RSFTNVNSRMLYFAPDLVFN ATGGCTGTCATTCAGTACTCCTGGATGGGGCTCAT ACACGUGGACGACCAGAUGGCUGUCAUUC GGTGTTTGCCATGGGCTGGCGATCCTTCACCAATG AGUACUCCUGGAUGGGGCUCAUGGUGUU TCAACTCCAGGATGCTCTACTTCGCCCCTGATCTG UGCCAUGGGCUGGCGAUCCUUCACCAAUG GTTTTCAAT UCAACUCCAGGAUGCUCUACUUCGCCCCU GAUCUGGUUUUCAAU 102 (BSS) 166/465 GTGGATGGGCTGAAAAATCAAAAATTCTTTGATG GUGGAUGGGCUGAAAAAUCAAAAAUUCUU VDGLKNQKFFDELRMNYIKELDRIIACKR AACTTCGAATGAACTACATCAAGGAACTCGATCGT UGAUGAACUUCGAAUGAACUACAUCAAGG KNPTSCSRRFYQLTKLLDSVQPASATYTW ATCATTGCATGCAAAAGAAAAAATCCCACATCCTG AACUCGAUCGUAUCAUUGCAUGCAAAAGA TTRWLSFSTPGWGSWCLPWAGDPSPM CTCAAGACGCTTCTACCAGCTCACCAAGCTCCTGG AAAAAUCCCACAUCCUGCUCAAGACGCUUC STPGCSTSPLIWFSM ACTCCGTGCAGCCTGCTTCCGCAACTTACACGTGG UACCAGCUCACCAAGCUCCUGGACUCCGUG ACGACCAGATGGCTGTCATTCAGTACTCCTGGATG CAGCCUGCUUCCGCAACUUACACGUGGAC GGGCTCATGGTGTTTGCCATGGGCTGGCGATCCTT GACCAGAUGGCUGUCAUUCAGUACUCCUG CACCAATGTCAACTCCAGGATGCTCTACTTCGCCC GAUGGGGCUCAUGGUGUUUGCCAUGGGC CTGATCTGGTTTTCAATG UGGCGAUCCUUCACCAAUGUCAACUCCAG GAUGCUCUACUUCGCCCCUGAUCUGGUUU UCAAUG FOLH1 neo- antigen DNA sequence RNA sequence Protein Sequence   1 167/466 GTGGTATGTCACTCAGAAAGAATCGTAATGGGTA GUGGUAUGUCACUCAGAAAGAAUCGUAAU VVCHSERIVMGILINFKIGIFEIKLNIIYSYVS TATTGATAAATTTTAAAATTGGTATATTTGAAATAA GGGUAUAUUGAUAAAUUUUAAAAUUGGU VYICVCLYCLSSPYGLKLNFIIIRGYSEVEKF AGTTGAATATTATATATAGTTATGTGAGTGTTTAT AUAUUUGAAAUAAAGUUGAAUAUUAUAU NSVLNLRRMA ATATGTGTGTGTTTATATTGTTTATCTTCTCCCTAT AUAGUUAUGUGAGUGUUUAUAUAUGUGU GGATTAAAACTGAATTTCATAATTATAAGAGGTTA GUGUUUAUAUUGUUUAUCUUCUCCCUAU TTCTGAAGTGGAAAAATTTAACTCAGTATTAAATC GGAUUAAAACUGAAUUUCAUAAUUAUAAG TAAGGAGAATGGCCTAA AGGUUAUUCUGAAGUGGAAAAAUUUAAC UCAGUAUUAAAUCUAAGGAGAAUGGCCUA A   2 168/467 ATGTCACTTCACACAGAAGAAAACATCAGTATGTC AUGUCACUUCACACAGAAGAAAACAUCAG MSLHTEENISMSESTLGNMHKIIPSQRPH AGAGAGCACACTGGGGAATATGCACAAGATTATC UAUGUCAGAGAGCACACUGGGGAAUAUGC GLPGQPGLRGSLSQHTIWEMDQITLLVN CCAAGCCAGAGGCCTCACGGCCTACCTGGCCAGC ACAAGAUUAUCCCAAGCCAGAGGCCUCACG VITL CTGGGCTGAGAGGATCACTATCTCAGCACACTATT GCCUACCUGGCCAGCCUGGGCUGAGAGGA TGGGAAATGGATCAAATCACACTTTTAGTAAATGT UCACUAUCUCAGCACACUAUUUGGGAAAU TATCACTCTATAG GGAUCAAAUCACACUUUUAGUAAAUGUUA UCACUCUAUAG   3 169/468 ATGAACACTTGTGAACCTAATAGCCATATGAAGAA AUGAACACUUGUGAACCUAAUAGCCAUAU MNTCEPNSHMKKITFLISLDAPCTNDSYA AATAACATTTCTAATATCTTTGGATGCCCCATGTAC GAAGAAAAUAACAUUUCUAAUAUCUUUGG FAFS TAATGACAGTTATGCTTTTGCATTTTCTTGA AUGCCCCAUGUACUAAUGACAGUUAUGCU UUUGCAUUUUCUUGA   4 170/469 CTGTCATTATTTATAATTTTATCACACATGGCTGTA CUGUCAUUAUUUAUAAUUUUAUCACACAU LSLFIILSHMAVSFTCFGIMYF TCCTTTACATGTTTTGGCATTATGTATTTTTGA GGCUGUAUCCUUUACAUGUUUUGGCAUU AUGUAUUUUUGA   5 171/470 TTGACACTTCAGAACTCCCCAGAAACTTGTCTTCT UUGACACUUCAGAACUCCCCAGAAACUUG LTLQNSPETCLLGQCVKLFMKKCQARGA GGGCCAATGTGTAAAGCTGTTTATGAAGAAATGT UCUUCUGGGCCAAUGUGUAAAGCUGUUU LLQIWQRTISGEALGRWVLLATMNFRK CAAGCCAGAGGGGCTCTACTACAAATTTGGCAAA AUGAAGAAAUGUCAAGCCAGAGGGGCUCU WVP GGACAATTTCAGGAGAAGCTCTTGGCCGCTGGGT ACUACAAAUUUGGCAAAGGACAAUUUCAG TCTCCTGGCCACCATGAACTTCAGGAAGTGGGTG GAGAAGCUCUUGGCCGCUGGGUUCUCCUG CCATAG GCCACCAUGAACUUCAGGAAGUGGGUGCC AUAG   6 172/471 CTGGGCACTGGTGTAGCTCTGTATGCCCTCCGTGT CUGGGCACUGGUGUAGCUCUGUAUGCCCU LGTGVALYALRVRCWRCHLHCQSLPRVH CAGATGCTGGAGATGTCATTTGCATTGCCAGAGTT CCGUGUCAGAUGCUGGAGAUGUCAUUUGC TESRLKSTLLEHLSNAFYSQSLTSLTRDKEE TGCCAAGGGTGCACACAGAAAGCAGATTGAAAAG AUUGCCAGAGUUUGCCAAGGGUGCACACA LFNGPRSIYEDNQVGVWSG CACCCTCTTGGAACATCTCTCCAATGCCTTCTACTC GAAAGCAGAUUGAAAAGCACCCUCUUGGA ACAAAGTTTAACATCATTAACACGTGACAAAGAA ACAUCUCUCCAAUGCCUUCUACUCACAAAG GAACTATTTAATGGGCCCAGATCTATTTATGAAGA UUUAACAUCAUUAACACGUGACAAAGAAG CAATCAAGTGGGAGTTTGGAGTGGATAA AACUAUUUAAUGGGCCCAGAUCUAUUUAU GAAGACAAUCAAGUGGGAGUUUGGAGUG GAUAA   7 173/472 ATGCCCCATGTACTAATGACAGTTATGCTTTTGCA AUGCCCCAUGUACUAAUGACAGUUAUGCU MPHVLMTVMLLHFLEFYVYLSFLCHYL TTTTCTTGAATTTTATGTTTATTTATCTTTCCTCTGT UUUGCAUUUUCUUGAAUUUUAUGUUUAU CATTATTTATAA UUAUCUUUCCUCUGUCAUUAUUUAUAA   8 174/473 CTGTATCCTTTACATGTTTTGGCATTATGTATTTTT CUGUAUCCUUUACAUGUUUUGGCAUUAU LYPLHVLALCIFELFVKTIIPCVIFRDLIFFID GAACTTTTTGTAAAGACAATCATACCATGTGTAAT GUAUUUUUGAACUUUUUGUAAAGACAAU F TTTCAGGGACTTGATTTTTTTCATTGACTTTTAA CAUACCAUGUGUAAUUUUCAGGGACUUGA UUUUUUUCAUUGACUUUUAA   9 175/474 ATGGTGAATTTGGAGCAGCCAATGAAGAGTCCCC AUGGUGAAUUUGGAGCAGCCAAUGAAGAG MVNLEQPMKSPLTLWPRSKLRSRCSVAL TCACATTGTGGCCTCGCTCAAAGTTAAGAAGTCGC UCCCCUCACAUUGUGGCCUCGCUCAAAGU EESASN TGTAGTGTTGCCCTTGAAGAATCTGCTTCAAATTG UAAGAAGUCGCUGUAGUGUUGCCCUUGAA A GAAUCUGCUUCAAAUUGA  10 176/475 ATGCCCTCCGTGTCAGATGCTGGAGATGTCATTTG AUGCCCUCCGUGUCAGAUGCUGGAGAUGU MPSVSDAGDVICIARVCQGCTQKAD CATTGCCAGAGTTTGCCAAGGGTGCACACAGAAA CAUUUGCAUUGCCAGAGUUUGCCAAGGGU GCAGATTGA GCACACAGAAAGCAGAUUGA  11 177/476 GTGACAAAGAAGAACTATTTAATGGGCCCAGATC GUGACAAAGAAGAACUAUUUAAUGGGCCC VTKKNYLMGPDLFMKTIKWEFGVDNPN TATTTATGAAGACAATCAAGTGGGAGTTTGGAGT AGAUCUAUUUAUGAAGACAAUCAAGUGGG LDNW GGATAACCCAAATTTGGATAACTGGTGA AGUUUGGAGUGGAUAACCCAAAUUUGGA UAACUGGUGA  12 178/477 TTGAATTTGTGTGGTATGTCACTCAGAAAGAATCG UUGAAUUUGUGUGGUAUGUCACUCAGAA LNLCGMSLRKNRNGYIDKF TAATGGGTATATTGATAAATTTTAA AGAAUCGUAAUGGGUAUAUUGAUAAAUU UUAA  13 179/478 ATGTGTGTGTTTATATTGTTTATCTTCTCCCTATGG AUGUGUGUGUUUAUAUUGUUUAUCUUCU MCVFILFIFSLWIKTEFHNYKRLF ATTAAAACTGAATTTCATAATTATAAGAGGTTATT CCCUAUGGAUUAAAACUGAAUUUCAUAAU CTGA UAUAAGAGGUUAUUCUGA  14 180/479 TTGAATTTTATGTTTATTTATCTTTCCTCTGTCATTA UUGAAUUUUAUGUUUAUUUAUCUUUCCU LNFMFIYLSSVIIYNFITHGCILYMFWHYV TTTATAATTTTATCACACATGGCTGTATCCTTTACA CUGUCAUUAUUUAUAAUUUUAUCACACAU FLNFL TGTTTTGGCATTATGTATTTTTGAACTTTTTGTAA GGCUGUAUCCUUUACAUGUUUUGGCAUU AUGUAUUUUUGAACUUUUUGUAA  15 181/480 ATGAAATATTGTCTAGTAATATGTAAAGAGAAGTC AUGAAAUAUUGUCUAGUAAUAUGUAAAG MKYCLVICKEKSQEYVMSRCKELLLSPW TCAAGAATATGTGATGAGCAGATGTAAGGAATTG AGAAGUCUCAAGAAUAUGUGAUGAGCAGA CTCTTGTCTCCATGGTGA UGUAAGGAAUUGCUCUUGUCUCCAUGGU GA  16 182/481 GTGTTGCCCTTGAAGAATCTGCTTCAAATTGACAC GUGUUGCCCUUGAAGAAUCUGCUUCAAAU VLPLKNLLQIDTSELPRNLSSGPMCKAVY TTCAGAACTCCCCAGAAACTTGTCTTCTGGGCCAA UGACACUUCAGAACUCCCCAGAAACUUGUC EEMSSQRGSTTNLAKDNFRRSSWPLGSP TGTGTAAAGCTGTTTATGAAGAAATGTCAAGCCA UUCUGGGCCAAUGUGUAAAGCUGUUUAU GHHELQEVGAIAAA GAGGGGCTCTACTACAAATTTGGCAAAGGACAAT GAAGAAAUGUCAAGCCAGAGGGGCUCUAC TTCAGGAGAAGCTCTTGGCCGCTGGGTTCTCCTGG UACAAAUUUGGCAAAGGACAAUUUCAGGA CCACCATGAACTTCAGGAAGTGGGTGCCATAGCA GAAGCUCUUGGCCGCUGGGUUCUCCUGGC GCAGCCTGA CACCAUGAACUUCAGGAAGUGGGUGCCAU AGCAGCAGCCUGA  17 183/482 ATGCTGGAGATGTCATTTGCATTGCCAGAGTTTGC AUGCUGGAGAUGUCAUUUGCAUUGCCAGA MLEMSFALPEFAKGAHRKQIEKHPLGTSL CAAGGGTGCACACAGAAAGCAGATTGAAAAGCAC GUUUGCCAAGGGUGCACACAGAAAGCAGA QCLLLTKFNIINT CCTCTTGGAACATCTCTCCAATGCCTTCTACTCACA UUGAAAAGCACCCUCUUGGAACAUCUCUC AAGTTTAACATCATTAACACGTGA CAAUGCCUUCUACUCACAAAGUUUAACAU CAUUAACACGUGA  18 184/483 CTGAATGGTGCAGGAGACCCTCTCACACCAGGTT CUGAAUGGUGCAGGAGACCCUCUCACACC LNGAGDPLTPGYPANEYAYRRGIAEAVG ACCCAGCAAATGAATATGCTTATAGGCGTGGAATT AGGUUACCCAGCAAAUGAAUAUGCUUAUA LPSIPVHPIGYYDAQKLLEVVYKILQ GCAGAGGCTGTTGGTCTTCCAAGTATTCCTGTTCA GGCGUGGAAUUGCAGAGGCUGUUGGUCU TCCAATTGGATACTATGATGCACAGAAGCTCCTAG UCCAAGUAUUCCUGUUCAUCCAAUUGGAU AGGTGGTTTATAAAATCCTCCAATGA ACUAUGAUGCACAGAAGCUCCUAGAGGUG GUUUAUAAAAUCCUCCAAUGA  19 (BSS) 185/484 CTGAGAACATCAAGAAGTTCTTATAGGTGGTTTAT CUGAGAACAUCAAGAAGUUCUUAUAGGUG LRTSRSSYRWFIKSSNEATNITPKHNMKA AAAATCCTCCAATGAAGCTACTAACATTACTCCAA GUUUAUAAAAUCCUCCAAUGAAGCUACUA FLDELKAENIKKFL AGCATAATATGAAAGCATTTTTGGATGAATTGAAA ACAUUACUCCAAAGCAUAAUAUGAAAGCA GCTGAGAACATCAAGAAGTTCTTA UUUUUGGAUGAAUUGAAAGCUGAGAACA UCAAGAAGUUCUUA  20 (BSS) 186/485 TTGAACCACCTCCTCCAGGATATGAAAATGTTTCG UUGAACCACCUCCUCCAGGAUAUGAAAAU LNHLLQDMKMFRILYHLSVLSLLKECQRF GATATTGTACCACCTTTCAGTGCTTTCTCTCCTCAA GUUUCGGAUAUUGUACCACCUUUCAGUGC STHHYLNHLLQDMKMFRILYHLSVLSLLK GGAATGCCAGAGATTTTCAACACATCATTATTTGA UUUCUCUCCUCAAGGAAUGCCAGAGAUUU ECQ ACCACCTCCTCCAGGATATGAAAATGTTTCGGATA UCAACACAUCAUUAUUUGAACCACCUCCUC TTGTACCACCTTTCAGTGCTTTCTCTCCTCAAGGAA CAGGAUAUGAAAAUGUUUCGGAUAUUGU TGCCAG ACCACCUUUCAGUGCUUUCUCUCCUCAAG GAAUGCCAG Nkx3.1 neo- antigen DNA sequence RNA sequence Protein Sequence   1 187/486 GTGTGCACACCAAAGCTATTGGAGATTTGCGTGG GUGUGCACACCAAAGCUAUUGGAGAUUUG VCTPKLLEICVEISDSSLVRQ AAATCTCAGATTCTTCACTGGTGAGACAATGA CGUGGAAAUCUCAGAUUCUUCACUGGUGA GACAAUGA   2 188/487 ATGGTATGCCAACTTAAGTATTTACAGGGTGGCCC AUGGUAUGCCAACUUAAGUAUUUACAGGG MVCQLKYLQGGPNRTRCTRCDFKTSCIN AAATAGAACAAGATGCACTCGCTGTGATTTTAAGA UGGCCCAAAUAGAACAAGAUGCACUCGCU RTPLQEGGPGQENLRLSKTGA CAAGCTGTATAAACAGAACTCCACTGCAAGAGGG GUGAUUUUAAGACAAGCUGUAUAAACAGA GGGGCCGGGCCAGGAGAATCTCCGCTTGTCCAAG ACUCCACUGCAAGAGGGGGGGCCGGGCCA ACAGGGGCCTAA GGAGAAUCUCCGCUUGUCCAAGACAGGGG CCUAA   3 189/488 ATGAGCAGAGAGCAAAGGAGAAATCTGGCTGTCC AUGAGCAGAGAGCAAAGGAGAAAUCUGGC MSREQRRNLAVLPFSFCYLR TTCCATTTTCATTCTGTTATCTCAGGTGA UGUCCUUCCAUUUUCAUUCUGUUAUCUCA GGUGA   4 190/489 TTGGGCTCCACATTGCAATGTTCAATGCCACGTGC UUGGGCUCCACAUUGCAAUGUUCAAUGCC LGSTLQCSMPRAADTDRSTSQHKRQGSL TGCTGACACCGACCGGAGTACTAGCCAGCACAAA ACGUGCUGCUGACACCGACCGGAGUACUA NCFLLFTFLLK AGGCAGGGTAGCCTGAATTGCTTTCTGCTCTTTAC GCCAGCACAAAAGGCAGGGUAGCCUGAAU ATTTCTTTTAAAATAA UGCUUUCUGCUCUUUACAUUUCUUUUAA AAUAA   5 191/490 CTGAGTACTCTTTCTCTCCCCTCCTCTGAATTTAATT CUGAGUACUCUUUCUCUCCCCUCCUCUGA LSTLSLPSSEFNSFNLQFARITHFTVMYIVL CTTTCAACTTGCAATTTGCAAGGATTACACATTTCA AUUUAAUUCUUUCAACUUGCAAUUUGCAA QKKKKSVFV CTGTGATGTATATTGTGTTGCAAAAAAAAAAAAAA GGAUUACACAUUUCACUGUGAUGUAUAU AGTGTCTTTGTTTAA UGUGUUGCAAAAAAAAAAAAAAAGUGUCU UUGUUUAA   6 192/491 CTGACAGGTGAATTGGATGGTTCTCAGAACCATTT CUGACAGGUGAAUUGGAUGGUUCUCAGA LTGELDGSQNHFTQTACFYPV CACCCAGACAGCCTGTTTCTATCCTGTTTAA ACCAUUUCACCCAGACAGCCUGUUUCUAU CCUGUUUAA   7 193/492 CTGAAAACACTTCAGGCGCCCTTCCAAGGCTTCCC CUGAAAACACUUCAGGCGCCCUUCCAAGGC LKTLQAPFQGFPKPLSSRRSAPELPSPTLR CAAACCCCTAAGCAGCCGCAGAAGCGCTCCCGAG UUCCCCAAACCCCUAAGCAGCCGCAGAAGC CTGCCTTCTCCCACACTCAGGTGA GCUCCCGAGCUGCCUUCUCCCACACUCAGG UGA   8 194/493 CTGCCTTCCCCAGGGTGTCTCTATGAAAAGCACAA CUGCCUUCCCCAGGGUGUCUCUAUGAAAA LPSPGCLYEKHKGPRSGSKRCAHQSYWR GGGGCCAAGGTCAGGGAGCAAGAGGTGTGCACA GCACAAGGGGCCAAGGUCAGGGAGCAAGA FAWKSQILHW CCAAAGCTATTGGAGATTTGCGTGGAAATCTCAG GGUGUGCACACCAAAGCUAUUGGAGAUUU ATTCTTCACTGGTGA GCGUGGAAAUCUCAGAUUCUUCACUGGUG A   9 195/494 CTGTTTGAAGGGGAGAGAGGGAAAATCAAGTGG CUGUUUGAAGGGGAGAGAGGGAAAAUCA LFEGERGKIKWYFPALCMILDELYTQGFC TATTTTCCAGCACTTTGTATGATTTTGGATGAGTTG AGUGGUAUUUUCCAGCACUUUGUAUGAU SATPSSCVTEYQL TACACCCAAGGATTCTGTTCTGCAACTCCATCCTCC UUUGGAUGAGUUGUACACCCAAGGAUUCU TGTGTCACTGAATATCAACTCTGA GUUCUGCAACUCCAUCCUCCUGUGUCACU GAAUAUCAACUCUGA  10 196/495 CTGTTGGCCTTGGAATATGGCCAAGGCTCTCTCTG CUGUUGGCCUUGGAAUAUGGCCAAGGCUC LLALEYGQGSLCPCKREGQIESLQENALM TCCCTGTAAAAGAGAGGGGCAAATAGAGAGTCTC UCUCUGUCCCUGUAAAAGAGAGGGGCAAA LSTYLHGRGRWVGGDENISFSYSFLFLLK CAAGAGAACGCCCTCATGCTCAGCACATATTTGCA UAGAGAGUCUCCAAGAGAACGCCCUCAUG WYANLSIYRVAQIEQDALAVILRQAV TGGGAGGGGGAGATGGGTGGGAGGAGATGAAA CUCAGCACAUAUUUGCAUGGGAGGGGGAG ATATCAGCTTTTCTTATTCCTTTTTATTCCTTTTAAA AUGGGUGGGAGGAGAUGAAAAUAUCAGC ATGGTATGCCAACTTAAGTATTTACAGGGTGGCCC UUUUCUUAUUCCUUUUUAUUCCUUUUAA AAATAGAACAAGATGCACTCGCTGTGATTTTAAGA AAUGGUAUGCCAACUUAAGUAUUUACAGG CAAGCTGTATAA GUGGCCCAAAUAGAACAAGAUGCACUCGC UGUGAUUUUAAGACAAGCUGUAUAA  11 197/496 CTGGAGAATTTAGAATCAGAAGTTTCCTGGAGTTT CUGGAGAAUUUAGAAUCAGAAGUUUCCUG LENLESEVSWSFQAIIYTVS TCAGGCTATCATATATACTGTATCCTGA GAGUUUUCAGGCUAUCAUAUAUACUGUA UCCUGA  12 198/497 TTGGGGGCAGATTCTGAATTGGCTAAAAGACATG UUGGGGGCAGAUUCUGAAUUGGCUAAAA LGADSELAKRHAFLKLATLISFL CATTTTTAAAACTAGCAACTCTTATTTCTTTCCTTTA GACAUGCAUUUUUAAAACUAGCAACUCUU A AUUUCUUUCCUUUAA  13 199/498 TTGAGAATCTTTGCATGCAGAGGAGGTAAGAGGT UUGAGAAUCUUUGCAUGCAGAGGAGGUA LRIFACRGGKRYWIFTEEEHSAE ATTGGATTTTCACAGAGGAAGAACACAGCGCAGA AGAGGUAUUGGAUUUUCACAGAGGAAGA ATGA ACACAGCGCAGAAUGA  14 200/499 CTGTCCAGTGGAGGGCTCATGGGTGGGACATGGA CUGUCCAGUGGAGGGCUCAUGGGUGGGA LSSGGLMGGTWKRRQPRPWGAQSTEQ AAAGAAGGCAGCCTAGGCCCTGGGGAGCCCAGTC CAUGGAAAAGAAGGCAGCCUAGGCCCUGG ARD CACTGAGCAAGCAAGGGACTGA GGAGCCCAGUCCACUGAGCAAGCAAGGGA CUGA  15 201/500 GTGAGCCTTTTGCAGGAAAAGGCTAAGAAAAAGG GUGAGCCUUUUGCAGGAAAAGGCUAAGAA VSLLQEKAKKKENHSKTQQETVQMLWE AAAACCATTCTAAAACACAACAAGAAACTGTCCAA AAAGGAAAACCAUUCUAAAACACAACAAGA LCLLPIMGPQNG ATGCTTTGGGAACTGTGTTTATTGCCTATAATGGG AACUGUCCAAAUGCUUUGGGAACUGUGUU TCCCCAAAATGGGTAA UAUUGCCUAUAAUGGGUCCCCAAAAUGGG UAA  16 202/501 TTGGCCAATTTCACCCCATTTTCTGTGGTTTGGGCT UUGGCCAAUUUCACCCCAUUUUCUGUGGU LANFTPFSVVWAPHCNVQCHVLLTPTGV CCACATTGCAATGTTCAATGCCACGTGCTGCTGAC UUGGGCUCCACAUUGCAAUGUUCAAUGCC LASTKGRVA ACCGACCGGAGTACTAGCCAGCACAAAAGGCAGG ACGUGCUGCUGACACCGACCGGAGUACUA GTAGCCTGA GCCAGCACAAAAGGCAGGGUAGCCUGA  17 203/502 TTGTGTTGCAAAAAAAAAAAAAAAGTGTCTTTGTT UUGUGUUGCAAAAAAAAAAAAAAAGUGUC LCCKKKKKVSLFKITWFVNPSCFFPIGTSH TAAAATTACTTGGTTTGTGAATCCATCTTGCTTTTT UUUGUUUAAAAUUACUUGGUUUGUGAAU CCCCATTGGAACTAGTCATTAA CCAUCUUGCUUUUUCCCCAUUGGAACUAG UCAUUAA  18 204/503 GTGAATTGGATGGTTCTCAGAACCATTTCACCCAG GUGAAUUGGAUGGUUCUCAGAACCAUUUC VNWMVLRTISPRQPVSILFNKLVWVLYM ACAGCCTGTTTCTATCCTGTTTAATAAATTAGTTTG ACCCAGACAGCCUGUUUCUAUCCUGUUUA HNKPCSNLSHKSL GGTTCTCTACATGCATAACAAACCCTGCTCCAATC AUAAAUUAGUUUGGGUUCUCUACAUGCA TGTCACATAAAAGTCTGTGA UAACAAACCCUGCUCCAAUCUGUCACAUAA AAGUCUGUGA  19 205/504 CTGCGTGGGCAGCTGGAGCCCAGCTTTTTGGTAA CUGCGUGGGCAGCUGGAGCCCAGCUUUUU LRGQLEPSFLVMPAQVTTIMIKNCLPQG TGCCAGCTCAGGTGACAACCATTATGATCAAAAAC GGUAAUGCCAGCUCAGGUGACAACCAUUA VSMKSTRGQGQGARGVHTKAIGDLRGN TGCCTTCCCCAGGGTGTCTCTATGAAAAGCACAAG UGAUCAAAAACUGCCUUCCCCAGGGUGUC LRFFTGETMKQQRQ GGGCCAAGGTCAGGGAGCAAGAGGTGTGCACAC UCUAUGAAAAGCACAAGGGGCCAAGGUCA CAAAGCTATTGGAGATTTGCGTGGAAATCTCAGA GGGAGCAAGAGGUGUGCACACCAAAGCUA TTCTTCACTGGTGAGACAATGAAACAACAGAGAC UUGGAGAUUUGCGUGGAAAUCUCAGAUU AGTGA CUUCACUGGUGAGACAAUGAAACAACAGA GACAGUGA  20 206/505 TTGCTTCTGGCTACCTGTTTGAAGGGGAGAGAGG UUGCUUCUGGCUACCUGUUUGAAGGGGA LLLATCLKGREGKSSGIFQHFV GAAAATCAAGTGGTATTTTCCAGCACTTTGTATGA GAGAGGGAAAAUCAAGUGGUAUUUUCCAG CACUUUGUAUGA  21 207/506 ATGGGAGGGGGAGATGGGTGGGAGGAGATGAA AUGGGAGGGGGAGAUGGGUGGGAGGAGA MGGGDGWEEMKISAFLIPFYSF AATATCAGCTTTTCTTATTCCTTTTTATTCCTTTTAA UGAAAAUAUCAGCUUUUCUUAUUCCUUU UUAUUCCUUUUAA  22 208/507 CTGTATAAACAGAACTCCACTGCAAGAGGGGGGG CUGUAUAAACAGAACUCCACUGCAAGAGG LYKQNSTARGGAGPGESPLVQDRGLRRV CCGGGCCAGGAGAATCTCCGCTTGTCCAAGACAG GGGGGCCGGGCCAGGAGAAUCUCCGCUUG STLLLGAVAFFY GGGCCTAAGGAGGGTCTCCACACTGCTGCTAGGG UCCAAGACAGGGGCCUAAGGAGGGUCUCC GCTGTTGCATTTTTTTATTAG ACACUGCUGCUAGGGGCUGUUGCAUUUU UUUAUUAG  23 209/508 CTGTATCCTGAAAGGCAACATAATTCTTCCTTCCCT CUGUAUCCUGAAAGGCAACAUAAUUCUUC LYPERQHNSSFPPFKILCSFLQQLLTKGLH CCTTTTAAAATTTTGTGTTCCTTTTTGCAGCAATTA CUUCCCUCCUUUUAAAAUUUUGUGUUCCU FSPDF CTCACTAAAGGGCTTCATTTTAGTCCAGATTTTTAG UUUUGCAGCAAUUACUCACUAAAGGGCUU CAUUUUAGUCCAGAUUUUUAG  24 210/509 ATGCCTCGCTTATTTAGCCCGAGATCTGGTCTTTTT AUGCCUCGCUUAUUUAGCCCGAGAUCUGG MPRLFSPRSGLFFFFFFFFSVSPKLYLS TTTTTTTTTTTTTTTTTTTTTTCCGTCTCCCCAAAGCT UCUUUUUUUUUUUUUUUUUUUUUUUUU TTATCTGTCTTGA UUCCGUCUCCCCAAAGCUUUAUCUGUCUU GA  25 211/510 TTGCATGCAGAGGAGGTAAGAGGTATTGGATTTT UUGCAUGCAGAGGAGGUAAGAGGUAUUG LHAEEVRGIGFSQRKNTAQNEGPGLLSCP CACAGAGGAAGAACACAGCGCAGAATGAAGGGC GAUUUUCACAGAGGAAGAACACAGCGCAG VEGSWVGHGKEGSLGPGEPSPLSKQGTE CAGGCTTACTGAGCTGTCCAGTGGAGGGCTCATG AAUGAAGGGCCAGGCUUACUGAGCUGUCC GGTGGGACATGGAAAAGAAGGCAGCCTAGGCCC AGUGGAGGGCUCAUGGGUGGGACAUGGA TGGGGAGCCCAGTCCACTGAGCAAGCAAGGGACT AAAGAAGGCAGCCUAGGCCCUGGGGAGCC GAGTGA CAGUCCACUGAGCAAGCAAGGGACUGAGU GA  26 212/511 ATGGGTAACCTAGACTTCAGAGAGAATGAGCAGA AUGGGUAACCUAGACUUCAGAGAGAAUGA MGNLDFRENEQRAKEKSGCPSIFILLSQV GAGCAAAGGAGAAATCTGGCTGTCCTTCCATTTTC GCAGAGAGCAAAGGAGAAAUCUGGCUGUC SW ATTCTGTTATCTCAGGTGAGCTGGTAG CUUCCAUUUUCAUUCUGUUAUCUCAGGUG AGCUGGUAG  27 213/512 TTGAAGTTTAGTCAGCACCCCCACCAAACTTTATTT UUGAAGUUUAGUCAGCACCCCCACCAAACU LKFSQHPHQTLFFYVFFATYECFENKVPM TTCTATGTGTTTTTTGCAACATATGAGTGTTTTGAA UUAUUUUUCUAUGUGUUUUUUGCAACAU SLLDL AATAAAGTACCCATGTCTTTATTAGATTTA AUGAGUGUUUUGAAAAUAAAGUACCCAUG UCUUUAUUAGAUUUA  28 (BSS) 214/513 GTGCGGGCCGGGCGGGTGCATTCAGGCCAAGGC GUGCGGGCCGGGCGGGUGCAUUCAGGCCA VRAGRVHSGQGGAAGMLRVPEPRPGEA GGGGCCGCCGGGATGCTCAGGGTTCCGGAGCCG AGGCGGGGCCGCCGGGAUGCUCAGGGUUC KAEGAAPPTPSKPLTSFLIQDILRDGAQR CGGCCCGGGGAGGCGAAAGCGGAGGGGGCCGC CGGAGCCGCGGCCCGGGGAGGCGAAAGCG QGGRTSSQRQRDPEPEPEPEPEGGRSRA GCCGCCGACCCCGTCCAAGCCGCTCACGTCCTTCC GAGGGGGCCGCGCCGCCGACCCCGUCCAAG GAQNDQLSTGPRAAPEEAETLAETEPGG TCATCCAGGACATCCTGCGGGACGGCGCGCAGCG CCGCUCACGUCCUUCCUCAUCCAGGACAUC AGRAGAFRPRRGRRDAQGSGAAARGGE GCAAGGCGGCCGCACGAGCAGCCAGAGACAGCG CUGCGGGACGGCGCGCAGCGGCAAGGCGG SGGGRAADPVQAAHVLPHPGHPAGRRA CGACCCGGAGCCGGAGCCAGAGCCAGAGCCAGA CCGCACGAGCAGCCAGAGACAGCGCGACCC AARRPHEQPETARPGAGARARARGRTQ GGGAGGACGCAGCCGCGCCGGGGCGCAGAACGA GGAGCCGGAGCCAGAGCCAGAGCCAGAGG PRRGAERPAEHRAPRRAGGGRDAGRDR CCAGCTGAGCACCGGGCCCCGCGCCGCGCCGGAG GAGGACGCAGCCGCGCCGGGGCGCAGAAC A GAGGCCGAGACGCTGGCAGAGACCGAGCCAGGC GACCAGCUGAGCACCGGGCCCCGCGCCGCG GGTGCGGGCCGGGCGGGTGCATTCAGGCCAAGG CCGGAGGAGGCCGAGACGCUGGCAGAGAC CGGGGCCGCCGGGATGCTCAGGGTTCCGGAGCC CGAGCCAGGCGGUGCGGGCCGGGCGGGUG GCGGCCCGGGGAGGCGAAAGCGGAGGGGGCCG CAUUCAGGCCAAGGCGGGGCCGCCGGGAU CGCCGCCGACCCCGTCCAAGCCGCTCACGTCCTTC GCUCAGGGUUCCGGAGCCGCGGCCCGGGG CTCATCCAGGACATCCTGCGGGACGGCGCGCAGC AGGCGAAAGCGGAGGGGGCCGCGCCGCCG GGCAAGGCGGCCGCACGAGCAGCCAGAGACAGC ACCCCGUCCAAGCCGCUCACGUCCUUCCUC GCGACCCGGAGCCGGAGCCAGAGCCAGAGCCAG AUCCAGGACAUCCUGCGGGACGGCGCGCA AGGGAGGACGCAGCCGCGCCGGGGCGCAGAACG GCGGCAAGGCGGCCGCACGAGCAGCCAGA ACCAGCTGAGCACCGGGCCCCGCGCCGCGCCGGA GACAGCGCGACCCGGAGCCGGAGCCAGAGC GGAGGCCGAGACGCTGGCAGAGACCGAGCC CAGAGCCAGAGGGAGGACGCAGCCGCGCC GGGGCGCAGAACGACCAGCUGAGCACCGG GCCCCGCGCCGCGCCGGAGGAGGCCGAGAC GCUGGCAGAGACCGAGCC NPY neo- antigen DNA sequence RNA sequence Protein sequence   1 215/514 CTGGCTCTCACCCCTCGGAGACGCTCGCCCGACAG CUGGCUCUCACCCCUCGGAGACGCUCGCCC LALTPRRRSPDSIVLAAQPRPRASHHAR CATAGTACTTGCCGCCCAGCCACGCCCGCGCGCCA GACAGCAUAGUACUUGCCGCCCAGCCACGC GCCACCATGCTAGGTAA CCGCGCGCCAGCCACCAUGCUAGGUAA   2 216/515 GTGCCTGGGTGCGCTGGCCGAGGCGTACCCCTCC GUGCCUGGGUGCGCUGGCCGAGGCGUACC VPGCAGRGVPLQAGQPGRGRTSGGHG AAGCCGGACAACCCGGGCGAGGACGCACCAGCG CCUCCAAGCCGGACAACCCGGGCGAGGACG QILLGAATLHQPHHQAEIWKTIQPRDTD GAGGACATGGCCAGATACTACTCGGCGCTGCGAC CACCAGCGGAGGACAUGGCCAGAUACUAC FRPLDERKHRKCSQNSA ACTACATCAACCTCATCACCAGGCAGAGATATGGA UCGGCGCUGCGACACUACAUCAACCUCAUC AAACGATCCAGCCCAGAGACACTGATTTCAGACCT ACCAGGCAGAGAUAUGGAAAACGAUCCAG CTTGATGAGAGAAAGCACAGAAAATGTTCCCAGA CCCAGAGACACUGAUUUCAGACCUCUUGA ACTCGGCTTGA UGAGAGAAAGCACAGAAAAUGUUCCCAGA ACUCGGCUUGA   3 217/516 GTGGTGATGGGAAATGAGACTTGCTCTCTGGCCT GUGGUGAUGGGAAAUGAGACUUGCUCUC VVMGNETCSLAFSYFQPIFHRVKRESTHP TTTCCTATTTTCAGCCCATATTTCATCGTGTAAAAC UGGCCUUUUCCUAUUUUCAGCCCAUAUUU TNACSHCAEFCNVFLCHHCIYVCLNKVSC GAGAATCCACCCATCCTACCAATGCATGCAGCCAC CAUCGUGUAAAACGAGAAUCCACCCAUCCU IQK TGTGCTGAATTCTGCAATGTTTTCCTTTGTCATCAT ACCAAUGCAUGCAGCCACUGUGCUGAAUU TGTATATATGTGTGTTTAAATAAAGTATCATGCAT CUGCAAUGUUUUCCUUUGUCAUCAUUGU TCAAAAGTGA AUAUAUGUGUGUUUAAAUAAAGUAUCAU GCAUUCAAAAGUGA   4 218/517 ATGCATGCAGCCACTGTGCTGAATTCTGCAATGTT AUGCAUGCAGCCACUGUGCUGAAUUCUGC MHAATVLNSAMFSFVIIVYMCV TTCCTTTGTCATCATTGTATATATGTGTGTTTAA AAUGUUUUCCUUUGUCAUCAUUGUAUAU AUGUGUGUUUAA   5 219/518 GTGCGCTGGCCGAGGCGTACCCCTCCAAGCCGGA GUGCGCUGGCCGAGGCGUACCCCUCCAAG VRWPRRTPPSRTTRARTHQRRTWPDTT CAACCCGGGCGAGGACGCACCAGCGGAGGACAT CCGGACAACCCGGGCGAGGACGCACCAGCG RRCDTTSTSSPGRDMENDPAQRH GGCCAGATACTACTCGGCGCTGCGACACTACATCA GAGGACAUGGCCAGAUACUACUCGGCGCU ACCTCATCACCAGGCAGAGATATGGAAAACGATC GCGACACUACAUCAACCUCAUCACCAGGCA CAGCCCAGAGACACTGA GAGAUAUGGAAAACGAUCCAGCCCAGAGA CACUGA   6 220/519 TTGCTCTCTGGCCTTTTCCTATTTTCAGCCCATATTT UUGCUCUCUGGCCUUUUCCUAUUUUCAGC LLSGLFLFSAHISSCKTRIHPSYQCMQPLC CATCGTGTAAAACGAGAATCCACCCATCCTACCAA CCAUAUUUCAUCGUGUAAAACGAGAAUCC TGCATGCAGCCACTGTGCTGA ACCCAUCCUACCAAUGCAUGCAGCCACUGU GCUGA   7 (BSS) 221/520 CTGATTTCAGACCTCTTGATGAGAGAAAGCACAG CUGAUUUCAGACCUCUUGAUGAGAGAAAG LISDLLMRESTENVPRTRYGKRSSPETLIS AAAATGTTCCCAGAACTCGATATGGAAAACGATCC CACAGAAAAUGUUCCCAGAACUCGAUAUG DLLMRESTENVPRT AGCCCAGAGACACTGATTTCAGACCTCTTGATGAG GAAAACGAUCCAGCCCAGAGACACUGAUU AGAAAGCACAGAAAATGTTCCCAGAACT UCAGACCUCUUGAUGAGAGAAAGCACAGA AAAUGUUCCCAGAACU   8 (BSS) 222/521 GTGCCTGGGTGCGCTGGCCGAGGCGTACCCCTCC GUGCCUGGGUGCGCUGGCCGAGGCGUACC VPGCAGRGVPLQAGQPGRGRTSGGHG AAGCCGGACAACCCGGGCGAGGACGCACCAGCG CCUCCAAGCCGGACAACCCGGGCGAGGACG QILLGAATLHQPHHQAEMLGNKRLGLSG GAGGACATGGCCAGATACTACTCGGCGCTGCGAC CACCAGCGGAGGACAUGGCCAGAUACUAC LTLALSLLVCLGAEAYPSKPDNPGEDAPA ACTACATCAACCTCATCACCAGGCAGAGATGCTAG UCGGCGCUGCGACACUACAUCAACCUCAUC EDMARYYSALRHYINLITRQ GTAACAAGCGACTGGGGCTGTCCGGACTGACCCT ACCAGGCAGAGAUGCUAGGUAACAAGCGA CGCCCTGTCCCTGCTCGTGTGCCTGGGTGCGCTGG CUGGGGCUGUCCGGACUGACCCUCGCCCU CCGAGGCGTACCCCTCCAAGCCGGACAACCCGGG GUCCCUGCUCGUGUGCCUGGGUGCGCUGG CGAGGACGCACCAGCGGAGGACATGGCCAGATA CCGAGGCGUACCCCUCCAAGCCGGACAACC CTACTCGGCGCTGCGACACTACATCAACCTCATCA CGGGCGAGGACGCACCAGCGGAGGACAUG CCAGGCAG GCCAGAUACUACUCGGCGCUGCGACACUAC AUCAACCUCAUCACCAGGCAG SPDEF neo- antigen DNA sequence RNA sequence Protein sequence   1 223/522 CTGACTTCCTCCCAGCACATTCCTGCACTCTGCCGT CUGACUUCCUCCCAGCACAUUCCUGCACUC LTSSQHIPALCRVHTAPQTQSSKPAASSL GTCCACACTGCCCCACAGACCCAGTCCTCCAAGCC UGCCGUGUCCACACUGCCCCACAGACCCAG QAPQVGPCHGASRQPWAGGRGLPTGT TGCTGCCAGCTCCCTGCAAGCCCCTCAGGTTGGGC UCCUCCAAGCCUGCUGCCAGCUCCCUGCAA QP CTTGCCACGGTGCCAGCAGGCAGCCCTGGGCTGG GCCCCUCAGGUUGGGCCUUGCCACGGUGC GGGTAGGGGACTCCCTACAGGCACGCAGCCCTGA CAGCAGGCAGCCCUGGGCUGGGGGUAGGG GACUCCCUACAGGCACGCAGCCCUGA   2 224/523 GTGGCCTCAGCTGCCCACACCTCTTCCCGGCCCCT GUGGCCUCAGCUGCCCACACCUCUUCCCGG VASAAHTSSRPLKLALQQTAPWAPGS GAAGTTGGCACTGCAGCAGACAGCTCCCTGGGCA CCCCUGAAGUUGGCACUGCAGCAGACAGC CCAGGCAGCTAA UCCCUGGGCACCAGGCAGCUAA   3 225/524 TTGACATGCTGTACCCTGAGGACAGCAGCTGGGC UUGACAUGCUGUACCCUGAGGACAGCAGC LTCCTLRTAAGQPRPLGPAVGRSHLRSLS AGCCAAGGCCCCTGGGGCCAGCAGTCGGGAGGA UGGGCAGCCAAGGCCCCUGGGGCCAGCAG SARSLTAKPQRAAWTWCPAG GCCACCTGAGGAGCCTGAGCAGTGCCCGGTCATT UCGGGAGGAGCCACCUGAGGAGCCUGAGC GACAGCCAAGCCCCAGCGGGCAGCCTGGACTTGG AGUGCCCGGUCAUUGACAGCCAAGCCCCAG TGCCCGGCGGGCTGA CGGGCAGCCUGGACUUGGUGCCCGGCGGG CUGA   4 226/525 ATGTGCAGAAGTGGCTCCTGTGGACAGAGCACCA AUGUGCAGAAGUGGCUCCUGUGGACAGAG MCRSGSCGQSTNTGCPPWARPSRSWR ATACCGGCTGCCCCCCATGGGCAAGGCCTTCCAG CACCAAUACCGGCUGCCCCCCAUGGGCAAG ARSCAPCRRSSSASARPWVGMCCTPTW GAGCTGGCGGGCAAGGAGCTGTGCGCCATGTCG GCCUUCCAGGAGCUGGCGGGCAAGGAGCU TSGSQRPG GAGGAGCAGTTCCGCCAGCGCTCGCCCCTGGGTG GUGCGCCAUGUCGGAGGAGCAGUUCCGCC GGGATGTGCTGCACGCCCACCTGGACATCTGGAA AGCGCUCGCCCCUGGGUGGGGAUGUGCUG GTCAGCGGCCTGGATGA CACGCCCACCUGGACAUCUGGAAGUCAGCG GCCUGGAUGA   5 227/526 CTGGGGCGATTCACTACTGTGCCTCGACCAGTGA CUGGGGCGAUUCACUACUGUGCCUCGACC LGRFTTVPRPVRRAGPTARWTHHAPGSP GGAGAGCTGGACCGACAGCGAGGTGGACTCATC AGUGAGGAGAGCUGGACCGACAGCGAGGU STCGSSSRSCYSSPTAMAASLGGSTRRRA ATGCTCCGGGCAGCCCATCCACCTGTGGCAGTTCC GGACUCAUCAUGCUCCGGGCAGCCCAUCCA SSKLRTQPRWPGCGASARTVPP TCAAGGAGTTGCTACTCAAGCCCCACAGCTATGGC CCUGUGGCAGUUCCUCAAGGAGUUGCUAC CGCTTCATTAGGTGGCTCAACAAGGAGAAGGGCA UCAAGCCCCACAGCUAUGGCCGCUUCAUUA TCTTCAAAATTGAGGACTCAGCCCAGGTGGCCCG GGUGGCUCAACAAGGAGAAGGGCAUCUUC GCTGTGGGGCATCCGCAAGAACCGTCCCGCCATG AAAAUUGAGGACUCAGCCCAGGUGGCCCG A GCUGUGGGGCAUCCGCAAGAACCGUCCCG CCAUGA   6 228/527 CTGGCCCAGGGCCTGAAACCCGCCCTCAGGGGCC CUGGCCCAGGGCCUGAAACCCGCCCUCAGG LAQGLKPALRGLSPACPASARP TCTCTCCTGCCTGCCCTGCCTCAGCCAGGCCCTGA GGCCUCUCUCCUGCCUGCCCUGCCUCAGCC AGGCCCUGA   7 229/528 CTGACCTTCCAGAGCCCAAGGTCAGGGAGGGGCA CUGACCUUCCAGAGCCCAAGGUCAGGGAG LTFQSPRSGRGNQLPQGDMGPLGPSGP ACCAACTGCCCCAGGGGGATATGGGTCCTCTGGG GGGCAACCAACUGCCCCAGGGGGAUAUGG WGRGASSSGPAAPLEDRGRQGCSPTPA GCCTTCGGGACCCTGGGGCAGGGGTGCTTCCTCC GUCCUCUGGGGCCUUCGGGACCCUGGGGC SDPSISRAEPTEGQ TCAGGCCCAGCTGCTCCCCTGGAGGACAGAGGGA AGGGGUGCUUCCUCCUCAGGCCCAGCUGC GACAGGGCTGCTCCCCAACACCTGCCTCTGACCCC UCCCCUGGAGGACAGAGGGAGACAGGGCU AGCATTTCCAGAGCAGAGCCTACAGAAGGGCAGT GCUCCCCAACACCUGCCUCUGACCCCAGCA GA UUUCCAGAGCAGAGCCUACAGAAGGGCAG UGA   8 230/529 ATGGTGCAGGGAGACATCTGCACCCCTGAGTTGG AUGGUGCAGGGAGACAUCUGCACCCCUGA MVQGDICTPELGSQECPREWIIKILEN GCAGCCAGGAGTGCCCCCGGGAATGGATAATAAA GUUGGGCAGCCAGGAGUGCCCCCGGGAAU GATACTAGAGAACTGA GGAUAAUAAAGAUACUAGAGAACUGA   9 231/530 CTGCACTCTGCCGTGTCCACACTGCCCCACAGACC CUGCACUCUGCCGUGUCCACACUGCCCCAC LHSAVSTLPHRPSPPSLLPAPCKPLRLGLA CAGTCCTCCAAGCCTGCTGCCAGCTCCCTGCAAGC AGACCCAGUCCUCCAAGCCUGCUGCCAGCU TVPAGSPGLGVGDSLQARSPETSEGHPL CCCTCAGGTTGGGCCTTGCCACGGTGCCAGCAGG CCCUGCAAGCCCCUCAGGUUGGGCCUUGC RVARPPVANLSAASATSPAGPWFRWPP CAGCCCTGGGCTGGGGGTAGGGGACTCCCTACAG CACGGUGCCAGCAGGCAGCCCUGGGCUGG RCLAETRQWPQLPTPLPGP GCACGCAGCCCTGAGACCTCAGAGGGCCACCCCT GGGUAGGGGACUCCCUACAGGCACGCAGC TGAGGGTGGCCAGGCCCCCAGTGGCCAACCTGAG CCUGAGACCUCAGAGGGCCACCCCUUGAG TGCTGCCTCTGCCACCAGCCCTGCTGGCCCCTGGT GGUGGCCAGGCCCCCAGUGGCCAACCUGA TCCGCTGGCCCCCCAGATGCCTGGCTGAGACACG GUGCUGCCUCUGCCACCAGCCCUGCUGGCC CCAGTGGCCTCAGCTGCCCACACCTCTTCCCGGCC CCUGGUUCCGCUGGCCCCCCAGAUGCCUG CCTGA GCUGAGACACGCCAGUGGCCUCAGCUGCCC ACACCUCUUCCCGGCCCCUGA  10 232/531 CTGGAGTCCCAGTCCACCCGCCACGCCCGAGCAG CUGGAGUCCCAGUCCACCCGCCACGCCCGA LESQSTRHARAGPVRLLPLLL GGCCTGTCCGCCTTCTACCTCTCCTACTTTGA GCAGGGCCUGUCCGCCUUCUACCUCUCCU ACUUUGA  11 233/532 CTGCAAGCTGCTCAACATCACCGCAGATCCCATGG CUGCAAGCUGCUCAACAUCACCGCAGAUCC LQAAQHHRRSHGLEPQQCAEVAPVDRA ACTGGAGCCCCAGCAATGTGCAGAAGTGGCTCCT CAUGGACUGGAGCCCCAGCAAUGUGCAGA PIPAAPHGQGLPGAGGQGAVRHVGGAV GTGGACAGAGCACCAATACCGGCTGCCCCCCATG AGUGGCUCCUGUGGACAGAGCACCAAUAC PPALAPGWGCAARPPGHLEVSGLDERA GGCAAGGCCTTCCAGGAGCTGGCGGGCAAGGAG CGGCUGCCCCCCAUGGGCAAGGCCUUCCAG DFTWGDSLLCLDQ CTGTGCGCCATGTCGGAGGAGCAGTTCCGCCAGC GAGCUGGCGGGCAAGGAGCUGUGCGCCAU GCTCGCCCCTGGGTGGGGATGTGCTGCACGCCCA GUCGGAGGAGCAGUUCCGCCAGCGCUCGC CCTGGACATCTGGAAGTCAGCGGCCTGGATGAAA CCCUGGGUGGGGAUGUGCUGCACGCCCAC GAGCGGACTTCACCTGGGGCGATTCACTACTGTG CUGGACAUCUGGAAGUCAGCGGCCUGGAU CCTCGACCAGTGA GAAAGAGCGGACUUCACCUGGGGCGAUUC ACUACUGUGCCUCGACCAGUGA  12 234/533 CTGGACCGACAGCGAGGTGGACTCATCATGCTCC CUGGACCGACAGCGAGGUGGACUCAUCAU LDRQRGGLIMLRAAHPPVAVPQGVATQ GGGCAGCCCATCCACCTGTGGCAGTTCCTCAAGG GCUCCGGGCAGCCCAUCCACCUGUGGCAG APQLWPLH AGTTGCTACTCAAGCCCCACAGCTATGGCCGCTTC UUCCUCAAGGAGUUGCUACUCAAGCCCCAC ATTAG AGCUAUGGCCGCUUCAUUAG  13 235/534 GTGGGGCATCCGCAAGAACCGTCCCGCCATGAAC GUGGGGCAUCCGCAAGAACCGUCCCGCCA VGHPQEPSRHELRQAEPLHPPVLQEGHH TACGACAAGCTGAGCCGCTCCATCCGCCAGTATTA UGAACUACGACAAGCUGAGCCGCUCCAUCC PEARHLPAPRLPVRAPHLSAWPRA CAAGAAGGGCATCATCCGGAAGCCAGACATCTCC GCCAGUAUUACAAGAAGGGCAUCAUCCGG CAGCGCCTCGTCTACCAGTTCGTGCACCCCATCTG AAGCCAGACAUCUCCCAGCGCCUCGUCUAC AGTGCCTGGCCCAGGGCCTGA CAGUUCGUGCACCCCAUCUGAGUGCCUGG CCCAGGGCCUGA  14 236/535 CTGCCTGCCCTGCCTCAGCCAGGCCCTGAGATGG CUGCCUGCCCUGCCUCAGCCAGGCCCUGAG LPALPQPGPEMGENGQSALLL GGGAAAACGGGCAGTCTGCTCTGCTGCTCTGA AUGGGGGAAAACGGGCAGUCUGCUCUGCU GCUCUGA  15 237/536 GTGCTTCCTCCTCAGGCCCAGCTGCTCCCCTGGAG GUGCUUCCUCCUCAGGCCCAGCUGCUCCCC VLPPQAQLLPWRTEGDRAAPQHLPLTPA GACAGAGGGAGACAGGGCTGCTCCCCAACACCTG UGGAGGACAGAGGGAGACAGGGCUGCUCC FPEQSLQKGSDSTKATGSPGLSLLHPPAS CCTCTGACCCCAGCATTTCCAGAGCAGAGCCTACA CCAACACCUGCCUCUGACCCCAGCAUUUCC HSAPHLAWCRETSAPLSWAARSAPGNG GAAGGGCAGTGACTCGACAAAGGCCACAGGCAG AGAGCAGAGCCUACAGAAGGGCAGUGACU TCCAGGCCTCTCTCTGCTCCATCCCCCTGCCTCCCA CGACAAAGGCCACAGGCAGUCCAGGCCUCU TTCTGCACCACACCTGGCATGGTGCAGGGAGACA CUCUGCUCCAUCCCCCUGCCUCCCAUUCUG TCTGCACCCCTGAGTTGGGCAGCCAGGAGTGCCC CACCACACCUGGCAUGGUGCAGGGAGACA CCGGGAATGGATAA UCUGCACCCCUGAGUUGGGCAGCCAGGAG UGCCCCCGGGAAUGGAUAA  16 238/537 CTGTCTGACTTCCTCCCAGCACATTCCTGCACTCTG CUGUCUGACUUCCUCCCAGCACAUUCCUGC LSDFLPAHSCTLPCPHCPTDPVLQACCQL CCGTGTCCACACTGCCCCACAGACCCAGTCCTCCA ACUCUGCCGUGUCCACACUGCCCCACAGAC PASPSGWALPRCQQAALGWG AGCCTGCTGCCAGCTCCCTGCAAGCCCCTCAGGTT CCAGUCCUCCAAGCCUGCUGCCAGCUCCCU GGGCCTTGCCACGGTGCCAGCAGGCAGCCCTGGG GCAAGCCCCUCAGGUUGGGCCUUGCCACG CTGGGGGTAG GUGCCAGCAGGCAGCCCUGGGCUGGGGGU AG  17 239/538 GTGCCTGGCCCAGGGCCTGAAACCCGCCCTCAGG GUGCCUGGCCCAGGGCCUGAAACCCGCCCU VPGPGPETRPQGPLSCLPCLSQALRWGK GGCCTCTCTCCTGCCTGCCCTGCCTCAGCCAGGCC CAGGGGCCUCUCUCCUGCCUGCCCUGCCUC TGSLLCCSDLPEPKVREGQPTAPGGYGSS CTGAGATGGGGGAAAACGGGCAGTCTGCTCTGCT AGCCAGGCCCUGAGAUGGGGGAAAACGGG GAFGTLGQGCFLLRPSCSPGGQRETGLLP GCTCTGACCTTCCAGAGCCCAAGGTCAGGGAGGG CAGUCUGCUCUGCUGCUCUGACCUUCCAG NTCL GCAACCAACTGCCCCAGGGGGATATGGGTCCTCT AGCCCAAGGUCAGGGAGGGGCAACCAACU GGGGCCTTCGGGACCCTGGGGCAGGGGTGCTTCC GCCCCAGGGGGAUAUGGGUCCUCUGGGGC TCCTCAGGCCCAGCTGCTCCCCTGGAGGACAGAG CUUCGGGACCCUGGGGCAGGGGUGCUUCC GGAGACAGGGCTGCTCCCCAACACCTGCCTCTGA UCCUCAGGCCCAGCUGCUCCCCUGGAGGAC AGAGGGAGACAGGGCUGCUCCCCAACACC UGCCUCUGA  18 240/539 GTGACTCGACAAAGGCCACAGGCAGTCCAGGCCT GUGACUCGACAAAGGCCACAGGCAGUCCA VTRQRPQAVQASLCSIPLPPILHHTWHG CTCTCTGCTCCATCCCCCTGCCTCCCATTCTGCACC GGCCUCUCUCUGCUCCAUCCCCCUGCCUCC AGRHLHP ACACCTGGCATGGTGCAGGGAGACATCTGCACCC CAUUCUGCACCACACCUGGCAUGGUGCAG CTGA GGAGACAUCUGCACCCCUGA TP53 neo- antigen DNA sequence RNA sequence Protein sequence   1 241/540 CTGACATTCTCCACTTCTTGTTCCCCACTGACAGCC CUGACAUUCUCCACUUCUUGUUCCCCACU LTFSTSCSPLTASHPHLSLPCHFGFWVFEP TCCCACCCCCATCTCTCCCTCCCCTGCCATTTTGGG GACAGCCUCCCACCCCCAUCUCUCCCUCCCC LLAIGVRQKHPGLPFALSRGSTEQVGLH TTTTGGGTCTTTGAACCCTTGCTTGCAATAGGTGT UGCCAUUUUGGGUUUUGGGUCUUUGAAC WCFVVGRRMGSRTYQLRF GCGTCAGAAGCACCCAGGACTTCCATTTGCTTTGT CCUUGCUUGCAAUAGGUGUGCGUCAGAAG CCCGGGGCTCCACTGAACAAGTTGGCCTGCACTG CACCCAGGACUUCCAUUUGCUUUGUCCCG GTGTTTTGTTGTGGGGAGGAGGATGGGGAGTAG GGGCUCCACUGAACAAGUUGGCCUGCACU GACATACCAGCTTAGATTTTAA GGUGUUUUGUUGUGGGGAGGAGGAUGG GGAGUAGGACAUACCAGCUUAGAUUUUAA   2 242/541 TTGGGCAGCTGGTTAGGTAGAGGGAGTTGTCAAG UUGGGCAGCUGGUUAGGUAGAGGGAGUU LGSWLGRGSCQVSAGPAKPCLTTSW TCTCTGCTGGCCCAGCCAAACCCTGTCTGACAACC GUCAAGUCUCUGCUGGCCCAGCCAAACCCU TCTTGGTGA GUCUGACAACCUCUUGGUGA   3 243/542 ATGGGATTGGGGTTTTCCCCTCCCATGTGCTCAAG AUGGGAUUGGGGUUUUCCCCUCCCAUGU MGLGFSPPMCSRLALKVLSFSKV ACTGGCGCTAAAAGTTTTGAGCTTCTCAAAAGTCT GCUCAAGACUGGCGCUAAAAGUUUUGAGC AG UUCUCAAAAGUCUAG   4 244/543 TTGTTCCCTCTCCCTGTTGGTCGGTGGGTTGGTAG UUGUUCCCUCUCCCUGUUGGUCGGUGGG LFPLPVGRWVGSFYSWAAG TTTCTACAGTTGGGCAGCTGGTTAG UUGGUAGUUUCUACAGUUGGGCAGCUGG UUAG   5 245/544 CTGACTCAGACTGACATTCTCCACTTCTTGTTCCCC CUGACUCAGACUGACAUUCUCCACUUCUU LTQTDILHFLFPTDSLPPPSLPPLPFWVLG ACTGACAGCCTCCCACCCCCATCTCTCCCTCCCCTG GUUCCCCACUGACAGCCUCCCACCCCCAUC L CCATTTTGGGTTTTGGGTCTTTGA UCUCCCUCCCCUGCCAUUUUGGGUUUUGG GUCUUUGA   6 246/545 CTGTCCCTCACTGTTGAATTTTCTCTAACTTCAAGG CUGUCCCUCACUGUUGAAUUUUCUCUAAC LSLTVEFSLTSRPISVKCWHLHLPHRVHCE CCCATATCTGTGAAATGCTGGCATTTGCACCTACC UUCAAGGCCCAUAUCUGUGAAAUGCUGGC G TCACAGAGTGCATTGTGAGGGTTAA AUUUGCACCUACCUCACAGAGUGCAUUGU GAGGGUUAA   7 247/546 CTGGCCTTGAAACCACCTTTTATTACATGGGGTCT CUGGCCUUGAAACCACCUUUUAUUACAUG LALKPPFITWGLELDPLEGACSLSLLVGGL AGAACTTGACCCCCTTGAGGGTGCTTGTTCCCTCT GGGUCUAGAACUUGACCCCCUUGAGGGUG VVSTVGQLVR CCCTGTTGGTCGGTGGGTTGGTAGTTTCTACAGTT CUUGUUCCCUCUCCCUGUUGGUCGGUGGG GGGCAGCTGGTTAGGTAG UUGGUAGUUUCUACAGUUGGGCAGCUGG UUAGGUAG   8 248/547 TTGTCAAGTCTCTGCTGGCCCAGCCAAACCCTGTC UUGUCAAGUCUCUGCUGGCCCAGCCAAAC LSSLCWPSQTLSDNLLVNLST TGACAACCTCTTGGTGAACCTTAGTACCTAA CCUGUCUGACAACCUCUUGGUGAACCUUA GUACCUAA   9 249/548 CTGGATCCACCAAGACTTGTTTTATGCTCAGGGTC CUGGAUCCACCAAGACUUGUUUUAUGCUC LDPPRLVLCSGSISFFFFFFFFLFL AATTTCTTTTTTCTTTTTTTTTTTTTTTTTTCTTTTTCT AGGGUCAAUUUCUUUUUUCUUUUUUUUU TTGA UUUUUUUUUCUUUUUCUUUGA  10 250/549 GTGTTGCCCAGGCTGGTCTCAAACTCCTGGGCTCA GUGUUGCCCAGGCUGGUCUCAAACUCCU GVLPRLVSNSWAQAIHLSQPPRVLGLQL GGCGATCCACCTGTCTCAGCCTCCCAGAGTGCTGG GGCUCAGGCGAUCCACCUGUCUCAGCCUCC GATTACAATTGTGA CAGAGUGCUGGGAUUACAAUUGUGA ERG neo- antigen DNA sequences RNA sequences Protein sequences   1 251/550 CTGGACCGGTCACGGCCACCCCACGCCCCAGTCG CUGGACCGGUCACGGCCACCCCACGCCCCA LDRSRPPHAPVESCSTISFHSAQN AAAGCTGCTCAACCATCTCCTTCCACAGTGCCCAA GUCGAAAGCUGCUCAACCAUCUCCUUCCAC AACTGA AGUGCCCAAAACUGA   2 252/551 TTGGCAGTTCCTCCTGGAGCTCCTGTCGGACAGCT UUGGCAGUUCCUCCUGGAGCUCCUGUCGG LAVPPGAPVGQLQLQLHHLGRHQRGVQ CCAACTCCAGCTGCATCACCTGGGAAGGCACCAA ACAGCUCCAACUCCAGCUGCAUCACCUGGG DDGSRRGGPALGRAEEQTQHELR CGGGGAGTTCAAGATGACGGATCCCGACGAGGT AAGGCACCAACGGGGAGUUCAAGAUGACG GGCCCGGCGCTGGGGAGAGCGGAAGAGCAAACC GAUCCCGACGAGGUGGCCCGGCGCUGGGG CAACATGAACTACGATAA AGAGCGGAAGAGCAAACCCAACAUGAACUA CGAUAA   3 253/552 GTGGCCCATCAACAGACGTTGATATGCAACTGCAT GUGGCCCAUCAACAGACGUUGAUAUGCAA VAHQQTLICNCMACAVLVEIKYIPFDGQL GGCATGTGCTGTTTTGGTTGAAATCAAATACATTC CUGCAUGGCAUGUGCUGUUUUGGUUGAA SAFSNCEDDPKFPTPLQYYRDYELKGGTE CGTTTGATGGACAGCTGTCAGCTTTCTCAAACTGT AUCAAAUACAUUCCGUUUGAUGGACAGCU DVYRVSV GAAGATGACCCAAAGTTTCCAACTCCTTTACAGTA GUCAGCUUUCUCAAACUGUGAAGAUGACC TTACCGGGACTATGAACTAAAAGGTGGGACTGAG CAAAGUUUCCAACUCCUUUACAGUAUUAC GATGTGTATAGAGTGAGCGTGTGA CGGGACUAUGAACUAAAAGGUGGGACUGA GGAUGUGUAUAGAGUGAGCGUGUGA   4 254/553 CTGGACTCAGGACATTTGGGGACTGTGTACAATG CUGGACUCAGGACAUUUGGGGACUGUGU LDSGHLGTVYNELWRLEGSCSQCYTKPS AGTTATGGAGACTCGAGGGTTCATGCAGTCAGTG ACAAUGAGUUAUGGAGACUCGAGGGUUCA VRRKDTA TTATACCAAACCCAGTGTTAGGAGAAAGGACACA UGCAGUCAGUGUUAUACCAAACCCAGUGU GCGTAA UAGGAGAAAGGACACAGCGUAA   5 255/554 ATGGCCTTCTTGGCTGCCACAATCAGAAATCACGC AUGGCCUUCUUGGCUGCCACAAUCAGAAA MAFLAATIRNHAGILGRRPPVFL AGGCATTTTGGGTAGGCGGCCTCCAGTTTTCCTTT UCACGCAGGCAUUUUGGGUAGGCGGCCUC GA CAGUUUUCCUUUGA   6 256/555 ATGCTTAATGTTTACAATATGAAGTTATTAGTTCTT AUGCUUAAUGUUUACAAUAUGAAGUUAU MLNVYNMKLLVLRMQNVCNKISLA AGAATGCAGAATGTATGTAATAAAATAAGCTTGG UAGUUCUUAGAAUGCAGAAUGUAUGUAA CCTAG UAAAAUAAGCUUGGCCUAG   7 257/556 TTGGGATTCACTAGCCCTGAGCCTGATGTTGCTGG UUGGGAUUCACUAGCCCUGAGCCUGAUGU LGFTSPEPDVAGYPLKTMFISII CTATCCCTTGAAGACAATGTTTATTTCCATAATCTA UGCUGGCUAUCCCUUGAAGACAAUGUUUA G UUUCCAUAAUCUAG   8 258/557 ATGTTTTCCATTAGATCCCTCAACCCTCCACCCCCA AUGUUUUCCAUUAGAUCCCUCAACCCUCC MFSIRSLNPPPPVQVISKSYEQLG GTCCAGGTTATTAGCAAGTCTTATGAGCAACTGG ACCCCCAGUCCAGGUUAUUAGCAAGUCUU GATAA AUGAGCAACUGGGAUAA   9 259/558 GTGGCACCTGCAACCCAGGAGCAGGAGCCGGAG GUGGCACCUGCAACCCAGGAGCAGGAGCC VAPATQEQEPEELPSDSRCSRDGYSSGA GAGCTGCCCTCTGACAGCAGGTGCAGCAGAGATG GGAGGAGCUGCCCUCUGACAGCAGGUGCA GKVMGHRESTDVLQRPKVTHCLEKEKKI GCTACAGCTCAGGAGCTGGGAAGGTGATGGGGC GCAGAGAUGGCUACAGCUCAGGAGCUGGG FFKKLVYLASH ACAGGGAAAGCACAGATGTTCTGCAGCGCCCCAA AAGGUGAUGGGGCACAGGGAAAGCACAGA AGTGACCCATTGCCTGGAGAAAGAGAAGAAAATA UGUUCUGCAGCGCCCCAAAGUGACCCAUU TTTTTTAAAAAGCTAGTTTATTTAGCTTCTCATTAA GCCUGGAGAAAGAGAAGAAAAUAUUUUUU AAAAAGCUAGUUUAUUUAGCUUCUCAUUA A  10 260/559 ATGAATCAAAAGTGCCTCAAGAGGAATGAAAAAA AUGAAUCAAAAGUGCCUCAAGAGGAAUGA MNQKCLKRNEKSFTGAGEGSRGRDPKTL GCTTTACTGGGGCTGGGGAAGGAAGCCGGGGAA AAAAAGCUUUACUGGGGCUGGGGAAGGAA GRELLKSYYRNEEDAKNVTNMDISSVD GAGATCCAAAGACTCTTGGGAGGGAGTTACTGAA GCCGGGGAAGAGAUCCAAAGACUCUUGGG GTCTTACTACAGAAATGAGGAGGATGCTAAAAAT AGGGAGUUACUGAAGUCUUACUACAGAAA GTCACGAATATGGACATATCATCTGTGGACTGA UGAGGAGGAUGCUAAAAAUGUCACGAAUA UGGACAUAUCAUCUGUGGACUGA  11 261/560 GTGCTGTTTTGGTTGAAATCAAATACATTCCGTTT GUGCUGUUUUGGUUGAAAUCAAAUACAU VLFWLKSNTFRLMDSCQLSQTVKMTQSF GATGGACAGCTGTCAGCTTTCTCAAACTGTGAAG UCCGUUUGAUGGACAGCUGUCAGCUUUCU QLLYSITGTMN ATGACCCAAAGTTTCCAACTCCTTTACAGTATTACC CAAACUGUGAAGAUGACCCAAAGUUUCCA GGGACTATGAACTAA ACUCCUUUACAGUAUUACCGGGACUAUGA ACUAA  12 262/561 CTGTGTACAATGAGTTATGGAGACTCGAGGGTTC CUGUGUACAAUGAGUUAUGGAGACUCGA LCTMSYGDSRVHAVSVIPNPVLGERTQR ATGCAGTCAGTGTTATACCAAACCCAGTGTTAGGA GGGUUCAUGCAGUCAGUGUUAUACCAAAC NGERGSSRIQKQKCASLSLFVK GAAAGGACACAGCGTAATGGAGAAAGGGGAAGT CCAGUGUUAGGAGAAAGGACACAGCGUAA AGTAGAATTCAGAAACAAAAATGCGCATCTCTTTC UGGAGAAAGGGGAAGUAGUAGAAUUCAG TTTGTTTGTCAAATGA AAACAAAAAUGCGCAUCUCUUUCUUUGUU UGUCAAAUGA  13 263/562 GTGGGGGCTTTGTTCTCCACAGGGTCAGGTAAGA GUGGGGGCUUUGUUCUCCACAGGGUCAG VGALFSTGSGKRWPSWLPQSEITQAFW GATGGCCTTCTTGGCTGCCACAATCAGAAATCACG GUAAGAGAUGGCCUUCUUGGCUGCCACAA VGGLQFSFESRTLCVCQNEVYKSMFFPLF CAGGCATTTTGGGTAGGCGGCCTCCAGTTTTCCTT UCAGAAAUCACGCAGGCAUUUUGGGUAGG I TGAGTCGCGAACGCTGTGCGTTTGTCAGAATGAA CGGCCUCCAGUUUUCCUUUGAGUCGCGAA GTATACAAGTCAATGTTTTTCCCCCTTTTTATATAA CGCUGUGCGUUUGUCAGAAUGAAGUAUAC AAGUCAAUGUUUUUCCCCCUUUUUAUAUA A  14 264/563 ATGAAAACATGTGCTGAATGTTGTGGATTTTGTGT AUGAAAACAUGUGCUGAAUGUUGUGGAU MKTCAECCGFCVIIYFVQELVQGRAKEIG TATAATTTACTTTGTCCAGGAACTTGTGCAAGGGA UUUGUGUUAUAAUUUACUUUGUCCAGGA CLAPKWRQPLQVLLASPPVFYF GAGCCAAGGAAATAGGATGTTTGGCACCCAAATG ACUUGUGCAAGGGAGAGCCAAGGAAAUAG GCGTCAGCCTCTCCAGGTCCTTCTTGCCTCCCCTCC GAUGUUUGGCACCCAAAUGGCGUCAGCCU TGTCTTTTATTTCTAG CUCCAGGUCCUUCUUGCCUCCCCUCCUGUC UUUUAUUUCUAG  15 265/564 TTGGAACAGAAGGACCCCGGGTTTCACATTGGAG UUGGAACAGAAGGACCCCGGGUUUCACAU LEQKDPGFHIGASIFMPGMERGL CCTCCATATTTATGCCTGGAATGGAAAGAGGCCTA UGGAGCCUCCAUAUUUAUGCCUGGAAUGG TGA AAAGAGGCCUAUGA  16 266/565 GTGAACAAGCTACCACTCGTAAGGCAAACTGTATT GUGAACAAGCUACCACUCGUAAGGCAAAC VNKLPLVRQTVLLLANKASWIAAISHFTET ATTACTGGCAAATAAAGCGTCATGGATAGCTGCA UGUAUUAUUACUGGCAAAUAAAGCGUCAU RDNV ATTTCTCACTTTACAGAAACAAGGGATAACGTCTA GGAUAGCUGCAAUUUCUCACUUUACAGAA G ACAAGGGAUAACGUCUAG  17 267/566 CTGCTACATCAGAGTTACCTGGGCACTGTGGCTTG CUGCUACAUCAGAGUUACCUGGGCACUGU LLHQSYLGTVAWDSLALSLMLLAIP GGATTCACTAGCCCTGAGCCTGATGTTGCTGGCTA GGCUUGGGAUUCACUAGCCCUGAGCCUGA TCCCTTGA UGUUGCUGGCUAUCCCUUGA  18 268/567 ATGCTGCCAACCTTGGTCCAGGTGAAGGCAACTC AUGCUGCCAACCUUGGUCCAGGUGAAGGC MLPTLVQVKATQKVKIQGDRAKALAETS AAAAGGTGAAAATACAAGGTGACCGTGCGAAGG AACUCAAAAGGUGAAAAUACAAGGUGACC CGCTAGCCGAAACATCTTAG GUGCGAAGGCGCUAGCCGAAACAUCUUAG  19 269/568 GTGCTGTGGATGTTTTGGCAGTGGGCTTTGAAGT GUGCUGUGGAUGUUUUGGCAGUGGGCUU VLWMFWQWALKSAGHDYQCS CGGCAGGACACGATTACCAATGCTCCTGA UGAAGUCGGCAGGACACGAUUACCAAUGC UCCUGA  20 270/569 GTGTCATTTGGATTAGACGGAGCCCAACCATCCAT GUGUCAUUUGGAUUAGACGGAGCCCAACC VSFGLDGAQPSIILQQPGKAHKVPVSP CATTTTGCAGCAGCCTGGGAAGGCCCACAAAGTG AUCCAUCAUUUUGCAGCAGCCUGGGAAGG CCCGTATCTCCTTAG CCCACAAAGUGCCCGUAUCUCCUUAG  21 271/570 ATGATTATCATATTCAATTTTAACAGATGTTTTCCA AUGAUUAUCAUAUUCAAUUUUAACAGAUG MIIIFNFNRCFPLDPSTLHPQSRLLASLMS TTAGATCCCTCAACCCTCCACCCCCAGTCCAGGTT UUUUCCAUUAGAUCCCUCAACCCUCCACCC NWDNFG ATTAGCAAGTCTTATGAGCAACTGGGATAATTTTG CCAGUCCAGGUUAUUAGCAAGUCUUAUGA GATAA GCAACUGGGAUAAUUUUGGAUAA  22 272/571 CTGTACAATCTTACTCCTGCTGGCAAGAGATTTGT CUGUACAAUCUUACUCCUGCUGGCAAGAG LYNLTPAGKRFVFFSCLQLAFGPCMW CTTCTTTTCTTGTCTTCAATTGGCTTTCGGGCCTTG AUUUGUCUUCUUUUCUUGUCUUCAAUUG TATGTGGTAA GCUUUCGGGCCUUGUAUGUGGUAA  23 273/572 ATGTGGCACCTGCAACCCAGGAGCAGGAGCCGGA AUGUGGCACCUGCAACCCAGGAGCAGGAG MWHLQPRSRSRRSCPLTAGAAEMATAQ GGAGCTGCCCTCTGACAGCAGGTGCAGCAGAGAT CCGGAGGAGCUGCCCUCUGACAGCAGGUG ELGR GGCTACAGCTCAGGAGCTGGGAAGGTGA CAGCAGAGAUGGCUACAGCUCAGGAGCUG GGAAGGUGA  24 274/573 GTGAGGACCAGTCGTTGTTTGAGTGTGCCTACGG GUGAGGACCAGUCGUUGUUUGAGUGUGC VRTSRCLSVPTERHTWLRQR AACGCCACACCTGGCTAAGACAGAGATGA CUACGGAACGCCACACCUGGCUAAGACAGA GAUGA  25 275/574 ATGGCTCAAGGAACTCTCCTGATGAATGCAGTGT AUGGCUCAAGGAACUCUCCUGAUGAAUGC MAQGTLLMNAVWPKAGRWWAAQTPL GGCCAAAGGCGGGAAGATGGTGGGCAGCCCAGA AGUGUGGCCAAAGGCGGGAAGAUGGUGG G CACCGTTGGGATGA GCAGCCCAGACACCGUUGGGAUGA  26 276/575 ATGGCCTTCCAGACGTCAACATCTTGTTATTCCAG AUGGCCUUCCAGACGUCAACAUCUUGUUA MAFQTSTSCYSRTSMGRNCAR AACATCGATGGGAAGGAACTGTGCAAGATGA UUCCAGAACAUCGAUGGGAAGGAACUGUG CAAGAUGA  27 277/576 ATGCTAGAAACACAGGGGGTGCAGCTTTTATTTTC AUGCUAGAAACACAGGGGGUGCAGCUUUU MLETQGVQLLFSQ1LQYILKLRKELQLGQI CCAAATACTTCAGTATATCCTGAAGCTACGCAAAG AUUUUCCCAAAUACUUCAGUAUAUCCUGA YHMSPPGDQPGPVTATPRPSRKLLNHLL AATTACAACTAGGCCAGATTTACCATATGAGCCCC AGCUACGCAAAGAAUUACAACUAGGCCAG PQCPKLKTSVLS CCAGGAGATCAGCCTGGACCGGTCACGGCCACCC AUUUACCAUAUGAGCCCCCCAGGAGAUCA CACGCCCCAGTCGAAAGCTGCTCAACCATCTCCTT GCCUGGACCGGUCACGGCCACCCCACGCCC CCACAGTGCCCAAAACTGAAGACCAGCGTCCTCA CAGUCGAAAGCUGCUCAACCAUCUCCUUCC GTTAG ACAGUGCCCAAAACUGAAGACCAGCGUCCU CAGUUAG  28 278/577 TTGGACCAACAAGTAGCCGCCTTGCAAATCCAGG UUGGACCAACAAGUAGCCGCCUUGCAAAU LDQQVAALQIQAVARSSFGSSSWSSCRT CAGTGGCCAGATCCAGCTTTGGCAGTTCCTCCTGG CCAGGCAGUGGCCAGAUCCAGCUUUGGCA APTPAASPGKAPTGSSR AGCTCCTGTCGGACAGCTCCAACTCCAGCTGCATC GUUCCUCCUGGAGCUCCUGUCGGACAGCU ACCTGGGAAGGCACCAACGGGGAGTTCAAGATG CCAACUCCAGCUGCAUCACCUGGGAAGGCA A CCAACGGGGAGUUCAAGAUGA  29 279/578 ATGGGAAGCGCTACGCCTACAAGTTCGACTTCCAC AUGGGAAGCGCUACGCCUACAAGUUCGAC MGSATPTSSTSTGSPRPSSPTPRSHLCTST GGGATCGCCCAGGCCCTCCAGCCCCACCCCCCGG UUCCACGGGAUCGCCCAGGCCCUCCAGCCC PQTSRTWAPITPTHRR AGTCATCTCTGTACAAGTACCCCTCAGACCTCCCG CACCCCCCGGAGUCAUCUCUGUACAAGUAC TACATGGGCTCCTATCACGCCCACCCACAGAAGAT CCCUCAGACCUCCCGUACAUGGGCUCCUAU GA CACGCCCACCCACAGAAGAUGA  30 280/579 TTGCTGCCCCAAACCCATACTGGAATTCACCAACT UUGCUGCCCCAAACCCAUACUGGAAUUCAC LLPQTHTGIHQLGVYTPTLGSPPAICLLIW GGGGGTATATACCCCAACACTAGGCTCCCCACCA CAACUGGGGGUAUAUACCCCAACACUAGG ALTTKDLAEAFPISVHSPAHRHKLYRRT GCCATATGCCTTCTCATCTGGGCACTTACTACTAA CUCCCCACCAGCCAUAUGCCUUCUCAUCUG AGACCTGGCGGAGGCTTTTCCCATCAGCGTGCATT GGCACUUACUACUAAAGACCUGGCGGAGG CACCAGCCCATCGCCACAAACTCTATCGGAGAACA CUUUUCCCAUCAGCGUGCAUUCACCAGCCC TGA AUCGCCACAAACUCUAUCGGAGAACAUGA  31 281/580 ATGAAAAAAGCTTTACTGGGGCTGGGGAAGGAA AUGAAAAAAGCUUUACUGGGGCUGGGGAA MKKALLGLGKEAGEEIQRLLGGSY GCCGGGGAAGAGATCCAAAGACTCTTGGGAGGG GGAAGCCGGGGAAGAGAUCCAAAGACUCU AGTTACTGA UGGGAGGGAGUUACUGA  32 282/581 ATGAGGAGGATGCTAAAAATGTCACGAATATGGA AUGAGGAGGAUGCUAAAAAUGUCACGAAU MRRMLKMSRIWTYHLWTDLVKDSVCRS CATATCATCTGTGGACTGACCTTGTAAAAGACAGT AUGGACAUAUCAUCUGUGGACUGACCUUG MKS GTATGTAGAAGCATGAAGTCTTAA UAAAAGACAGUGUAUGUAGAAGCAUGAAG UCUUAA  33 283/582 CTGTATTTAAAAATAGAAACATATCAAAAACAAGA CUGUAUUUAAAAAUAGAAACAUAUCAAAA LYLKIETYQKQEKRHERDCGPSTDVDMQ GAAAAGACACGAGAGAGACTGTGGCCCATCAACA ACAAGAGAAAAGACACGAGAGAGACUGUG LHGMCCFG GACGTTGATATGCAACTGCATGGCATGTGCTGTTT GCCCAUCAACAGACGUUGAUAUGCAACUG TGGTTGA CAUGGCAUGUGCUGUUUUGGUUGA  34 284/583 GTGATTGTAGACAGAGGGGTGAAGAAGGAGGAG GUGAUUGUAGACAGAGGGGUGAAGAAGG VIVDRGVKKEEEEAEKEETRAGKETSQA GAAGAGGCAGAGAAGGAGGAGACCAGGGCTGG AGGAGGAAGAGGCAGAGAAGGAGGAGACC MKTGLRTFGDCVQ GAAAGAAACTTCTCAAGCAATGAAGACTGGACTC AGGGCUGGGAAAGAAACUUCUCAAGCAAU AGGACATTTGGGGACTGTGTACAATGA GAAGACUGGACUCAGGACAUUUGGGGACU GUGUACAAUGA  35 285/584 ATGGAGAAAGGGGAAGTAGTAGAATTCAGAAAC AUGGAGAAAGGGGAAGUAGUAGAAUUCA MEKGEVVEFRNKNAHLFLCLSNENFNW AAAAATGCGCATCTCTTTCTTTGTTTGTCAAATGAA GAAACAAAAAUGCGCAUCUCUUUCUUUGU NCLIFKRNIQDLIIMWGLCSPQGQVRDG AATTTTAACTGGAATTGTCTGATATTTAAGAGAAA UUGUCAAAUGAAAAUUUUAACUGGAAUU LLGCHNQKSRRHFG CATTCAGGACCTCATCATTATGTGGGGGCTTTGTT GUCUGAUAUUUAAGAGAAACAUUCAGGAC CTCCACAGGGTCAGGTAAGAGATGGCCTTCTTGG CUCAUCAUUAUGUGGGGGCUUUGUUCUC CTGCCACAATCAGAAATCACGCAGGCATTTTGGGT CACAGGGUCAGGUAAGAGAUGGCCUUCUU AG GGCUGCCACAAUCAGAAAUCACGCAGGCA UUUUGGGUAG  36 286/585 TTGAGTCGCGAACGCTGTGCGTTTGTCAGAATGA UUGAGUCGCGAACGCUGUGCGUUUGUCA LSRERCAFVRMKYTSQCFSPFLYNNYITY AGTATACAAGTCAATGTTTTTCCCCCTTTTTATATA GAAUGAAGUAUACAAGUCAAUGUUUUUCC AFIHYELISASQRHTTKETIDIMWP ATAATTATATAACTTATGCATTTATACACTACGAGT CCCUUUUUAUAUAAUAAUUAUAUAACUUA TGATCTCGGCCAGCCAAAGACACACGACAAAAGA UGCAUUUAUACACUACGAGUUGAUCUCGG GACAATCGATATAATGTGGCCTTGA CCAGCCAAAGACACACGACAAAAGAGACAA UCGAUAUAAUGUGGCCUUGA  37 287/586 TTGCCTCCCCTCCTGTCTTTTATTTCTAGCCCCTTTT UUGCCUCCCCUCCUGUCUUUUAUUUCUAG LPPLLSFISSPFWNRRTPGFTLEPPYLCLE GGAACAGAAGGACCCCGGGTTTCACATTGGAGCC CCCCUUUUGGAACAGAAGGACCCCGGGUU WKEAYEAGVVIEKF TCCATATTTATGCCTGGAATGGAAAGAGGCCTATG UCACAUUGGAGCCUCCAUAUUUAUGCCUG AAGCTGGGGTTGTCATTGAGAAATTCTAG GAAUGGAAAGAGGCCUAUGAAGCUGGGG UUGUCAUUGAGAAAUUCUAG  38 288/587 CTGCAATTTCTCACTTTACAGAAACAAGGGATAAC CUGCAAUUUCUCACUUUACAGAAACAAGG LQFLTLQKQGITSRFAAGFLFQELSLGRQL GTCTAGATTTGCTGCGGGGTTTCTCTTTCAGGAGC GAUAACGUCUAGAUUUGCUGCGGGGUUU TCTCACTAGGTAGACAGCTTTAG CUCUUUCAGGAGCUCUCACUAGGUAGACA GCUUUAG  39 289/588 CTGGCAGTTAGGCTGACCCAAACTGTGCTAATGG CUGGCAGUUAGGCUGACCCAAACUGUGCU LAVRLTQTVLMEKISHFYFGMQSQDTPT AAAAGATCAGTCATTTTTATTTTGGAATGCAAAGT AAUGGAAAAGAUCAGUCAUUUUUAUUUU FFIEIHIYLDNHSVLSSRLSHEQDHKNKT CAAGACACACCTACATTCTTCATAGAAATACACAT GGAAUGCAAAGUCAAGACACACCUACAUU TTACTTGGATAATCACTCAGTTCTCTCTTCAAGACT CUUCAUAGAAAUACACAUUUACUUGGAUA GTCTCATGAGCAAGATCATAAAAACAAGACATGA AUCACUCAGUUCUCUCUUCAAGACUGUCU CAUGAGCAAGAUCAUAAAAACAAGACAUG A  40 290/589 TTGGATAACATGATAATACTGAGTTCCTTCAAATA UUGGAUAACAUGAUAAUACUGAGUUCCUU LDNMIILSSFKYIILKLFQNGINSLLLL CATAATTCTTAAATTGTTTCAAAATGGCATTAACTC CAAAUACAUAAUUCUUAAAUUGUUUCAAA TCTGTTACTGTTGTAA AUGGCAUUAACUCUCUGUUACUGUUGUA A  41 291/590 TTGCATGAACCTTTTCTCTCTGTTTGTCCCTGTCTCT UUGCAUGAACCUUUUCUCUCUGUUUGUCC LHEPFLSVCPCLLACPDVYSDSCTILLLLAR TGGCTTGCCCTGATGTATACTCAGACTCCTGTACA CUGUCUCUUGGCUUGCCCUGAUGUAUACU DLSSFLVFNWLSGLVCGKITKSQSRLCFCS ATCTTACTCCTGCTGGCAAGAGATTTGTCTTCTTTT CAGACUCCUGUACAAUCUUACUCCUGCUG CTTGTCTTCAATTGGCTTTCGGGCCTTGTATGTGGT GCAAGAGAUUUGUCUUCUUUUCUUGUCU AAAATCACCAAATCACAGTCAAGACTGTGTTTTTG UCAAUUGGCUUUCGGGCCUUGUAUGUGG TTCCTAG UAAAAUCACCAAAUCACAGUCAAGACUGU GUUUUUGUUCCUAG  42 292/591 ATGTCCCGGAGGGGTTCACAAAGTGCTTTGTCAG AUGUCCCGGAGGGGUUCACAAAGUGCUUU MSRRGSQSALSGLLQLEGSLLLLSLLHRC GACTGCTGCAGTTAGAAGGCTCACTGCTTCTCCTA GUCAGGACUGCUGCAGUUAGAAGGCUCAC GTCNPGAGAGGAAL AGCCTTCTGCACAGATGTGGCACCTGCAACCCAG UGCUUCUCCUAAGCCUUCUGCACAGAUGU GAGCAGGAGCCGGAGGAGCTGCCCTCTGA GGCACCUGCAACCCAGGAGCAGGAGCCGGA GGAGCUGCCCUCUGA  43 293/592 GTGCAGCAGAGATGGCTACAGCTCAGGAGCTGG GUGCAGCAGAGAUGGCUACAGCUCAGGAG VQQRWLQLRSWEGDGAQGKHRCSAAP GAAGGTGATGGGGCACAGGGAAAGCACAGATGT CUGGGAAGGUGAUGGGGCACAGGGAAAGC QSDPLPGEREENIF TCTGCAGCGCCCCAAAGTGACCCATTGCCTGGAG ACAGAUGUUCUGCAGCGCCCCAAAGUGAC AAAGAGAAGAAAATATTTTTTAA CCAUUGCCUGGAGAAAGAGAAGAAAAUAU UUUUUAA  44 (BSS) 294/593 ATGCAGTGTGGCCAAAGGCGGGAAGATGGTGGG AUGCAGUGUGGCCAAAGGCGGGAAGAUGG MQCGQRREDGGQPRHRWDELRQLHG CAGCCCAGACACCGTTGGGATGAACTACGGCAGC UGGGCAGCCCAGACACCGUUGGGAUGAAC GEAHATPKHDHERAQSYRASRNSPDECS TACATGGAGGAGAAGCACATGCCACCCCCAAACA UACGGCAGCUACAUGGAGGAGAAGCACAU VAKGGKMVGSPDTVGMNYGSYMEEKH TGACCACGAACGAGCGCAGAGTTATCGTGCCAGC GCCACCCCCAAACAUGACCACGAACGAGCG MPPPNMTTNERRVIVPA AGGAACTCTCCTGATGAATGCAGTGTGGCCAAAG CAGAGUUAUCGUGCCAGCAGGAACUCUCC GCGGGAAGATGGTGGGCAGCCCAGACACCGTTG UGAUGAAUGCAGUGUGGCCAAAGGCGGGA GGATGAACTACGGCAGCTACATGGAGGAGAAGC AGAUGGUGGGCAGCCCAGACACCGUUGGG ACATGCCACCCCCAAACATGACCACGAACGAGCG AUGAACUACGGCAGCUACAUGGAGGAGAA CAGAGTTATCGTGCCAGCA GCACAUGCCACCCCCAAACAUGACCACGAA CGAGCGCAGAGUUAUCGUGCCAGCA  45 (BSS) 295/594 GTGGCCAAAGGCGGGAAGATGGTGGGCAGCCCA GUGGCCAAAGGCGGGAAGAUGGUGGGCA VAKGGKMVGSPDTVGMNYGSYMEEKH GACACCGTTGGGATGAACTACGGCAGCTACATGG GCCCAGACACCGUUGGGAUGAACUACGGC MPPPNMTTNERRVIVPAGTLLMNAVW AGGAGAAGCACATGCCACCCCCAAACATGACCAC AGCUACAUGGAGGAGAAGCACAUGCCACCC PKAGRWWAAQTPLG GAACGAGCGCAGAGTTATCGTGCCAGCAGGAACT CCAAACAUGACCACGAACGAGCGCAGAGUU CTCCTGATGAATGCAGTGTGGCCAAAGGCGGGAA AUCGUGCCAGCAGGAACUCUCCUGAUGAA GATGGTGGGCAGCCCAGACACCGTTGGGATGA UGCAGUGUGGCCAAAGGCGGGAAGAUGG UGGGCAGCCCAGACACCGUUGGGAUGA  46 296/595 ATGGAGTACAGACCATGTGCGGCAGTGGCTGGA AUGGAGUACAGACCAUGUGCGGCAGUGGC MEYRPCAAVAGVGGERIWPSRRQHLVIP (BSS + RCA) GTGGGCGGTGAAAGAATATGGCCTTCCAGACGTC UGGAGUGGGCGGUGAAAGAAUAUGGCCU EHRWEGTVQDDQGRLPEAHPQLQRRH AACATCTTGTTATTCCAGAACATCGATGGGAAGGA UCCAGACGUCAACAUCUUGUUAUUCCAGA PSLTSPLPQRESYAMEYRPCAAVAGVGG ACTGTGCAAGATGACCAAGGACGACTTCCAGAGG ACAUCGAUGGGAAGGAACUGUGCAAGAUG ERIWPSRRQHLVIPEHRWEGTVQDDQG CTCACCCCCAGCTACAACGCCGACATCCTTCTCTCA ACCAAGGACGACUUCCAGAGGCUCACCCCC RLPEAHPQLQRRHPSLTSPLPQR CATCTCCACTACCTCAGAGAGAATCCTACGCTATG AGCUACAACGCCGACAUCCUUCUCUCACAU GAGTACAGACCATGTGCGGCAGTGGCTGGAGTG CUCCACUACCUCAGAGAGAAUCCUACGCUA GGCGGTGAAAGAATATGGCCTTCCAGACGTCAAC UGGAGUACAGACCAUGUGCGGCAGUGGCU ATCTTGTTATTCCAGAACATCGATGGGAAGGAACT GGAGUGGGCGGUGAAAGAAUAUGGCCUU GTGCAAGATGACCAAGGACGACTTCCAGAGGCTC CCAGACGUCAACAUCUUGUUAUUCCAGAA ACCCCCAGCTACAACGCCGACATCCTTCTCTCACAT CAUCGAUGGGAAGGAACUGUGCAAGAUGA CTCCACTACCTCAGAGA CCAAGGACGACUUCCAGAGGCUCACCCCCA GCUACAACGCCGACAUCCUUCUCUCACAUC UCCACUACCUCAGAGA  47 297/596 GTGCGGCAGTGGCTGGAGTGGGCGGTGAAAGAA GUGCGGCAGUGGCUGGAGUGGGCGGUGA VRQWLEWAVKEYGLPDVNILLFQNIDGK (BSS + RCA) TATGGCCTTCCAGACGTCAACATCTTGTTATTCCA AAGAAUAUGGCCUUCCAGACGUCAACAUC ELCKMTKDDFQRLTPSYNADILLSHLHYL GAACATCGATGGGAAGGAACTGTGCAAGATGACC UUGUUAUUCCAGAACAUCGAUGGGAAGGA RENPTLWSTDHVRQWLEWAVKEYGLPD AAGGACGACTTCCAGAGGCTCACCCCCAGCTACA ACUGUGCAAGAUGACCAAGGACGACUUCC VNILLFQNIDGKELCKMTKDDFQRLTPSY ACGCCGACATCCTTCTCTCACATCTCCACTACCTCA AGAGGCUCACCCCCAGCUACAACGCCGACA NADILLSHLHYLRE GAGAGAATCCTACGCTATGGAGTACAGACCATGT UCCUUCUCUCACAUCUCCACUACCUCAGAG GCGGCAGTGGCTGGAGTGGGCGGTGAAAGAATA AGAAUCCUACGCUAUGGAGUACAGACCAU TGGCCTTCCAGACGTCAACATCTTGTTATTCCAGA GUGCGGCAGUGGCUGGAGUGGGCGGUGA ACATCGATGGGAAGGAACTGTGCAAGATGACCAA AAGAAUAUGGCCUUCCAGACGUCAACAUC GGACGACTTCCAGAGGCTCACCCCCAGCTACAAC UUGUUAUUCCAGAACAUCGAUGGGAAGGA GCCGACATCCTTCTCTCACATCTCCACTACCTCAGA ACUGUGCAAGAUGACCAAGGACGACUUCC GAG AGAGGCUCACCCCCAGCUACAACGCCGACA UCCUUCUCUCACAUCUCCACUACCUCAGAG AG  48 298/597 TTGACTTCAGATGATGTTGATAAAGCCTTACAAAA UUGACUUCAGAUGAUGUUGAUAAAGCCU LTSDDVDKALQNSPRLMHARNTAPLPHL (BSS + RCA) CTCTCCACGGTTAATGCATGCTAGAAACACAGCTC UACAAAACUCUCCACGGUUAAUGCAUGCU TSDDVDKALQNSPRLMHARNT CTCTTCCACATTTGACTTCAGATGATGTTGATAAA AGAAACACAGCUCCUCUUCCACAUUUGAC GCCTTACAAAACTCTCCACGGTTAATGCATGCTAG UUCAGAUGAUGUUGAUAAAGCCUUACAAA AAACACA ACUCUCCACGGUUAAUGCAUGCUAGAAAC ACA  49 299/598 GTGCAGCTTTTATTTTCCCAAATACTTCAGTATATC GUGCAGCUUUUAUUUUCCCAAAUACUUCA VQLLFSQILQYILKLRKELQLGQGVQLLFS (BSS + RCA) CTGAAGCTACGCAAAGAATTACAACTAGGCCAGG GUAUAUCCUGAAGCUACGCAAAGAAUUAC QILQYILKLRKELQLGQ GGGTGCAGCTTTTATTTTCCCAAATACTTCAGTATA AACUAGGCCAGGGGGUGCAGCUUUUAUU TCCTGAAGCTACGCAAAGAATTACAACTAGGCCA UUCCCAAAUACUUCAGUAUAUCCUGAAGC G UACGCAAAGAAUUACAACUAGGCCAG

REFERENCES

-   1. http://www.who.int/cancer/en/ -   2. Ott P A, et al., An immunogenic personal neoantigen vaccine for     patients with melanoma. Nature 2017; 547(7662):217-221. -   3. Sahin U, et al., Personalized RNA mutanome vaccines mobilize     poly-specific therapeutic immunity against cancer. Nature 2017;     547(7662):222-226. -   4. Guarnerio J, et al., Oncogenic Role of Fusion-circRNAs Derived     from Cancer-Associated

Chromosomal Translocations. Cell 2016; 165(2):289-302.

-   5. Capel B, et al., Circular transcripts of the testis-determining     gene Sry in adult mouse testis. Cell 1993; 73(5):1019-1030. -   6. Salzman J, et al., Circular RNAs are the predominant transcript     isoform from hundreds of human genes in diverse cell types. PLoS One     2012; 7(2):e30733. -   7. Abe N, et al., Rolling Circle Translation of Circular RNA in     Living Human Cells. Sci Rep 2015; 5:16435. -   8. Legnini I, et al., Circ-ZNF609 Is a Circular RNA that Can Be     Translated and Functions in Myogenesis. Mol Cell 2017; 66(1):22-37     e29. -   9. Rowe R C et al., Handbook of Pharmaceutical Excipients.     Pharmaceutical Press, 2012 -   10. Wen E P et al., Vaccine Development and Manufacturing, John     Wiley & Sons, 17 Nov. 2014 -   11. http://en.wikipedia.org/wiki/Peptide_synthesis -   12. http://en.wikipedia.org/wiki/Expression_vector -   13. Creighton T E, Proteins—Structures and Molecular     properties—Second edition. WH Freeman and Company. 

1.-24. (canceled)
 25. An endogenous tumor-derived circRNA, for use as a vaccine in the prophylaxis and/or treatment of cancer, preferably prostate cancer, breast cancer, colon cancer, lung cancer and/or pancreatic cancer.
 26. The endogenous tumor-derived circRNA for use as vaccine according to claim 25, comprising an RNA nucleotide sequence selected from SEQ ID No: 1 to
 299. 27. A vaccine comprising an endogenous tumor-derived circRNA according to claim
 25. 28. A protein derived from a tumor-derived endogenous circRNA according to claim 25, for use as prophylactic or therapeutic vaccine in the treatment of cancer, preferably prostate cancer, breast cancer, colon cancer, lung cancer and pancreatic cancer.
 29. The protein for use as a vaccine according to claim 28, wherein said protein comprises an amino acid sequence selected from SEQ ID No: 301 to
 598. 30. A vaccine comprising a protein according to claim
 28. 31. DNA which encodes for a circRNA according to claim
 25. 32. DNA which encodes for a protein according to claim
 28. 33. A vaccine vector or genetic vector which comprises of DNA according to claim
 31. 34. A vaccine vector or genetic vector which comprises DNA expressing an RNA that translates a protein derived from at least one protein encoded by at least one tumor-derived circRNA according to claim
 28. 35. An endogenous tumor-derived circRNA for use as a vaccine in the prophylaxis and/or treatment of cancer, obtainable by a method comprising the steps of: a. extracting total RNA content from tumor cells; and b. enriching circRNA by enzyme digestion of linear RNA.
 36. A pharmaceutical composition comprising the protein derived from a tumor-derived circRNA, according to claim
 28. 37. A method of preparing an endogenous tumor-derived circRNA vaccine, comprising the steps of: a. extracting total RNA content from tumor cells of a patient; b. enriching circRNA from the extracted total RNA by enzyme digestion of linear RNA; and c. mixing the enriched circRNA to pharmaceutically acceptable excipients suitable for vaccines.
 38. A method of preparing a protein derived from endogenous tumor-derived circRNA for use as a vaccine, comprising the steps of: a. extracting total RNA content from tumor cells of a patient; b. enriching circRNA from the extracted total RNA by enzyme digestion of linear RNA; c. identifying neoantigen proteins; and d. detecting personalized/general potential of the protein as immunogen.
 39. A method of preparing an endogenous tumor-derived circRNA, comprising: a. extracting total RNA content from tumor cells of a patient; b. enriching circRNA from the extracted total RNA by enzyme digestion of linear RNA; and c. returning the enriched circRNA to antigen presenting cells ex vivo; wherein the antigen presenting cells generate an immune response.
 40. A personalized method of treating a cancer patient comprising: a. extracting total RNA content from tumor cells of a patient; b. enriching circRNA from the extracted total RNA by enzyme digestion of linear RNA; c. mixing the enriched circRNA to pharmaceutically acceptable excipients; and d. administering an effective amount of the mixed circRNA to the patient.
 41. A method of treating a cancer patient comprising: a. extracting total RNA content from tumor cells of a patient; b. enriching circRNA from the extracted total RNA by enzyme digestion of linear RNA; c. identifying an immunogenic potential of neoantigen proteins from circRNA; and d. administering an effective amount of the neoantigen protein to the patient. 